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Abstract 
Positron emission tomography (PET) is a powerful, non-invasive in vivo imaging 
technique used for diagnostics and drug development.  The synthesis of 
18
F-PET tracers is 
challenging due to the short half-life of the unnatural isotope that necessitates late-stage 
fluorination, and the limited reactivity of nucleophilic fluoride, the preferred and widely 
accessible form of 
18
F.  This thesis describes the development of an electrophilic fluorination 
reagent derived from fluoride.  The reagent can be employed in a late-stage fluorination reaction 
of palladium aryl complexes to give access to small molecule aryl fluorides.  The reagent can be 
made from [
18
F]fluoride and used to synthesize radiolabeled small molecules for PET imaging 
experiments.  Two small molecules known to interact with the serotonergic system were 
synthesized, radiolabeled, and imaged in rats and non-human primates and evaluated for use as 
PET tracers.  
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1.1 Positron Emission Tomography 
Positron emission tomography (PET) is a powerful, non-invasive imaging technology 
that can be used to identify and characterize human disease.  PET can provide critical information 
about normal or aberrant human physiology.  Experiments using PET can be designed to provide 
two distinct types of information: i) the disposition (i.e., pharmacokinetics and biodistribution) of 
a radiolabeled compound; and ii) the measurement of a physiological parameter using a 
radiotracer (e.g., receptor concentration/occupancy, enzyme activity, or metabolism).
1
  These two 
“classes” of imaging experiments are synergistic and provide a means for direct characterization 
of drug interactions and their downstream biological consequences.
2
 
PET imaging employs molecules labeled with positron-emitting isotopes, such as carbon-
11 (
11
C), nitrogen-13 (
13
N), oxygen-15 (
15
O), and fluorine-18 (
18
F) (Table 1.1).  During an 
experiment, in which a radiolabeled molecule is injected into a subject, decay will occur, and the 
emitted positron will encounter its anti-matter partner, an electron.  They annihilate and produce 
two high energy gamma rays that travel in anti-parallel directions.  The timing and location of 
detection of the gamma rays by a PET scanner allows for the computed tomography of the place 
of annihilation, and therefore the location of the molecule in vivo.  Summation of the annihilation 
events leads to a PET image of the radiolabeled molecule. 
Currently, PET is most recognized as a clinical tool for the diagnosis of cancer
3
 due to 
                                                          
1.  Serdons, K.; Terwinghe, C.; Van Vermaelen, P.; Laere, K.; Kung, H.; Mortelmans, L.; Bormans, G.; Verbruggen, A. J. 
Med. Chem. 2009, 52, 1428. 
2. (a) Antoni, G.; Langstrom, B. Handb. Exp. Pharmacol. 2008, 177; (b) Fowler, J. S.; Wolf, A. P. Acc. Chem. Res. 1997, 30, 
181.  
3. (a) Wood, K. A.; Hoskin, P. J.; Saunders, M. I. Clin. Oncol. 2007, 19, 237; (b) Weber, W. A. J. Clin. Oncol. 2006, 24, 
3282; (c) Oriuchi, N.; Higuchi, T.; Ishikita, T.; Miyakubo, M.; Hanaoka, H.; Iida, Y.; Endo, K. Cancer Sci. 2006, 97, 1291; 
  
 
 
3 
the radiotracer 2-[
18
F]fluoro-2-deoxy-D-glucose ([
18
F]FDG),
4
 Over two million PET scans are 
performed each year with [
18
F]FDG.  [
18
F]FDG has revolutionized clinical practices in oncology,
5
 
and its role in medical research and patient care is rapidly evolving.
6
 Over the past decade, PET 
imaging has had an impact in studying neurological diseases,
7
 and gene therapy.
8
 Importantly, 
PET is also beginning to expedite the development of new pharmaceuticals.
8a, 9
  
Table 1.1. Commonly employed PET isotopes with half-lives, nuclear reaction, target, and target products.  
                                                                                                                                                                             
 
 
 
(d) Jadvar, H.; Alavi, A.; Gambhir, S. S. J. Nucl. Med. 2009, 50, 1820. 
4. (a) Gambhir, S. S. Nat. Rev. Cancer 2002, 2, 683; (b) Rigo, P.; Paulus, P.; Kaschten, B. J.; Hustinx, R.; Bury, T.; 
Jerusalem, G.; Benoit, T.; Foidart Willems, J. Eur. J. Nucl. Med. 1996, 23, 1641. 
5. (a) Gambhir, S. S.; Czernin, J.; Schwimmer, J.; Silverman, D. H. S.; Coleman, R. E.; Phelps, M. E. J. Nucl. Med. 2001, 42, 
1S; (b) Rohren, E. M.; Turkington, T. G.; Coleman, R. E. Radiology 2004, 231, 305.  
6. (a) Kelloff, G.; Hoffman, J. M.; Johnson, B.; Scher, H. I.; Siegel, B. A.; Cheng, E. Y.; Cheson, B. D.; O'Shaughnessy, J.; 
Guyton, K. Z.; Mankoff, D. A.; Shankar, L.; Larson, S. M.; Sigman, C. C.; Schilsky, R. L.; Sullivan, D. C. Clin. Cancer 
Res. 2005, 11, 2785; (b) Patterson, J. C., 2nd; Mosley, M. L. Mol. Imaging Biol. 2005, 7, 197. 
7. (a) Herholz, K.; Heiss, W. D. Mol. Imaging Biol. 2004, 6, 239; (b) Jacobs, A. H.; Li, H.; Winkeler, A.; Hilker, R.; Knoess, 
C.; Ruger, A.; Galldiks, N.; Schaller, B.; Sobesky, J.; Kracht, L.; Monfared, P.; Klein, M.; Vollmar, S.; Bauer, B.; Wagner, 
R.; Graf, R.; Wienhard, K.; Herholz, K.; Heiss, W. D. Eur. J. Nuc. Med. Mol. Imaging 2003, 30, 1051.  
8. (a) Winkeler, A.; Sena-Esteves, M.; Paulis, L. E. M.; Li, H.; Waerzeggers, Y.; Ruckriem, B.; Himmelreich, U.; Klein, M.; 
Monfared, P.; Rueger, M. A.; Heneka, M.; Vollmar, S.; Hoehn, M.; Fraefel, C.; Graf, R.; Wienhard, K.; Heiss, W. D.; 
Jacobs, A. H. PLoS ONE 2007, 2, 1; (b) Raty, J. K.; Liimatainen, T.; Kaikkonen, M. U.; Grahn, O.; Airenne, K. J.; Yla-
Herttuala, S. Mol. Ther. 2007, 15, 1579; (c) Kang, J. H.; Chung, J. K. J. Nucl. Med. 2008, 49, 164S; (d) Massoud, T. F.; 
Singh, A.; Gambhir, S. S. Am. J. Neuroradiol. 2008, 29, 229; (e) Massoud, T. F.; Singh, A.; Gambhir, S. S. Am. J. 
Neuroradiol. 2008, 29, 409.  
9. (a) Hargreaves, R. J. Clin. Pharmacol. Ther. 2008, 83, 349; (b) Wang, J. L.; Maurer, L. Curr. Top. Med. Chem. 2005, 5, 
1053;  (c) Wagner, C. C.; Muller, M.; Lappin, G.; Langer, O. Curr. Opin. Drug Discov. Devel. 2008, 11, 104. 
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While several positron-emitting nuclei are available for PET imaging as noted above, the 
non-natural isotope fluorine-18 (
18
F) is the nucleus of choice for many applications in PET 
imaging due to its half-life of 110 minutes, which provides an opportunity for radiotracer 
distribution in the subject,
10
 as well as its widespread availability. The 
18
F-nucleus is typically 
attached by a carbon–fluorine (CF) bond in 18F-PET tracers.11 Carbon–fluorine bond formation 
is extremely challenging.
12
 While simple molecules such as [
18
F]FDG can be efficiently prepared 
(see Figure 1.5), more complex, biomedically interesting molecules often cannot.  Furthermore 
[
18
F]FDG contains a Csp3F bond.  Generally, Csp3F bonds are easier to synthesize than Csp2F 
bonds through nucleophilic displacement reactions or enol/enolate chemistry.  Methods to form 
Csp2F bonds will be discussed in the following section. 
 
1.2 Late-Stage Fluorination of Arenes 
Methods to form of Csp2F bonds in complex substrates has been a long-standing 
challenge in synthetic organic chemistry.  Traditionally, aryl fluorides have been synthesized 
                                                          
10. Miller, P. W.; Long, N. J.; Vilar, R.; Gee, A. D. Angew. Chem., Int. Ed. 2008, 47, 8998.  
11. Schirrmacher, R.; Wangler, C.; Schirrmacher, E. Mini-Rev. Org. Chem. 2007, 4, 317.  
12. (a) Furuya, T.; Kuttruff, C. A.; Ritter, T. Curr. Opin. Drug Discov. Devel. 2008, 11, 803 (12) Grushin, V. V. Acc. 
Chem. Res. 2010, 43, 160; (b) Furuya, T.; Klein, E. M. N.; Ritter, T. Synthesis 2010, 1804. 
  
 
 
5 
through the Balz-Schiemann reaction
13
 and the Wallach reaction
14
 (Figure 1.1). The Balz 
Schiemann reaction is the thermolysis of aryl diazonium tetrafluoroborates and the Wallach 
reaction is the acidic decomposition of triazenes.  Due to the harsh condition employed for these 
transformations (heat and/or strong acid), sensitive functionality should not be present during the 
reaction.  As such, the substrate scope of these classic reactions is limited. 
Nucleophilic aromatic substitution is widely used for the construction of aryl fluorides.
15
  
With an appropriate electron-withdrawing group on the arene (e.g., nitro, cyano, carboxyl, 
carboxyl derivative, keto), fluoride can replace an appropriate leaving group (e.g., nitro, cyano, 
halo, trialkyl ammonium).  Electron-neutral and electron-rich aromatic rings are rarely or cannot 
be employed in nucleophilic aromatic substitution reactions.   
There are properties of fluorine that make synthesis with the element difficult and have 
hindered the development of more robust reactions than the traditional one described above.
16
  
Elemental fluorine is highly reactive and difficult to work with.  The invention of alternative 
electrophilic fluorination reagents, such as xenon difluoride, pyridinium fluorides, and 
Selectfluor® (F-TEDA), has been instrumental in electrophilic fluorine chemistry research.  
Fluoride, on the other hand, has the smallest ionic radius, is a strong base when dry, and is weakly 
nucleophilic when wet due to the high hydration energy.
17
 
                                                          
13. Balz, G.; Schiemann, G. Ber. Dtsch. Chem. Ges. 1927, 60, 1186. 
14. Wallach, O. Liebigs Ann. Chem. 1886, 235, 233. 
15. (a) Gottlieb, H. B. J. Am. Chem. Soc. 1936, 58, 532; (b) Adams, D. J.; Clark, J. H. Chem. Soc. Rev. 1999, 28, 225. 
16. O'Hagan, D. Chem. Soc. Rev. 2008, 37, 308.  
17. Emsley, J. Chem. Soc. Rev. 1980, 9, 91. 
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Figure 1.1. Traditional methods to synthesize aryl fluorides. 
Yet, despite the difficulty of working with electrophilic fluorine and nucleophilic 
fluoride, incorporation of the element into small molecules and polymers is desirable.
18
  Fluorine 
uniquely affects the properties of organic molecules through strong polar interactions due to the 
atom’s high electronegativity.16 For pharmaceuticals, fluorine can make a molecule more 
bioavailable, lipophilic, and metabolically stable, and can increase the strength of a compound’s 
interactions with a target protein.
18b
 Fluorine chemistry research has therefore been an active 
pursuit.  Recent advances in transition-metal-mediated fluorination reactions of arenes will be 
highlighted here. 
 In 2002, the late transition metal copper, in the form of the electrophilic fluorination 
                                                          
18. (a) Kirk, K. L. Org. Process Res. Dev. 2008, 12, 305; (b) Muller, K.; Faeh, C.; Diederich, F. Science 2007, 317, 1881; (c) 
Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem. Soc. Rev. 2008, 37, 320; (d) Hung,  M. H.; Farnham, W. B.; 
Feiring, A. E., Rozen, S.  In Fluoropolymers; Hougham, G.; Cassidy, P. E.; Johns, K.; Davidson, T. Eds, Plenum 
Publishing Co: New York, 1999. 
  
 
 
7 
reagent CuF2, was used in the oxidation of benzene to fluorobenzene at 450 °C.
19
  The copper 
reagent can be regenerated after fluorination, and this reaction approach has the potential to lead 
to a practical copper-catalyzed synthesis of simple fluorinated arenes. Currently, only structurally 
simple arenes, such as fluorobenzene, fluorotoluenes and difluorobenzenes, can be synthesized 
with the CuF2-mediated process, and the reaction is characterized by low regioselectivity when 
substituents are present on the arene. 
Regioselective functionalization of Caryl–H (Ar–H) bonds by transition metals under less 
harsh conditions has been achieved through the use of directing groups.
20
 Covalently attached to 
the aryl ring, directing groups coordinate to a transition metal and lower the activation energy for 
C–H bond cleavage preferentially, by positioning the transition metal in proximity to specific C–
H bonds. The direct transformation of a C–H bond to a C–F bond is an attractive feature of 
directed electrophilic fluorination in terms of efficiency. Application of the directing group 
strategy to arene fluorination was first reported in 2006 by the Sanford Group
21
 (Equation 1.1). 
Phenyl pyridine derivatives were fluorinated at the ortho positions in the presence of Pd(OAc)2 
and an electrophilic fluorination reagent. A similar palladium-catalyzed directed electrophilic 
fluorination of Ar–H bonds of N-benzyltriflamide derivatives was reported by the Yu Group in 
2009
22
 (Equation 1.2). The triflamide directing group (–NHTf) can be easily converted into a 
variety of other functional groups. Current limitations of the directing group approach include the 
restriction that fluorine can only be incorporated at the position ortho to the directing group, the  
                                                          
19. Subramanian, M. A.; Manzer, L. E. Science 2002, 297, 1665.  
20. Cope, A. C.; Siekman, R. W. J. Am. Chem. Soc. 1965, 87, 3272. 
21. Hull, K. L.; Anani, W. Q.; Sanford, M. S. J. Am. Chem. Soc. 2006, 128, 7134. 
22. Wang, X.; Mei, T. S.; Yu, J. Q. J. Am. Chem. Soc. 2009, 131, 7520. 
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requirement for blocking groups to prevent ortho,ortho’-difluorination, and the need for a 
directing group itself.  If the directing group is part of the desired molecule, the approach is 
efficient, but directing groups and functional groups that are derived from directing groups are 
often not desired in the final molecule, and easily removable directing groups are rare. 
The mechanisms of the directed electrophilic fluorination reactions shown in Equations 
1.1 and 1.2 are still unknown. After cyclopalladation, the key C–F bond-forming event could 
occur either from a Pd(II) center without change in the oxidation state of the metal (as in the 
electrophilic fluorination of an aryl Grignard reagent
23
), or from a higher oxidation state 
palladium complex (such as a dinuclear Pd(III)
24
 or a Pd(IV)
25
 complex) via C–F reductive 
elimination. Reductive elimination from transition metal complexes to form C–F bonds was long 
                                                          
23. (a) Yamada, S.; Gavryushin, A.; Knochel, P. Angew. Chem., Int. Ed. 2010, 49, 2215; (b) Anbarasan, P.; Neumann, H.; 
Beller, M. Angew. Chem., Int. Ed. 2010, 49, 2219. 
24. (a) Powers, D. C.; Ritter, T. Nat. Chem. 2009, 1, 302; (b) Powers, D. C.; Geibel, M. A. L.; Klein, J.; Ritter, T. J. Am. Chem. 
Soc. 2009, 131, 17050; (c) Powers, D. C.; Xiao, D. Y.; Geibel, M. A. L.; Ritter, T. J. Am. Chem. Soc. 2010, 132, 14530; (d) 
Powers, D. C.; Benitez, D.; Tkatchouk, E.; Goddard, W. A.; Ritter, T. J. Am. Chem. Soc. 2010, 132, 14092. 
25. (a) Kaspi, A. W.; Yahav-Levi, A.; Goldberg, I.; Vigalok, A. Inorg. Chem. 2008, 47, 5; (b) Ball, N. D.; Sanford, M. S. J. 
Am. Chem. Soc. 2009, 131, 3796.  
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unknown. Only in 2008 was an isolated aryltransition metal fluoride complex reported to undergo 
C–F reductive elimination.26 
Carbon–fluorine reductive elimination was studied by the Ritter Group in the context of 
isolated Pd(II)–Ar complexes synthesized by transmetalation from aryl boronic acids.  In 2008, it 
was discovered that a variety of functionalized arylboronic acids are suitable substrates for 
transmetalation onto a palladium(II) complex; subsequent treatment with the electrophilic 
fluorination reagent F-TEDA-BF4 afforded the corresponding aryl fluorides (Figure 1.2).
27
 It was 
postulated that C–F bond formation occurred via fluorination of the transition metal, followed by 
C–F reductive elimination.  Studies on isolated arylpalladium(IV) fluoride complexes established 
the viability of Ar–F reductive elimination from a transition metal complex.26  
 
Figure 1.2. Palladium-mediated fluorination of aryl boronic acids with F-TEDA. (Yields given are for fluorination.) 
Transition-metal-catalyzed cross coupling between an electrophile and a nucleophile is 
potentially a general approach for C–F bond formation.  Studies of the use of palladium-, 
rhodium- and copper-based cross-coupling reactions for C–F bond formation have been 
                                                          
26. (a) Furuya, T.; Ritter, T. J. Am. Chem. Soc. 2008, 130, 10060; (b) Furuya, T.; Benitez, D.; Tkatchouk, E.; Strom, A. E.; 
Tang, P. P.; Goddard, W. A.; Ritter, T. J. Am. Chem. Soc. 2010, 132, 3793. 
27. Furuya, T.; Kaiser, H. M.; Ritter, T. Angew. Chem., Int. Ed. 2008, 47, 5993. 
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documented since the late 1990s,
28
 but only recently has successful fluorination by catalysis been 
achieved, due in large part to the development of metal complexes that can undergo C–F 
reductive elimination. 
Theoretical studies of the fundamental difficulties associated with C–F reductive 
elimination from arylpalladium(II) fluoride complexes were reported in 2007.
29
 Reductive 
elimination should occur most readily from a mononuclear, three-coordinate, ‘T’-shaped 
palladium complex, with the aryl ligand and the fluoride ligand oriented cis to each other. 
However, ‘T’-shaped arylpalladium(II) fluoride complexes are often less stable than their 
corresponding dimeric form, in which two ‘T’-shaped palladium complexes come together, with 
both fluorine ligands bound to both palladium atoms. Reductive elimination from such a bis-µ-
fluoride dimer is significantly more difficult than from the T-shaped monomer; in fact, to date, it 
has not been observed. Large ligands on palladium destabilize the dimer relative to the monomer 
and therefore increase the concentration of the mononuclear three-coordinate arylpalladium(II) 
fluoride complex for subsequent C–F reductive elimination. In line with this reasoning, the use of 
the bulky monodentate phosphine ligand t-Bu-XPhos resulted in C–F bond formation from an 
arylpalladium(II) fluoride complex, albeit in only 10% yield. This was a significant and 
promising result, but conclusive evidence for concerted C–F reductive elimination was not 
obtained and other mechanisms of C–F bond formation are possible.30 
The first palladium(0)-catalyzed Ar–F bond-forming cross-coupling reaction was 
reported in 2009 using aryl triflates (ArOTf) and CsF as a nucleophilic fluorine source (Figure 
                                                          
28. (a) Fraser, S. L.; Antipin, M. Y.; Khroustalyov, V. N.; Grushin, V. V. J. Am. Chem. Soc. 1997, 119, 4769; (b) Pilon, M. C.; 
Grushin, V. V. Organometallics 1998, 17, 1774; (c) Grushin, V. V. Chem.-Eur. J. 2002, 8, 1006. 
29. Yandulov, D. V.; Tran, N. T. J. Am. Chem. Soc. 2007, 129, 1342. 
30. Grushin, V. V.; Marshall, W. J. Organometallics 2007, 26, 4997. 
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1.3).
 31
 As predicted by theory, the use of a bulky monodentate phosphine ligand, t-BuBrettPhos,
32
 
to access three-coordinate arylpalladium(II) fluoride complexes was the key to success. An 
arylpalladium(II) fluoride complex supported by t-BuBrettPhos was shown to be effective for C–
F reductive elimination. Arenes with a wide range of electronic properties and a variety of 
heterocycles could be fluorinated with this method. Sterically congested arenes and arenes 
bearing electrophilic and nucleophilic functional groups could be fluorinated as well. For a few 
substrates, undesired constitutional isomers were formed as by-products when para-electron-
donating or meta-electron withdrawing groups were present. Although the mechanism for the 
formation of the constitutional isomers has not yet been elucidated, the isomers could arise from a 
competing benzyne pathway, owing to high reaction temperatures and dried, basic fluoride.  It 
has also been shown that the phosphine ligand can undergo in situ modification to generate a 
triaryl phosphine that is responsible for C–F bond formation for some substrates.33  The reaction  
 
Figure 1.3. Palladium-catalyzed cross-coupling reaction to form aryl fluorides using aryl triflates and cesium fluoride. 
                                                          
31. Watson, D. A.; Su, M. J.; Teverovskiy, G.; Zhang, Y.; Garcia-Fortanet, J.; Kinzel, T.; Buchwald, S. L. Science 2009, 325, 
1661. 
32. Fors, B. P.; Watson, D. A.; Biscoe, M. R.; Buchwald, S. L. J. Am. Chem. Soc. 2008, 130, 13552. 
33. Maimone, T. J.; Milner, P. J.; Kinzel, T.; Zhang, Y.; Takase, M. K.; Buchwald, S. L. J. Am. Chem. Soc. 2011, 133, 18106. 
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must be performed under anhydrous conditions, and substrates with protic functional groups were 
not demonstrated to undergo fluorination, possibly owing to the tendency of fluoride to form 
strong hydrogen bonds. Hydrogen-bond formation between protic functional groups or water with 
arylpalladium(II) fluorides could stabilize the ground state of the arylpalladium(II) fluoride 
complex, which increases the activation barrier to C–F reductive elimination.29 Water could also 
result in hydrolysis of the Pd–F bond at a rate faster than the rate of C–F reductive elimination. 
 
Figure 1.4. Silver-catalyzed fluorination of aryl stannanes with the electrophilic fluorination reagent F-TEDA. 
Reductive elimination of C–F bonds from transition metal fluorides need not be limited 
to palladium. The late transition metal silver has been shown to mediate the electrophilic 
fluorination of arylboronic acids
34
 and aryl stannanes.
35
 Following the initial discovery of general 
silver-mediated fluorination of arenes, a silver-catalyzed electrophilic A–F bond-forming reaction 
for aryl stannanes using Ag2O and the electrophilic fluorination reagent F-TEDA-PF6 was 
                                                          
34. Furuya, T.; Ritter, T. Org. Lett. 2009, 11, 2860.  
35. Furuya, T.; Strom, A. E.; Ritter, T. J. Am. Chem. Soc. 2009, 131, 1662.  
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developed (Figure 1.4).
36
 Several functional groups are tolerated under the reaction conditions. 
The reaction is applicable to late-stage fluorination of complex small molecules, including taxol, 
strychnine, and rifamycin derivatives. Few nucleophilic functional groups—including certain 
amines and sulfides that are generally compatible with nucleophilic fluorination reactions—are 
incompatible with the electrophilic fluorination reaction. Current challenges associated with the 
silver-catalyzed electrophilic fluorination include the use of toxic aryl stannane starting materials 
and the additional synthetic steps required for their preparation from Ar–OH or Ar–H bonds, 
typically via aryl triflates or aryl halides.
37
 
 
1.3 Synthesis with 18F 
Using the position-emitting 
18
F isotope exacerbates the challenge of Csp2F bond 
formation.  The relatively short half-life of 
18
F dictates severe restrictions on the chemical 
synthesis of PET tracers.
10, 38
  Introduction of
 18
F must occur at a late stage of the synthesis, 
ideally as the last step to avoid unproductive decay of the 
18
F-nucleus before injection into the 
body.  Due to the limited functional group compatibility of fluorination reactions employed today 
and the short half-life of 110 minutes, the synthesis of PET tracers is currently limited to a fairly 
small number of simple molecules.
11, 39
  Examples of the late-stage fluorination of 
18
F-PET tracers 
([
18
F]FDG,
40
 [
18
F]fallypride,
41
 [
18
F]F-DOPA
42
) are shown in Figure 1.5.  In these examples, 
                                                          
36. Tang, P. P.; Furuya, T.; Ritter, T. J. Am. Chem. Soc. 2010, 132, 12150.  
37. Azizian, H.; Eaborn, C.; Pidcock, A. J. Organomet. Chem. 1981, 215, 49.  
38. (a) Cai, L.; Lu, S.; Pike, V. W. Eur. J. Org. Chem. 2008, 2008, 2853; (b) Fowler, J. S.; Wolf, A. P. Acc. Chem. Res. 1997, 
30, 181. 
39. (a) Lasne, M. C.; Perrio, C.; Rouden, J.; Barre, L.; Roeda, D.; Dolle, F.; Crouzel, C. In Contrast Agents II; Springer: 
Berlin, 2002; Vol. 222, p 201; (b) Schubiger, P. A.; Lehmann, L.; Friebe, M. PET Chemistry: The Driving Force in 
Molecular Imaging; Springer: New York, 2007. 
40. Hamacher, K.; Coenen, H. H.; Stocklin, G. J.  Nucl. Med. 1986, 27, 235. 
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reaction times are short and there may or may not be a deprotection of sensitive functional groups 
after CF bond formation. 
 
Figure 1.5. Example late-stage fluorination to synthesize 
18
F-PET tracers. 
However, substrate scope and reaction time are not the only constraints of 
18
F-PET 
chemistry.  It is desirable to obtain PET images using high specific activity isotopes.  Specific 
activity is a measurement of isotopic enrichment (i.e. the ratio of position-emitting nuclei to 
natural, non-positron emitting nuclei), and is typically measured in terms of amount of 
                                                                                                                                                                             
 
 
 
41. Mukherjee, J.; Yang, Z. Y.; Das, M. K.; Brown, T. Nucl. Med. Biol. 1995, 22, 283. 
42. Namavari, M.; Bishop, A.; Satyamurthy, N.; Bida, G.; Barrio, J. R. Appl. Radiat. Isot. 1992, 43, 989. 
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radioactivity per moles of sample.
10
  For 
18
F chemistry, the 
18
F can be made either as [
18
F]fluoride 
or [
18
F]F2 (“F
–” or “F+”).  [18F]Fluoride ([18F]F–)  is much more widely available, easier to use, 
and is made at a specific activity typically 2 orders of magnitude greater than [
18
F]F2.
43
  High 
specific activity [
18
F]F
–
 provides higher quality images compared to [
18
F]F2 and is the preferred 
source of 
18
F.
38a, 44
  Nevertheless, using high specific activity isotopes means that the total amount 
of material is small, on the order nanomoles.  This dictates a need for unusually high chemical 
reaction rates and efficiencies, which are met by only a handful of methods. 
Recent advances in the synthesis of 
18
F-labeled molecules include work by Pike and 
Gouverneur.  Pike has shown that fluorination of diaryl iodinium salts is an efficient method to 
form aryl fluorides (Equation 1.3).
45
  The method has been applied a variety of useful 
molecules.
46
  The drawbacks of the method include the general difficulty to prepare diaryl 
iodonium salts, which can be unstable and lack functional group tolerance, and the lack of 
selectivity in CF bond formation.  Gouverneur has demonstrated that more useful and selective 
electrophilic fluorination reagents (compared to fluorine gas) can be synthesized with 
18
F.  This 
has allowed her to employ recently discovered electrophilic fluorination reactions in for the 
synthesis of 
18
F-labeled aryl fluorides (for example, see Equation 1.4).
 47
   However, the 
18
F-
labeled electrophilic fluorination reagents are ultimately derived from [
18
F]F2, which cannot be 
made in specific activities as high as [
18
F]fluoride.
43 
                                                          
43. Bergman, J.; Solin, O. Nucl. Med. Biol. 1997, 24, 677. 
44. (a) Ametamey, S. M.; Honer, M.; Schubiger, P. A. Chem. Rev. 2008, 108, 1501. 
45. (a) Pike, V. W.; Aigbirhio, F. I. J. Chem. Soc., Chem. Commun. 1995, 2215; (b) Ross, T.; Ermert, J.; Coenen, H. H. J. 
Labelled Compd. Radiopharm. 2005, 48, S153. 
46. (a) Zhang, M. R.; Kumata, K.; Suzuki, K. Tetrahedron Lett. 2007, 48, 8632; (b) Lee, B. C.; Kim, J. S.; Kim, B. S.; Son, J. 
Y.; Hong, S. K.; Park, H. S.; Moon, B. S.; Jung, J. H.; Jeong, J. M.; Kim, S. E. Bioorg. Med. Chem. 2011, 19, 2980. 
47. (a) Teare, H.; Robins, E. G.; Kirjavainen, A.; Forsback, S.; Sandford, G.; Solin, O.; Luthra, S. K.; Gouverneur, V. Angew. 
Chem., Int. Ed. 2010, 49, 6821; (b) Teare, H.; Robins, E. G.; Arstad, E.; Sajinder, K. L.; Gouverneur, V. Chem. Commun. 
2007, 2330. 
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Given the above considerations, a general method to synthesize 
18
F-labeled aryl fluorides 
employing [
18
F]F
–
 as the source of 
18
F would be a breakthrough in the field of PET imaging. 
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Note: For context, the initial developments of this research project, which preceded my contributions, are 
presented in this chapter (Section 2.1).  Dr. Takeru Furuya and Dan Choi observed the electrophilic nature 
of a Pd(IV)–F complex and used the complex for Pd-mediated C–F bond formation.  Dr. David Powers 
improved the efficiency of C–F bond formation and synthesized Pd(IV)–F complexes from fluoride via 
ligand metathesis.  Dr. Eunsung Lee synthesized and developed the route to the Pd(IV)–F complex from 
fluoride that we use in this research as well as performed the DFT calculations that are alluded to.  Dr. 
Eunsung Lee and I collaborated on the initial transition to radiochemistry (Section 2.3).   
2.1 Design and Synthesis of an Electrophilic Fluorination Reagent 
Derived from Fluoride 
During the course of an investigation into C–F reductive elimination and high-valent 
palladium reactivity, the Ritter Group synthesized a Pd(IV)–F complex containing a 
tetrapyrazolylborate ligand (Figure 2.1).
48
  The complex was synthesized from a Pd(II)–Ar 
complex using a pyridinium fluoride electrophilic fluorination reagent.  C–F reductive 
elimination from the complex was not observed.  However, when treated with 
triphenylphosphine, P–F bond formation was observed, suggesting that a 
                                                          
48. Choi, D. Harvard University 2008. 
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Figure 2.1. Initial observation that a Pd(IV)–F could behave as an electrophilic fluorination reagent. 
Pd(IV)–F could serve as an electrophilic fluorination reagent.  If a Pd(IV)–F could be synthesized 
from fluoride and a Pd(IV) complex through ligand metathesis of an X- or L-type ligand, then 
electrophilic fluorination reactions could be a means to make high specific activity 
18
F-PET 
tracers.  Specifically, 
18
F radiochemistry combined with the general, functional-group-tolerant 
electrophilic fluorination reactions described in Section 1.2 could drastically expand access to 
18
F-PET tracers. 
Previously, the Ritter Group reported the fluorination of palladium aryl complexes with 
the electrophilic fluorination reagent F-TEDA (Figure 1.2).
49
  F-TEDA can oxidize Pd(II)–Ar 
complexes, which subsequently afford aryl fluorides by C–F reductive elimination from 
                                                          
49.  Furuya, T.; Kaiser, H. M.; Ritter, T. Angew. Chem., Int. Ed. 2008, 47, 5993.  
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arylpalladium(IV) fluoride complexes.
50
  Replacement of F-TEDA by a fluorination reagent that 
mimics the function of F-TEDA, but is made from fluoride has the potential for use in the 
synthesis of high specific activity 
18
F radiotracers.  We designed and synthesized an 
organometallic complex made from fluoride (2.1 → 2.2, Equation 2.1) that behaves as an 
electrophilic fluorination reagent, and can use the reagent for the synthesis of small molecules via 
late-stage fluorination. 
 
Palladium complex 2.2 was envisioned to accomplish oxidative fluorine transfer by 
serving as an electrophile in SN2 reactions with nucleophilic attack occurring at the fluorine 
substituent.  The complexes 2.1 and 2.2 were designed based on the following five 
considerations:  i) The palladium center in 2.1 carries three formal positive charges (counter 
charges to two triflate anions and one negatively charged borate ligand) and should therefore 
capture negatively charged fluoride from solution.  High fluorophilicity of the palladium complex 
2.1 is required for radiochemistry applications due to the low effective concentration of fluoride 
in solution (roughly 10
-4
 M).  ii) The palladium centers in 2.1 and 2.2 are in the oxidation state 
+IV (Pd(IV)), a high oxidation state for palladium.  Late transition metals such as palladium, 
when in a high oxidation state, can function as an oxidant and transfer a ligand to a nucleophile, 
                                                          
50. (a) Furuya, T.; Ritter, T. J. Am. Chem. Soc. 2008, 130, 10060; (b) Furuya, T.; Benitez, D.; Tkatchouk, E.; Strom, A. E.; 
Tang, P. P.; Goddard, W. A.; Ritter, T. J. Am. Chem. Soc. 2010, 132, 3793. 
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while being reduced in the process to a lower oxidation state.
51
  The palladium in 2.2 can function 
as an electron acceptor, which rationalizes the reactivity of 2.2 as an oxidant.  iii) The supporting 
benzo[h]quinolyl and tetrapyrazole borate (Tp) ligands are multidentate ligands that were selected 
to impart stability on both 2.1 and 2.2 toward undesired reductive processes such as C–F 
reductive elimination.  Reductive elimination from 2.2 would likely require dissociation of one 
ligand to form a pentacoordinate palladium complex,
50
 and multidentate ligands such as Tp are 
less likely to dissociate and hence reduce the rate of potential reductive elimination.  iv) An 
octahedral Pd(IV) complex was chosen to avoid undesired nucleophilic attack at the transition 
metal.  The Pd–F bond is polarized toward fluorine, with partial negative charge on fluorine and 
positive charge on palladium.  Solely based on coulombic interactions, nucleophilic attack is 
expected at palladium rather than fluorine.  However, the orbitals available for nucleophilic attack 
on octahedral (t2g)
6
(eg)
0
 Pd(IV) complexes, the dx2-y2 and dz2 orbitals, are high in energy, and 
nucleophilic attack on high energy orbitals is disfavored.
52
  v) The multidentate supporting 
ligands in 2.2 feature aromatic substituents to prevent nucleophilic attack on the carbon and 
nitrogen atoms coordinated to palladium.  Complex 2.2 was devised to act as an electrophilic 
fluorination reagent through nucleophilic attack at the antibonding palladium–fluorine-based 
orbital (σ*Pd–F) at fluorine in an SN2 reaction.  In such a putative SN2 reaction, palladium would 
function as a leaving group, with concomitant reduction to the oxidation state +II (Pd(II)).  
Nucleophilic attack would occur at the lowest unoccupied molecular orbital (LUMO) of 2.  The 
calculated LUMO of 2.2 (Figure 2.2), shows that only the lobe on fluorine points into unoccupied 
space; no other LUMO lobe is available for nucleophilic attack because the aromatic ligands 
block the trajectories. 
                                                          
51. Stahl, S. S.; Labinger, J. A.; Bercaw, J. E. Angew. Chem., Int. Ed. 1998, 37, 2181.  
52. Cotton, F. Chemical Applications of Group Theory; 3 ed.; Wiley: New York, 1990.  
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Figure 2.2. X-ray structure and calculated LUMO of 2.2. 
Treatment of the palladium complex 2.1 with nucleophilic fluoride (KF) afforded the 
palladium fluoride complex 2.2 within five minutes in 90% yield (Equation 2.1).  The ability of 
2.2 to function as an electrophilic fluorination reagent was confirmed by fluorination of Pd(II) 
aryl complexes.  Two model substrates with limited functionality were chosen.  Pd(II)–Ar 
complexes 2.3 and 2.4 were treated with one equivalent of 2.2 at 85 °C in acetone in a sealed vial 
for 10 minutes (Figure 2.3)  Aryl fluorides 2.5 and 2.6 were obtained in high yield.  We propose 
that Pd(IV)–F complex 2.2 oxidizes the Pd(II)–Ar complexes by fluorine transfer to form high-
valent arylpalladium(IV) fluoride complexes, from which C–F reductive elimination can occur to 
form aryl fluoride products 2.5 and 2.6.   
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Figure 2.3. Complex 2.2 can behave as an electrophilic reagent in a Pd-mediated fluorination reaction. 
Oxidative fluorine transfer from 2.2 to 2.3, for example, could proceed by SN2 reaction as 
designed, with nucleophilic attack of the dz2-based orbital on palladium of 2.3 on the σ* Pd–F-
based orbital of the LUMO of 2.2, or via electron transfers
53
 from 2.3 to 2.2 with interposed or 
subsequent fluorine transfer.  Current data cannot distinguish between these mechanisms.  In 
addition, other pathways that intercept putative arylpalladium(IV) fluoride intermediates could 
potentially be used for C–F bond formation.  Palladium complex 2.2 is both an oxidant and a 
fluoride donor.  The oxidation equivalents are inherent in the transition metal oxidation state, and 
the fluorine substituent is negatively polarized, because fluorine is the most electronegative 
element.  But oxidation of 2.3 with an external oxidant followed by reaction with an independent 
                                                          
53. (a) Taube, H.; Myers, H. J. Am. Chem. Soc. 1954, 76, 2103; (b) Haim, A. Prog. Inorg. Chem. 1983, 30, 273. 
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fluoride source could also provide arylpalladium(IV) fluoride intermediates.  In such a stepwise 
approach, potential side reactions of putative intermediates, such as undesired reductive 
elimination reactions, must be prevented.  Conceptually, several combinations of an oxidant and a 
fluoride source are conceivable for successful oxidative fluorination. 
Scheme 2.1. Synthesis of electrophilic fluorination reagent 2.2 from fluoride. 
 
Pd(IV)–F was synthesized according to Scheme 2.1.  Cyclometalation using Pd(OAc)2 
with benzo[h]quinoline afforded the palladium dimer 2.7.  Ligand exchange with potassium 
tetrapyrazolylborate (2.8) gave the Pd(II) complex 2.9 that was oxidized to Pd(IV) using 
hypervalent iodine reagent 2.10.  While the oxidation was efficient with 2.10, the 4-
cyanopyridine was subsequently exchanged with picoline to provide a more stable complex 2.1.  
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Pd(IV) complex 2.1 efficiently captures fluoride as described above to give electrophilic 
fluorination reagent 2.2. 
Pd(II)–aryl complexes are synthesized in a modular fashion (Scheme 2.2).49 First, using 
the same palladium dimer 2.7 from Scheme 2.1, chloride for acetate ligand exchange afforded 
2.12, which underwent a nitrene insertion using the oxidant 2.13 of the PhINTs variety.  Pd(II)–
Cl complex 2.14 was then converted into Pd(II)–OAc complex 2.15.  This complex is the direct 
precursor to the Pd(II)–aryl complexes.  Transmetalation of an aryl boronic acids or pinacol esters 
on to the Pd center gives, for example, Pd(II)–aryl 2.3. 
Scheme 2.2. Synthesis of example Pd(II)–Ar complex 2.3. 
 
2.2 Application of New Electrophilic Fluorination Reagent to Late-
Stage Fluorination of Complex Molecules 
The fluorination reagent 2.2 was subsequently evaluated for late-stage fluorination.  
Fluorination of the Pd(II) aryl complexes 2.16–2.18 afforded aryl fluorides 2.19–2.21 in 67–72% 
yield (Figure 2.4).  The parent aryl fluorides (without protecting groups) of the molecules shown 
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in Figure 2.4 were selected in part based on their structure and exhibition of a variety of 
functional groups, akin to potential small-molecule PET tracers.
54
  The molecules are electron-
rich arenes, which would be challenging to prepare by conventional fluorination reactions with 
[
18
F]fluoride.  The protic functional groups of the molecules in Figure 2.4 are masked with 
protecting groups that are quickly removable with exposure to acidic conditions; protection is 
necessary for efficient fluorination.   Currently, arenes that have a non-hydrogen substituent ortho 
to the site of fluorine substitution cannot be used for late-stage fluorination with reagent 2.2.  
Tertiary amines are also not tolerated by the method. 
 
Figure 2.4. Late-stage fluorination of complex small molecules  with 2.2. 
Complex Pd(II)–aryl species such as 2.16–2.18 are prepared from the boronic esters.  For 
                                                          
54. (a) Kozikowski, A. P.; Cho, S. J.; Jensen, N. H.; Allen, J. A.; Svennebring, A. M.; Roth, B. L. ChemMedChem 2010, 5, 
1221; (b) Pomel, V.; Klicic, J.; Covini, D.; Church, D. D.; Shaw, J. P.; Roulin, K.; Burgat-Charvillon, F.; Valognes, D.; 
Camps, M.; Chabert, C.; Gillieron, C.; Francon, B.; Perrin, D.; Leroy, D.; Gretener, D.; Nichols, A.; Vitte, P. A.; Carboni, 
S.; Rommel, C.; Schwarz, M. K.; Ruckle, T. J. Med. Chem. 2006, 49, 3857; (c) Petersen, E. N.; Bechgaard, E.; Sortwell, R. 
J.; Wetterberg, L. Eur. J. Pharmacol. 1978, 52, 115. 
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2.16, a Sandmeyer reaction starting with 2-amino-5-chlorophenol gave aryl iodide 2.22 (Scheme 
2.3).  MOM protection of the phenol afforded 2.23, ready for two successive Pd-catalyzed cross-
coupling reactions.  First, the more reactive C–I bond was used in a Suzuki cross-coupling 
reaction with (5-formylfuran-2-yl)boronic acid to yield 2.24.  Subsequently, the C–Cl bond was 
used in a Pd-catalyzed borylation using modified conditions reported by Buchwald
55
 to install the 
requisite pinacol boronic ester of 2.25.  Knoevenagel reaction with an N-protected 
thiazolidinedione 2.26 led to the entire carbon skeleton.  The thiazolidinedione was protected 
with a dianisylmethyl (DAM) group.  It was discovered that an acidic N–H bond was not 
tolerated during the reaction and needed to be protected.  A protecting group that would remain 
intact during the transmetalation reaction and fluorination reaction and then be easily removed at 
the same time as the MOM group was desired.  The DAM protecting group
56
 satisfied these 
considerations.  Transmetalation of 2.27 on to complex 2.15 gave 2.16 ready for fluorination. 
                                                          
55.  Billingsley, K. L.; Barder, T. E.; Buchwald, S. L. Angew. Chem., Int. Ed. 2007, 46, 5359.  
56. Carlier, P. R.; Zhao, H.; MacQuarrie-Hunter, S. L.; DeGuzman, J. C.; Hsu, D. C. J. Am. Chem. Soc. 2006, 128, 15215.  
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Scheme 2.3. Synthesis of Pd(II)–Ar complex 2.16. 
 
For 2.17, commercially available 5-bromo-2-hydroxybenzaldehyde was alkylated with 
(bromomethyl)cyclopropane to afford 2.28 (Scheme 2.4).  A Horner-Wadsworth-Emmons 
olefination reaction gave 2.29, which was reduced with DIBAL-H to afford allylic alcohol 2.30.  
A Charette asymmetric cyclopropanation using a chiral non racemic dioxaborolane reagent was 
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employed to afford the cyclopropane 2.31 in high yield and high enantiomeric excess (ee).
57
  
Mesylation and displacement with azide gave 2.32.  A one-pot reduction-protection afforded the 
Boc-protected compound 2.33.  Aryl bromide 2.33 could be recrystallized to afford material that 
was greater than 99% ee.  Pd-catalyzed borylation gave 2.34 that was then used in the standard 
transmetalation reaction to afford Pd(II)–aryl complex 2.17. 
Complex 2.18 was synthesized according to Scheme 2.5.  Alkylation of 4-methoxyaniline 
with 1-(4-bromophenyl)-3-chloropropan-1-one gave 2.35.  Acylation, cyclization, and 
decarboxylation gave dihydropyridone 2.36.  Asymmetric conjugate reduction using a method 
developed by Buchwald
58
 led to enantioenriched lactam 2.37.  Claisen reaction was 
diastereoselective giving 2.38 as the only detectable isomer.  Reduction of the ester and amide led 
to alcohol 2.39.  A protecting group swap was needed to ease final deprotection after 
radiofluorination.  As such, the PMP group was removed using CAN and replaced with a Boc 
group in 2.40.  Sesamol was then used as the nucleophile in a Mitsunobu reaction to form aryl 
alkyl ether 2.41.  Borylation to afford 2.42 proceeded smoothly, which was followed by 
transmetalation on to 2.15 under standard conditions to give 2.18. 
                                                          
57. Charette, A. B.; Juteau, H.; Lebel, H.; Molinaro, C. J. Am. Chem. Soc. 1998, 120, 11943. 
58. Hughes, G.; Kimura, M.; Buchwald, S. L. J. Am. Chem. Soc. 2003, 125, 11253. 
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Scheme 2.4. Synthesis of Pd(II)–Ar complex 2.17. 
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Scheme 2.5. Synthesis of Pd(II)–Ar complex 2.18. 
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2.3 Transition from 
19
F Chemistry to 
18
F Radiochemistry 
The transition from 
19
F chemistry to 
18
F chemistry is challenging because the 
concentration of the limiting reagent, fluoride, changes from mM to µM, and syntheses must be 
performed in the presence of ionizing radiation and under a time constraint due to the 110-minute 
half-life of 
18
F.
59
  Therefore, reaction chemistry applicable to 
18
F chemistry must be robust and as 
simple as possible for broad applications in medical imaging.  Organometallic synthesis in a 
hospital setting would be impractical.  However, the palladium complexes discussed here can be 
prepared conveniently on scale, stored, and subsequently transported to imaging sites when 
needed.  The Pd(II)–Ar complexes such as 2.4 and 2.16–2.18 can be purified by chromatography 
or recrystallization and can be stored and transported in air at ambient temperature.  Palladium 
complex 2.1 is stable at room temperature and can be manipulated briefly in air.  Palladium 
complex 2.2 is stable toward heat (no observed decomposition for 24 hours at 100 ºC), and water 
(no observed decomposition in 10% aqueous acetonitrile solution after 3 hours at 23 ºC).  
Thermal stability and tolerance toward water are beneficial for practical PET applications, 
because reaction mixtures are often heated to increase reaction rates and [
18
F]fluoride is made 
from 
18
O-enriched water. 
We devised procedures to adapt our “cold” reaction to “hot” conditions such that the 
synthesis of 
18
F-radiolabeled molecules is operationally simple.  Pd(IV) complex 2.1 reacts with 
conventionally prepared solutions of potassium [
18
F]fluoride in acetone with 18-crown-6 and 
forms the 
18
F-reagent [
18
F]2.2 within 10 minutes (Figure 2.5).  Subsequent filtration over a 
polymer-supported resin and addition of the Pd(II)–Ar complexes such as 2.4 and 2.16–2.18 
afforded, upon heating for 10 minutes, the 
18
F-labeled aryl fluorides [
18
F]2.6 and [
18
F]2.19–2.21, 
                                                          
59.  (a) Fowler, J. S.; Wolf, A. P. Acc. Chem. Res. 1997, 30, 181; (b) Cai, L. S.; Lu, S. Y.; Pike, V. W. Eur. J. Org. Chem. 
2008, 2853. 
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respectively.  Azeotropic drying of aqueous [
18
F]fluoride, the two-step reaction sequence 
(fluoride capture (2.1 → [18F]2.2) followed by fluorine transfer (e.g., 2.4 → [18F]2.6)), results in 
an overall synthesis time of less than 40 minutes.  The efficiency of radiochemical synthesis is 
given in radiochemical yield, which is based on decay-corrected radioactivity rather than on mass 
of isolated material.
60
  Radiochemical yields (RCYs) as high as possible are desired, but even low 
RCYs can provide meaningful amounts of radiolabeled compounds for PET imaging, given 
enough starting [
18
F]fluoride.
61
  The 
18
F-fluorination method described here has afforded RCYs 
higher than 30%. 
 
Figure 2.5. Two-step late-stage radiofluorination of complex small molecules. 
Adapting the “hot” procedures described here to allow for the production of an amount of 
                                                          
60. Miller, P. W.; Long, N. J.; Vilar, R.; Gee, A. D. Angew. Chem., Int. Ed. 2008, 47, 8998.  
61. Chin, F. T.; Namavari, M.; Levi, J.; Subbarayan, M.; Ray, P.; Chen, X. Y.; Gambhir, S. S. Mol.  Imaging Biol. 2008, 10, 
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radioactivity suitable for imaging primates (5–10 mCi of final product per experiment) required 
the use of automation for safety reasons.  Eckert and Ziegler automated synthesis modules were 
programmed to perform the two-step radiochemistry reactions.  First [
18
F]fluoride in water is 
dried in a vial using acetonitrile and then acetone.  Then a solution of Pd(IV) complex 2.1 in 
acetone is added and stirred for 7.5 minutes.  The solution is then passed through a column of the 
polymer-supported resin via positive nitrogen pressure into a new vial containing the Pd(II)–Ar 
complex.  The procedures are modular and any of the Pd(II)–Ar complexes can be used.  After 
washing the first vial and the resin with 2-butanone, the combined organic solutions are heated at 
90 °C for 10 minutes.  The solvent is removed in favor of a mixture of hexanes and ethyl acetate.  
The reaction mixture is passed through a silica column and concentrated.  If,  after the synthesis 
of both [
18
F]2.20 and [
18
F]2.21, for example, a deprotection step is required, it can be 
accomplished by a short exposure to trifluoroacetic acid.  Concentration and dissolving in a 
minimal amount of aqueous acetonitrile followed by purification by HPLC, leads to chemically 
and radiochemically pure radiolabeled aryl fluorides [
18
F]2.43 and [
18
F]2.44 (see Figure 2.6) .  
Reformulation into a sterile saline solution for injection into a subject is then performed.  The 
entire method from end of bombardment (production of 
18
F) through reformulation can take less 
than 100 minutes.   
It should be noted that stoichiometric amounts of precious transition metals such as 
palladium are typically avoided in syntheses of health care products due to toxicity and cost 
considerations.  However, such considerations are different for the synthesis of PET tracers due to 
the small amount that is required.
62
  High-specific activity PET tracers are administered at a dose 
at least two orders of magnitude smaller than is common for pharmaceuticals because 
                                                          
62. Toyohara, J.; Sakata, M.; Wu, J.; Ishikawa, M.; Oda, K.; Ishii, K.; Iyo, M.; Hashimoto, K.; Ishiwata, K. Ann. Nucl. Med. 
2009, 23, 301.  
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pharmacological effects are not sought,
63
 and purification is often straightforward due to the small 
amount of tracer to be purified.  For example, inductively coupled plasma mass spectrometry 
(ICP-MS) analysis of a saline solution of [
18
F]2.43, purified by conventional HPLC technique 
afforded material with less than 5 parts per billion (ppb) palladium residue, commensurate with 
international recommendations on the palladium impurity profile for samples injected into 
humans, which demand less than 1000 ppb palladium.
64
  Similarly, the synthesis cost for the 
palladium complexes is small compared to the cost of 
18
F-isotope infrastructure and the cost 
associated with clinical imaging.
65
 
2.4 PET Imaging in Rats and Baboons Using 
18
F-Aryl Fluorides 
Derived from Pd(IV)–F 
We chose to focus our initial PET imaging experiments on neuroactive molecules.  We 
chose two molecules that are known to interact with the serotonergic system, 2.43 and 2.44 
(Figure 2.6).  Aryl fluoride 2.43 is a selective serotonin 2C receptor subtype (5-HT2C) agonist.
54a
 
To date, 5-HT2C radioligands for autoradiography and 5-HT2C radiotracers for imaging have not 
been described, and our basic understanding of these receptors is deficient.  This is in spite of 
growing associations between the 5-HT2C receptor subtype and brain-related disorders including 
depression
66 
and schizophrenia,
67
 as well as drug abuse,
68
 Parkinson’s disease,69 anxiety,70  and 
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obesity.
71
  Unfortunately, direct links between the diseases listed above and 5-HT2C receptor 
abnormalities have been difficult to discern due to the lack of a method to determine 5-HT2C 
receptor concentration in vivo.  Thus, the development of a selective 5-HT2C PET radiotracer 
could have a transformative impact on neuroscience research in this area. 
Paroxetine (2.44) is a selective serotonin reuptake inhibitor (SSRI), which functions by 
inhibiting the reuptake of presynaptic serotonin.
72
 The synthesis of [
18
F]paroxetine has not been 
previously accomplished.  Its synthesis could allow for the observation of paroxetine interacting 
with the serotonin transporter in vivo using PET imaging.
71
 The ability to study the binding 
properties of paroxetine could provide insight into the interactions between the serotonin 
transporter and small molecules, potentially useful for the development of more potent and 
selective antidepressants.
73
  Importantly, synthesis of [
18
F]2.43 and [
18
F]2.44 would demonstrate 
that 
18
F-labeled versions of CNS active drugs may be accessed more straightforwardly using our 
method, ultimately influencing for the development of pharmaceuticals development with our 
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method. 
 
Figure 2.6. Two small molecules known to interact with the serotonergic system and chosen for PET imaging. 
The syntheses of the required Pd(II)–aryl complexes were described in Section 2.2 and 
the large radioactivity scale reaction procedures via automation were described in Section 2.3.  
Starting with over 1 Ci of radioactive [
18
F]fluoride in water, 14 mCi of [
18
F]2.43 was produced 
after reformulation and [
18
F]2.44 was produced twice, furnishing 16 and 13 mCi after 
reformulation.  The procedures afford an amount of radiolabeled small molecule sufficient for 
imaging non-human primates (~5 mCi) and even humans (~10 mCi).  The specific activities of 
the samples were measured and, at the time of injection, the specific activity was at least 1 
Ci/µmol.  Standard GMP guidelines were followed to test the pH, sterility, pyrogenicity of the 
solutions, and the purity of the radiolabeled molecules.  All tests passed inspection. 
Typically, two anesthetized rats were scanned at a time.  One was administered a dose of 
the unlabeled molecule via a tail vein injection and then both were administered approximately 
300–500 µCi of radiolabeled aryl fluoride.  PET scanning proceeded for 90 minutes followed by 
a CT scan.  Images were reconstructed and biodistribution and pharmacokinetic data of the two 
radiolabeled molecules was obtained. 
For the 5-HT2C agonist, two adult Sprague Dawley rats were anesthetized.  One rat was 
administered via the tail vein 1.0 mg of 2.43 followed by 322 µCi of [
18
F]2.43.  The other rat was 
administered via the tail vein 385 µCi of [
18
F]2.43.  The experiment lasted 90 minutes followed 
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by a CT scan.   
After scanning, the rats were sacrificed and biodistribution determined by measuring the 
radioactivity of various organs.  A normalized summary is shown in Figure 2.7.  In rats, [
18
F]2.43 
was not successfully blocked in the brain by pretreatment with 2.43, suggesting ample 
nonspecific binding. 
 
Figure 2.7. Biodistribution of [
18
F]2.43 in rats. 
With non-human primates, an adult male baboon weighing 7.9 kg was administered 4.47 
mCi of [
18
F]2.43 and scanned for 120 minutes followed by an MRI scan (see Figures 2.8 and 2.9). 
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Figure 2.8. PET/MR scan of [
18
F]2.43 averaged over 120 minutes of upper body of baboon. 
  
 
 
40 
 
Figure 2.9. PET/MR scan of [
18
F]2.43 averaged over 120 minutes of brain of baboon. 
Time activity curves of radioactivity throughout the portions animal and different regions 
of the brain are shown in Figure 2.10.  As expected, there is a large initial spike in the heart and 
lungs due to intravenous injection of [
18
F]2.43 into the baboon. Agonist [
18
F]2.43 efficiently 
crosses the blood-brain barrier (as also seen for rats), but fails to differentiate itself in regions of 
the brain known to have varying amounts of 5-HT2C receptor concentrations.
74
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Figure 2.10. Time activity curves (decay corrected) for [
18
F]2.43 in baboon. 
PET imaging with radiolabeled paroxetine was also performed.  Two adult Sprague 
Dawley rats were anesthetized.  One rat was administered 1.0 mg of 2.44 followed by 522 µCi of 
[
18
F]2.44 via the tail vein.  The other rat was administered 457 µCi of [
18
F]2.44.  Both rats were 
scanned simultaneously for 90 minutes followed by a CT scan. 
The rats were then sacrificed and their organs harvested to determine biodistribution 
of[
18
F]2.44.  Results are summarized in Figure 2.11.  Similarly to 2.43, preadministration of 2.44 
failed to block significantly in the brain.  Non-specific binding is problematic with [
18
F]2.44. 
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Figure 2.11. Biodistribution of [
18
F]2.44 in rats. 
 Radiolabeled paroxetine was also administered to baboons.  An adult baboon weighing 
6.9 kg was intravenously administered 4.4 mCi of [
18
F]2.44 and scanned for 90 minutes followed 
by an MRI scan.  Additionally, an adult baboon weighing 6.6 kg was intravenously administered 
33 mg of citalopram followed by 3.40 mCi of [
18
F]2.44 and scanned for 180 minutes followed by 
an MRI scan.  Data was reconstructed and images data compared between the baseline 
(unblocked) and challenge (pretreated/blocked) experiments.  Figures 2.12 and 2.13 show PET, 
MRI, overlay close ups of the two baboon brain averaged over the respective experiments. 
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Figure 2.12. PET/MR scan of [
18
F]2.44 averaged over 90 minutes of brain of baboon. 
 
Figure 2.13. PET/MR scan of [
18
F]2.44 averaged over 90 minutes of brain of baboon pretreated with citalopram. 
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Similarities between the two experiments despite the challenge are also borne out in time 
activity curves of different regions of the brain (Figures 2.14 and 2.15).  While regions of the 
brain (with large amounts of white matter) like the corpus callosum that would be expected to 
have low uptake of 2.44, do show low uptake, other regions of the baboon brain are not 
differentiated.  For example, effective SERT imaging would show a large ratio for 
thalamus/hypothalamus to cerebellum due to the known densities of SERT in these regions.
75
 
 
 
Figure 2.14. Time activity curves (decay corrected) for [
18
F]2.44 in baboon brain. 
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Figure 2.15. Time activity curves (decay corrected) for [
18
F]2.44 in baboon brain pretreated with citalopram. 
 
In summary, both radiolabeled molecules [
18
F]2.43 and [
18
F]2.44 efficiently crossed the 
blood-brain barrier in rats and baboons.  From imaging and pharmacokinetic analysis, due to non-
specific binding and lack of blocking, these radiolabeled molecules will not find widespread use 
as PET tracers.  The key challenge moving forward will be to use our radiofluorination reaction 
to synthesize molecules that have the potential to have widespread use as PET tracers. 
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3.  CONCLUSION AND OUTLOOK 
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This thesis described the translational research from fundamental organometallic 
observations and experiments to applications in non-human primate molecular PET imaging.   A 
new electrophilic fluorination reagent was discovered that could be used in the late-stage 
fluorination of complex molecules.  Importantly, the electrophilic fluorination reagent can be 
derived from fluoride for the synthesis of high specific activity PET tracers.  We can now access 
18
F-labeled functionalized molecules, which would be particularly difficult to prepare with 
conventional fluorination reactions.  We have advanced the method to the point where we can 
now prepare sufficient amounts of radiolabeled molecules for PET imaging on a primate scale. 
The future goals of this research vary from chemistry advances to medical applications.  
From a fundamental chemistry standpoint, the ability of a Pd(IV) complex to capture fluoride and 
then behave as an electrophilic fluorination reagent is not well understood.  Can other complexes, 
palladium-based or otherwise, act in a similar manner?  A series of tuned electrophilic 
fluorination reagents, each with slightly varying reactivity would be beneficial in order to address 
the diverse substrate scope that is inherent in 
18
F-PET chemistry.  Specifically, a fluorination 
reaction that proceeds in the presence of tertiary amines, and a reaction that can fluorinate arenes 
with ortho substitution to the eventual place of fluorine would drastically widen substrate scope 
and utility.   
Since our power to predict radiolabeled molecules that will become useful PET tracers is 
limited, a means to rapidly access and assess small molecules for use as imaging agents is needed.  
Given current abilities, turning 2.43 and 2.44 into useful PET tracers would require a significant 
amount of time and effort.  We would need to maintain binding interactions with the target while 
modifying the structure to minimize nonspecific binding.  Each derivative would need to be 
synthesized, evaluated in vitro, radiolabeled, and imaged, which is impractical.  More modular 
chemistry and screening methods may be used to overcome this obstacle. 
  
 
 
48 
Finally, the chemistry and radiochemistry is at a point where it can be disseminated 
throughout the PET imaging community in order to reach its full potential.  The procedures to 
produce 
18
F-labeled molecules are reliable and sufficient for use in non-human primate imaging.  
Human imaging is well within reach and where this translation research will have its greatest 
societal impact. 
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4. EXPERIMENTAL FOR CHAPTERS 1–376 
                                                          
76. I thank Dr. Eunsung Lee for performing experiments in the following chapter including the development and synthesis of 
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4.1 Materials and Methods 
All air- and moisture-insensitive reactions were carried out under an ambient atmosphere, magnetically 
stirred, and monitored by thin layer chromatography (TLC) using EMD TLC plates pre-coated with 250 
m thickness silica gel 60 F254 plates and visualized by fluorescence quenching under UV light.  Flash 
chromatography was performed on Dynamic Adsorbents Silica Gel 40–63 m particle size using a forced 
flow of eluent at 0.3–0.5 bar pressure.  All air- and moisture-sensitive manipulations were performed using 
oven-dried glassware, including standard Schlenk and glovebox techniques under an atmosphere of 
nitrogen.  Methylene chloride was purged with nitrogen, dried by passage through activated alumina, and 
stored over 3Å molecular sieves.
77
  Benzene, benzene-d6, diethyl ether, toluene, pentane, dioxane, and THF 
were distilled from deep purple sodium benzophenone ketyl.  Methylene chloride-d2 was dried over CaH2 
and vacuum-distilled.  Acetonitrile and acetonitrile-d3 were dried over P2O5 and vacuum-distilled.  Pyridine 
was dried over CaH2 and distilled.  DMSO was distilled from sodium triphenylmethanide and stored over 
3Å sieves.
78
  Acetone was distilled over B2O3.  MeOH was degassed at –30 ºC under dynamic vacuum (10
-4
 
Torr) for one hour and stored over 3Å sieves.  Anhydrous DMF and dioxane bottles equipped with a 
SureSeal™ were purchased from Sigma Aldrich®. 18-Crown-6 was sublimed.  KF was ground finely and 
dried at 200 ºC under dynamic vacuum (10
-4
 Torr) before use.  Chloroform-d1, D2O, Pd(OAc)2, AgOAc, 
and all other chemicals were used as received.  All deutrated solvents were purchased from Cambridge 
Isotope Laboratories.  Pd(OAc)2, AgOAc, KBH4, and 18-crown-6 were purchased from Strem Chemicals. 
Benzo[h]quinoline was purchased from TCI.  (Diacetoxyiodo)benzene, potassium fluoride, 4-
cyanopyridine, -tetralone, pyrrolidine, p-toluenesulfonic acid, p-methoxybenzenesulfonamide, and F-
TEDA-BF4 (Selectfluor®) were purchased from Sigma-Aldrich®.  Pyrazole, TMSOTf, and trifluoroacetic 
acid were purchased from Oakwood Products.  Soda lime glass bottles were purchased from Qorpak®.  
NMR spectra were recorded on either a Varian Unity/Inova 600 spectrometer operating at 600 MHz for 
1
H 
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acquisitions, a Varian Unity/Inova 500 spectrometer operating at 500 MHz and 125 MHz for 
1
H and 
13
C 
acquisitions, respectively, a Varian Mercury 400 spectrometer operating at 375 MHz and 101 MHz for 
19
F 
and 
13
C acquisitions, respectively, or a Varian Mercury 300 spectrometer operating at 100 MHz for 
11
B 
acquisitions.  Chemical shifts were referenced to the residual proton solvent peaks (
1
H: CDCl3, 7.26; 
C6D6,  7.16; CD2Cl2,  5.32; D2O,  4.79; (CD3)2SO,  2.50; CD3CN,  1.94), solvent 
13
C signals (CDCl3, 
 77.16; C6D6,  128.06; CD2Cl2,  53.84; CD3CN,  1.32, (CD3)2SO,  39.52),
79
 dissolved or external neat 
PhF (
19
F,  –113.15 relative to CFCl3) or dissolved 3-nitrofluorobenzene (–112.0 ppm).  Signals are listed 
in ppm, and multiplicity identified as s = singlet, br = broad, d = doublet, t = triplet, q = quartet, quin = 
quintet, sep = septet, m = multiplet; coupling constants in Hz; integration.  Concentration under reduced 
pressure was performed by rotary evaporation at 25–30 ºC at appropriate pressure.  Purified compounds 
were further dried under high vacuum (0.01–0.05 Torr).  Yields refer to purified and spectroscopically pure 
compounds.  Elemental analysis was performed by Robertson Microlit Laboratories. 
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4.2 Experimental Procedures and Compound Characterization 
Synthesis of Pd(IV) complex 2.1 
Benzo[h]quinolinyl palladium acetate dimer (2.7) 
 
Based on a reported procedure:
80
  To benzo[h]quinoline (1.79 g, 10.0 mmol, 1.00 equiv) in MeOH (100 
mL) in a round-bottom flask open to air at 23 ºC was added Pd(OAc)2 (2.25 g, 10.0 mmol, 1.00 equiv).  
After stirring for 17 hours at 23 ºC, the solid was collected by filtration and washed with MeOH (50 mL) 
and diethyl ether (50 mL) to afford 3.19 g of the title compound as a yellow solid (93% yield).   
NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.80 (dd, J = 5.5, 1.5 Hz, 1H), 7.43 (dd, J = 
8.0, 1.5 Hz, 1H), 7.24–7.18 (m, 3H), 7.08 (dd, J = 7.0, 1.5 Hz, 1H), 6.97 (d, J = 9.0 Hz, 1H), 6.46 (dd, J = 
7.5, 5.0 Hz, 1H), 2.38 (s, 3H).  
13
C NMR (125 MHz, CDCl3, 23 ºC, ): 182.3, 152.9, 148.6, 148.5, 139.7, 
135.0, 132.2, 128.7, 127.6, 127.4, 124.7, 122.6, 121.8, 119.5, 24.9.  These spectroscopic data correspond to 
previously reported data. 
Potassium tetra(1H-pyrazol-1-yl)borate (2.8)  
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Based on a reported procedure:
81
  As solids, KBH4 (7.00 g, 0.130 mol, 1.00 equiv) and pyrazole (44.2 g, 
0.649 mol, 5.00 equiv) were combined in a round-bottom flask equipped with a reflux condenser under a 
N2 atmosphere.  This mixture was heated at 250 ºC for 16 hours.  The melt was then cooled to 23 °C.  The 
residue was dissolved in methanol (200 mL). The solution was added to diethyl ether (600 mL).  A 
precipitate formed that was isolated by filtration.  The precipitate was washed with additional diethyl ether 
(2 × 100 mL), affording 37.6 g of the title compound as a colorless solid (91% yield). 
Melting Point: 248–249 ºC.  NMR Spectroscopy:  1H NMR (600 MHz, D2O, 23 ºC, ): 7.49 (s, 4H), 7.19 
(d, J = 2.0 Hz, 4H), 6.14 (s, 4H).  
13
C NMR (125 MHz, D2O, 23 ºC, ):  138.9, 132.8, 102.4.  
11
B NMR 
(100 MHz, D2O, 23 ºC, ): –1.3.  Mass Spectrometry: LRMS-FIA (m/z): calcd for C12H12BN8 [M – K]ˉ, 
279.1; found, 279.1.  These spectroscopic data correspond to previously reported data (81). 
Benzo[h]quinolinyl (tetrapyrazolylborate)palladium (2.9) 
 
Based on a reported procedure:
82
  To benzo[h]quinolinyl palladium acetate dimer (2.7) (2.11 g, 3.07 mmol, 
1.00 equiv) in a round-bottom flask open to air in THF (120 mL) was added potassium tetra(1H-pyrazol-1-
yl)borate (KBpz4) (2.8) (1.95 g, 6.13 mmol, 2.00 equiv) in one portion at 23 ºC.  The solution was stirred at 
23 °C for 12 hours and then concentrated in vacuo.  The residue was dissolved in CH2Cl2 (200 mL), filtered 
through Celite eluting with additional CH2Cl2 (50 mL), and the solution was concentrated in vacuo.  The 
residual solid was triturated with diethyl ether (100 mL), collected by filtration, and subsequently dried to 
afford 3.28 g of the title compound as a light yellow solid (95%).  
NMR Spectroscopy: 
1
H NMR (400 MHz, CDCl3, 23 ºC, ): 8.50 (d, J = 4.8 Hz, 1H), 8.19 (d, J = 8.6 Hz, 
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1H), 7.95 (br s, 1H), 7.89 (br s, 1H), 7.75 (br s, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.66 (br s, 1H), 7.60 (br s, 
1H), 7.57 (d, J = 7.6 Hz, 1H), 7.48 (d, J = 8.6 Hz, 1H), 7.43 (dd, J = 7.6, 7.6 Hz, 1H), 7.36 (dd, J = 7.0, 5.7 
Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 6.92 (br s, 1H), 6.43 (br s, 2H), 6.29 (br s, 1H), 6.01 (br s, 1H). 
1
H NMR 
(400 MHz, CDCl3, –25 ºC, ): 8.46 (d, J = 5.1 Hz, 1H), 8.10 (d, J = 8.1 Hz, 1H), 7.94 (s, 1H), 7.89 (s, 1H), 
7.75 (s, 1H), 7.67 (d, J = 2.6 Hz, 1H), 7.60 (d, J = 9.0, 1H), 7.55–7.52 (m, 3H), 7.43 (dd, J = 7.5, 7.5 Hz, 
1H), 7.38 (d, J = 6.5 Hz, 1H), 7.37 (s, 1H), 7.33–7.29 (m, 2H), 6.83 (d, J = 2.1, 1H), 6.44 (d, J = 1.7, 2H), 
6.30 (dd, J = 1.9, 1.9 Hz, 1H), 6.05 (s, 1H).  
13
C NMR (125 MHz, CDCl3, 23 ºC, ):  155.5, 152.4, 148.2, 
144.0 (br), 142.4 (br), 141.9 (br), 141.7, 141.1 (br), 137.5, 137.4 (br), 137.0 (br), 135.7 (br), 134.1 (br), 
133.4, 132.1, 129.5, 128.6, 126.9, 123.1, 121.1, 106.3 (br), 106.2 (br), 105.3 (br).  
13
C NMR (101 MHz, 
CDCl3, –25 ºC, ):  155.0, 152.3, 148.0, 144.0, 142.4, 142.1, 141.3, 141.3, 137.5, 137.1, 136.7, 135.7, 
134.0, 133.1, 131.9, 129.1, 128.5, 126.6, 123.1, 123.1, 121.1, 106.5, 106.3, 105.5, 105.2.  Anal: calcd for 
C25H20BN9Pd: C, 53.27; H, 3.58; N, 22.36; found: C, 53.09; H, 3.64; N, 22.17. 
1,1'-(phenyl-λ3-iodanediyl)bis(4-cyanopyridinium) bis(trifluoromethanesulfonate) (2.10) 
 
Based on a reported procedure:
83
  All manipulations were carried out in a dry box under a N2 atmosphere.  
To (diacetoxyiodo)benzene (2.00 g, 6.21 mmol, 1.00 equiv) dissolved in CH2Cl2 (100 mL) in a round-
bottom flask was added TMSOTf (2.83 g, 12.7 mmol, 2.00 equiv) dropwise over 1 minute at 23 °C.  4-
Cyanopyridine (1.29 g, 12.7 mmol, 2.00 equiv) in CH2Cl2 (10 mL) was added to the solution dropwise over 
5 minutes to give a colorless precipitate and the mixture was stirred for 30 min vigorously at 23 °C.  The 
solid was filtered off and washed with CH2Cl2 (3 × 10 mL) and subsequently dried under vacuum to afford 
3.80 g of the title compound as a colorless solid (86%). 
                                                          
83.  Weiss, R.; Seubert, J. Angew. Chem., Int. Ed. Engl. 1994, 33, 891. 
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NMR Spectroscopy:  
1
H NMR (500 MHz, CD3CN, 23 ºC, ): 9.21 (d, J = 5.3 Hz, 4H), 8.74 (d, J = 7.5 Hz, 
2H), 8.11 (d, J = 6.4 Hz, 4H), 7.87 (t, J = 7.5 Hz, 1H), 7.71 (dd, J = 8.0, 8.0 Hz, 2H).  
13
C NMR (125 MHz, 
CD3CN, 23 ºC, ):  150.1, 137.4, 136.8, 134.7, 132.4, 128.8, 124.0, 121.9 (q, J = 319 Hz, triflate), 115.4.  
19
F NMR (375 MHz, CD3CN, 23 ºC, ): –77.5.  Anal: calcd for C20H13F6IN4O6S2: C, 33.82; H, 1.84; N, 
7.89; found: C, 33.63; H, 1.67; N, 7.68. 
Benzo[h]quinolinyl (tetrapyrazolylborate) Pd(IV) 4-cyanopyridine trifluoromethanesulfonate (2.11) 
 
All manipulations were carried out in a dry box under a N2 atmosphere.  To benzo[h]quinolinyl 
(tetrapyrazolylborate)palladium (2.9) (3.00 g, 5.32 mmol, 1.00 equiv) in a round-bottom flask in CH3CN 
(50 mL) at 23 ºC was added 1,1'-(phenyl-3-iodanediyl)bis(4-cyanopyridinium) 
bis(trifluoromethanesulfonate) (2.10) (3.89 g, 5.48 mmol, 1.03 equiv).  After stirring for 30 minutes, the 
reaction mixture was concentrated in vacuo.  The resulting residue was triturated with THF (3 × 30 mL) 
and collected by filtration as a light brown solid.  The solid was re-dissolved in CH3CN (10 mL), and the 
solution was concentrated in vacuo to afford 4.80 g of the title compound as a brown solid (93%).   
NMR Spectroscopy: 
1
H NMR (500 MHz, CD3CN, 23 ºC, ): 9.10 (d, J = 8.6 Hz, 1H), 8.97 (s, 1H), 8.97 (d, 
J = 9.6 Hz, 1H), 8.49 (d, J = 8.5 Hz, 1H), 8.41 (d, J = 9.6 Hz, 1H), 8.39 (d, J = 7.5 Hz, 1H), 8.35 (s, 1H), 
8.26 (d, J = 2.1 Hz, 1H), 8.09 (s, 1H), 8.06 (d, J = 2.1 Hz, 1H), 8.05 (s, 1H), 7.97 (dd, J = 7.0, 7.0 Hz, 1H), 
7.85 (dd, J = 8.0, 8.0 Hz, 1H), 7.77–7.70 (m, 5H), 7.43 (d, J = 2.3 Hz, 1H), 6.86 (s, 1H), 6.82 (dd, J = 2.7, 
2.7 Hz, 1H), 6.80 (s, 1H), 6.21 (d, J = 2.1 Hz, 1H), 6.10 (dd, J = 2.1, 2.1 Hz, 1H).  
13
C NMR (125 MHz, 
CD3CN, 23 ºC):  169.5, 153.5, 152.3, 148.2, 144.5, 144.4, 144.1, 144.0, 142.7, 140.8, 140.4, 140.0, 139.8, 
137.7, 134.0, 133.7, 133.5, 132.0, 131.7, 130.4, 130.3, 128.7, 127.7, 127.0, 121.9 (q, J = 319 Hz, triflate), 
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115.1, 112.2, 110.5, 110.5, 110.4, 109.6.  
19
F NMR (375 MHz, CD3CN, 23 ºC, ): –77.5.  Anal: calcd for 
C33H24BF6N11O6PdS2: C, 41.03; H, 2.50; N, 15.95; found: C, 40.78; H, 2.47; N, 15.67. 
Benzo[h]quinolinyl (tetrapyrazolylborate) Pd(IV) 4-picoline trifluoromethanesulfonate (2.1) 
 
All manipulations were carried out in a dry box under a N2 atmosphere.  To benzo[h]quinolinyl 
(tetrapyrazolylborate) Pd(IV) 4-cyanopyridine trifluoromethanesulfonate (2.11) (5.00 g, 5.16 mmol, 1.00 
equiv) in a round-bottom flask in CH3CN (15 mL) at 23 ºC was added 4-picoline (769 mg, 8.26 mmol, 1.60 
equiv).  After stirring for 2 minutes the reaction mixture was added dropwise over 5 minutes to 200 mL of 
diethyl ether (200 mL) while stirring vigorously at 23 ºC.  The resulting precipitate was collected by 
filtration as a light brown solid.  The solid was re-dissolved in CH3CN (10 mL), and the solution was 
concentrated in vacuo to afford 4.40 g of the title compound as a brown solid (89%).   
NMR Spectroscopy: 
1
H NMR (500 MHz, CD3CN, 23 ºC, ): 9.09 (d, J = 8.5 Hz, 1H), 8.97 (d, J = 8.5 Hz, 
1H), 8.97 (s, 1H), 8.47 (d, J = 9.6 Hz, 1H), 8.40 (d, J = 8.5 Hz, 1H), 8.38 (d, J = 8.6 Hz, 1H), 8.27 (d, J = 
9.6 Hz, 2H), 8.08 (s, 1H), 8.05 (d, J = 2.1 Hz, 1H), 7.98–7.95 (m, 2H), 7.84 (dd, J = 8.1, 8.1 Hz, 1H), 7.73 
(d, J = 8.5 Hz, 1H), 7.40 (d, J = 3.2 Hz, 1H), 7.32 (d, J = 7.5 Hz, 2H), 7.20 (d, J = 6.4 Hz, 2H), 6.85 (dd, J 
= 2.1, 2.1 Hz, 1H), 6.81 (s, 2H), 6.20 (d, J = 2.1 Hz, 1H), 6.09 (dd, J = 2.1, 2.1 Hz, 1H), 2.38 (s, 3H).  
13
C 
NMR (125 MHz, CD3CN, 23 ºC, ):  169.2, 158.7, 152.0, 151.1, 148.5, 144.4, 144.3, 144.1, 143.9, 142.6, 
140.6, 140.2, 139.9, 139.6, 137.7, 134.3, 133.5, 133.4, 131.7, 130.4, 130.2, 130.0, 128.6, 126.9, 121.9 (q, J 
= 319 Hz, triflate), 112.0, 110.3, 110.3, 109.6, 21.2.  
19
F NMR (375 MHz, CD3CN, 23 ºC, ): –77.5.  Anal: 
calcd for C33H27BF6N10O6PdS2: C, 41.50; H, 2.85; N, 14.67; found: C, 41.45; H, 2.72; N, 14.41.  X-ray 
quality crystals were obtained from 1.0 mL CH3CN solution that contained 20 mg of the title compound 
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layered slowly with 0.5 mL diethyl ether at 23 ºC. 
Synthesis of Pd(IV) fluoride complex 2.2 
Benzo[h]quinolinyl (tetrapyrazolylborate) Pd(IV) fluoride trifluoromethanesulfonate (2.2) 
 
In a glove box, to benzo[h]quinolinyl (tetrapyrazolylborate) Pd(IV) 4-picoline trifluoromethanesulfonate 
(2.1) (284 mg, 0.297 mmol, 1.00 equiv) dissolved in CH3CN (15 mL) in a soda lime glass bottle was added 
KF (17.3 mg, 0.297 mmol, 1.00 equiv) and 18-crown-6 (235 mg, 0.891 mmol, 3.00 equiv) in one portion at 
23 ºC.  The bottle was sealed, taken out of the glove box, sonicated at 23 °C for 5 minutes, immersed in an 
oil bath heated at 50 °C for 5 minutes while vigorously stirring the suspension.  CH3CN (10 mL) was added 
to the solution, and the solution was filtered through Celite, eluting with additional CH3CN (10 mL).  The 
filtrate was concentrated in vacuo.  The residue was triturated with THF (3 × 15 mL) and subsequently 
dried in vacuo to afford 195 mg of the title compound as an orange solid (90%). 
NMR Spectroscopy:  
1
H NMR (500 MHz, CD3CN, 23 ºC, ): 9.01 (d, J = 5.3 Hz, 1H), 8.96 (d, J = 8.5 Hz, 
1H), 8.79 (d, J = 3.2 Hz, 1H), 8.32 (s, 2H), 8.29 (d, J = 9.6 Hz, 1H), 8.27 (d, J = 2.1 Hz, 1H), 8.23 (d, J = 
8.6 Hz, 1H), 8.21 (d, J = 8.6 Hz, 1H), 8.16 (s, 1H), 7.97 (d, J = 5.4 Hz, 1H), 7.96 (d, J = 6.4 Hz, 1H), 7.83 
(dd, J = 8.1, 8.1 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 6.79–6.72 (m, 4H), 6.54 (d, J = 2.1 Hz, 1H), 6.11 (s, 1H).  
13
C NMR (125 MHz, DMSO-d6, 23 ºC, ):  165.0, 149.4, 149.2, 149.4, 149.2, 143.4, 143.0, 142.7, 142.7, 
142.2, 138.5, 137.6, 137.6, 137.0, 136.7, 134.8, 132.1, 130.3, 129.6, 127.6, 127.6, 126.4, 120.7 (q, J = 323 
Hz, triflate), 109.9, 109.6, 108.5, 108.5.  
19
F NMR (375 MHz, CD3CN, 23 ºC, ): –77.5 (s), –319.5 (s).  
Anal: calcd for C26H20BF4N9O3PdS: C, 42.67; H, 2.75; N, 17.23; found: C, 42.95; H, 2.95; N, 17.04.  X-ray 
quality crystals were obtained from 4 mL CH3CN solution that contained 20.0 mg of the title compound 
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slowly layered with 3.0 mL diethyl ether at 23 ºC. 
Thermal stability of 2.2: 2.2 was placed in a vial and heated for 24 hours at 100 ºC under dynamic vacuum 
(10
-4
 Torr).  The solid was analyzed by 
1
H and 
19
F NMR spectroscopy, and showed no decomposition.  
Tolerance of 2.2 toward water: 2.4 mg of 2.2 (3.3 mol) and THF (2.0 L) (internal standard) were 
dissolved in CD3CN (0.55 mL) in an NMR tube.  D2O (61 L) was added to the solution.  The solution was 
kept at +23 ºC for 3 hours and monitored by 
1
H and 
19
F NMR spectroscopy, which showed no 
decomposition (Figure 4.1). 
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Figure 4.1. NMR Spectra of 2.2 in 10% aqueous acetonitrile solution. 
  
 
 
60 
Synthesis of aryl palladium complexes (2.3–2.4 and 2.16–2.18) 
Benzo[h]quinolinyl palladium chloro dimer (2.12) 
 
Based on a reported procedure:
84
  To benzo[h]quinolinyl palladium acetate dimer (2.7) (4.27 g, 12.4 mmol, 
1.00 equiv) in a round-bottom flask open to air in EtOH (100 mL) at 0 ºC was added lithium chloride (10.5 
g, 24.8 mmol, 20.0 equiv).  The reaction mixture was warmed to 23 ºC and stirred for 1.0 hours.  The 
reaction mixture was filtered and the filter cake was washed with water (3 × 100 mL), MeOH (2 × 100 
mL), and diethyl ether (100 mL) to afford 3.89 g of the title compound as a pale yellow solid (98% yield).   
NMR Spectroscopy: 
1
H NMR (500 MHz, DMSO-d6, 23 ºC, δ):  9.44 (d, J = 4.5 Hz, 1H), 8.72 (br, 0.25H), 
8.67 (d, J = 7.5 Hz, 1H), 8.61 (br, 0.25H), 8.22 (d, J = 7.0 Hz, 1H), 7.91 (d, J = 9.0 Hz, 1H), 7.86–7.74 (m, 
3H), 7.73 (br, 0.25H), 7.60 (br, 0.25H), 7.53 (dd, J = 7.5, 7.0 Hz 1H), 7.38 (br, 0.25H); 
13
C NMR (125 
MHz, DMSO-d6, 23 ºC, δ):  153.9, 152.2, 150.7, 150.6, 148.0, 141.7, 139.9, 134.4, 130.8, 129.6, 129.4, 
127.5, 125.1, 124.4, 123.0, 122.9. Note: The complicated 
1
H and 
13
C NMR spectra are probably due to a 
mixture of the title compound and solvent adduct in DMSO-d6.  The title compound was not soluble in non-
coordinating solvents. 
[{(4-Methoxyphenyl)sulfonyl}imino]phenyliodinane (2.13) 
 
                                                          
84. Hartwell, G. E.; Lawrence, R. V.; Smas, M. J. J. Chem. Soc. D Chem. Comm. 1970, 912.  
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Based on a reported procedure:
85
:  To p-methoxybenzenesulfonamide (5.00 g, 26.7 mmol, 1.00 equiv) in a 
round-bottom flask open to air in methanol (100 mL) at 23 ºC was added potassium hydroxide (3.75 g, 66.8 
mmol, 2.50 equiv).  The reaction mixture was stirred at 23 ºC for 10 minutes and subsequently cooled to 0 
ºC. To the reaction mixture at 0 ºC was added iodobenzene diacetate (8.60 g, 26.7 mmol, 1.00 equiv). The 
reaction mixture was stirred at 0 ºC for 10 minutes and further stirred at 23 ºC for 2.0 hours. The reaction 
mixture was poured into cold water (700 mL) and kept at 0 ºC for 4 hours.  The suspension was filtered and 
the filter cake was washed with water (2 × 200 mL) and methanol (2 × 200 mL) to afford 7.90 g of the title 
compound as a colorless solid (76% yield).   
NMR Spectroscopy: 
1
H NMR (500 MHz, DMSO-d6, 23 ºC, δ): 7.70 (d, J = 7.5 Hz, 2H), 7.49–7.44 (m, 3H), 
7.32–7.28 (m, 2H), 6.78 (d, J = 8.5 Hz, 2H), 3.74 (s, 3H). 13C NMR (125 MHz, DMSO-d6, 23 ºC, δ): 160.6, 
136.9, 133.2, 130.5, 130.2, 128.0, 117.0, 113.4, 55.4. These spectroscopic data correspond to previously 
reported data.
86
  
Chloro palladium complex 2.14 
 
Based on a reported procedure:
87
  In a glove box under a N2 atmosphere, to chloropalladium dimer 2.12 
(6.00 g, 18.7 mmol, 1.00 equiv) in a round-bottom flask in CH3CN (100 mL) at 23 ºC was added pyridine 
(6.06 mL, 75.0 mmol, 4.00 equiv) and [{(4-methoxyphenyl)sulfonyl}imino]phenyliodinane (2.13) (10.9 g, 
28.1 mmol, 1.50 equiv).  The reaction mixture was stirred at 23 ºC for 48 hours and subsequently taken out 
                                                          
85. Muller, P.; Baud, C.; Jacquier, Y. Can. J. Chem. 1998, 76, 738. 
86. Taylor, S.; Gullick, J.; McMorn, P.; Bethell, D.; Page, P. C. B.; Hancock, F. E.; King, F.; Hutchings, G. J. J.Chem. Soc. 
Perk. Trans. 2 2001, 1714.  
87. Dick, A. R.; Remy, M. S.; Kampf, J. W.; Sanford, M. S. Organometallics 2007, 26, 1365.  
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of the glove box.  The reaction mixture was filtered and the filter cake was washed with diethyl ether (3 × 
30 mL) to afford 9.70 g of the title compound as a yellow solid (86% yield).   
NMR Spectroscopy:  
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 9.21 (dd, J = 5.2, 1.5 Hz, 1H), 9.01–8.99  (m, 
2H), 8.08 (dd, J = 7.9, 1.8 Hz, 1H), 7.88–7.73 (m, 5H), 7.47–7.43 (m, 3H), 7.35 (dd, J = 7.9, 5.5 Hz, 1H), 
7.11–7.08 (m, 2H), 6.19–6.15 (m, 2H), 3.56 (s, 3H); 13C NMR (125 MHz, CDCl3, 23 ºC, ):  160.9, 154.2, 
152.6, 141.9, 139.0, 138.6, 138.4, 136.0, 134.3, 130.4, 129.8, 128.4, 128.1, 127.7, 126.8, 125.6, 125.0, 
124.2, 122.1, 112.4, 55.4. 
Acetato palladium complex 2.15 
 
To chloro palladium complex 2.14 (5.00 g, 8.34 mmol, 1.00 equiv) in a round-bottom flask fitted with a 
reflux condenser open to air in CH2Cl2 (300 mL) at 23 ºC was added AgOAc (4.87 g, 29.2 mmol, 3.50 
equiv).  The suspension was stirred at 40 ºC for 3 hours. After cooling to 23 ºC, the suspension was filtered 
through a plug of Celite, eluting with additional CH2Cl2 (50 mL).  The filtrate was concentrated in vacuo 
and the residue was triturated with diethyl ether (100 mL).  The solid was collected by filtration and 
washed with diethyl ether (2 × 50 mL) to afford 5.07 g of the title compound as a yellow solid (95% yield). 
NMR Spectroscopy:  
1
H NMR (500 MHz, CDCl3, 23 ºC, ):  8.93 (d, J = 5.5 Hz, 2H), 8.70 (d, J = 5.5 Hz, 
1H), 8.01 (d, J = 7.9 Hz, 1H), 7.83 (d, J = 6.7 Hz, 1H), 7.80 (t, J = 7.6 Hz, 1H), 7.74–7.68 (m, 3H), 7.41–
7.36 (m, 3H), 7.27 (dd, J = 7.6, 5.2 Hz, 1H), 7.15 (d, J = 8.5 Hz, 2H), 6.13 (d, J = 8.5 Hz, 2H), 3.48 (s, 3H), 
1.78 (s, 3H); 
13
C NMR (125 MHz, CDCl3, 23 ºC, ):  177.4, 160.7, 151.6, 151.2, 141.7, 139.0, 138.4, 
138.2, 135.8, 134.4, 130.1, 129.9, 128.9, 128.1, 127.3, 126.7, 125.5, 124.8, 124.0, 121.8, 112.3, 55.2, 23.8.  
Anal: calcd for C27H23N3O5PdS: C, 53.34; H, 3.81; N, 6.91; found: C, 53.31; H, 3.69; N, 6.89. 
Aryl palladium complex 2.3 
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To acetato palladium complex 2.15 (0.550 g, 0.996 mmol, 1.00 equiv) in a round-bottom flask open to air 
in MeOH (10 mL) and benzene (10 mL) at 23 ºC was added (3-benzyloxyphenyl)boronic acid (0.268 g, 
1.18 mmol, 1.30 equiv) and K2CO3 (0.188 g, 1.36 mmol, 1.50 equiv).  The reaction mixture was stirred at 
23 ºC for 10 hours and then concentrated in vacuo.  To the solid residue was added CH2Cl2 (80 mL) and the 
solution was filtered through Celite, eluting with additional CH2Cl2 (30 mL). The solution was washed with 
water (3 × 20 mL), dried with Na2SO4, and concentrated in vacuo.  The residue was recrystallized by 
dissolving the solid in CH2Cl2 (10 mL) and layering with pentane (100 mL).  After 3 hours, the solid was 
collected by filtration to afford 624 mg of the title compound as a yellow solid (94% yield). 
NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ):  8.96 (d, J = 4.9 Hz, 2H), 8.30 (dd, J = 5.5, 1.2 
Hz, 1H), 7.90 (d, J = 7.9 Hz, 1H), 7.69–7.57 (m, 5H), 7.32 (d, J = 8.5 Hz, 1H), 7.27–7.20 (m, 7H), 7.09 (d, 
J = 8.5 Hz, 2H), 6.95 (dd, J = 7.3, 5.5 Hz, 1H), 6.69 (t, J = 7.6 Hz, 1H), 6.54 (d, J = 1.8 Hz, 1H), 6.50 (d, J 
= 7.3 Hz, 1H), 6.44 (dd, J = 7.9, 1.8 Hz, 1H), 6.14 (d, J = 8.5 Hz, 2H), 4.85 (d, J = 12.2 Hz, 1H), 4.79 (d, J 
= 12.2 Hz, 1H), 3.49 (s, 3H); 
13
C NMR (125 MHz, CDCl3, 23 ºC, ):  160.1, 158.1, 156.4, 153.8, 153.2, 
144.7, 143.4, 137.6, 137.5, 136.2, 136.1, 130.0, 129.8, 128.5, 127.7, 127.7, 127.6, 127.4, 127.3, 127.1, 
127.1, 124.8, 124.1, 123.5, 121.1, 120.7, 112.2, 109.9, 69.5, 55.2. Anal: calcd for C38H31N3O4PdS: C, 
62.34; H, 4.27; N, 5.74; found: C, 62.42; H, 4.19; N, 5.72.  X-ray quality crystals were obtained from the 
saturated MeOH solution of the title compound at 23 ºC. 
Aryl palladium complex 2.4 
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3-Pinacolatoboroestra-1,3,5-(10)-triene-17-one was prepared by modification of a published method:
88
  To 
a mixture of 3-(trifluoromethanesulfonyl)estrone (11.0 g, 27.3 mmol, 1.00 equiv) and Pd(dppf)Cl2
.
CH2Cl2 
(1.12g, 1.37 mmol, 0.0500 equiv) in a round-bottom flask in dioxane (100 ml) under a N2 atmosphere were 
added Et3N (22.9 ml, 16.6 g, 164 mmol, 6.00 equiv) and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (11.5 ml, 
10.1 g, 79.0 mmol, 2.89 equiv).
89
  The reaction mixture was heated at 100 °C for 20 hours while stirring.  
The reaction mixture was cooled to 23 ºC and concentrated in vacuo.  The residue was dissolved in 
EtOAc/hexanes (1:3 (v/v), 100 mL) and the solution was filtered through a pad of silica gel to remove 
palladium residue, eluting with additional EtOAc/hexanes (1:3 (v/v), 50 mL).  The filtrate was concentrated 
in vacuo and the residue was washed with cold (–15 ºC) pentane (3 × 10 mL) to afford 8.30 g of 3-
pinacolatoboroestra-1,3,5-(10)-triene-17-one as a colorless solid (80% yield). 
NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ):  7.60 (d, J = 7.8 Hz, 1H), 7.57 (s, 1H), 7.32 (d, 
J = 7.8 Hz, 1H), 2.95–2.88 (m, 2H), 2.53–2.44 (m, 2H), 2.35–2.29 (m, 1H), 2.18–1.95 (m, 4H), 1.67–1.40 
(m, 6H), 1.34 (s, 12 H), 0.91 (s, 3H).  
13
C NMR (125 MHz, CDCl3, 23 ºC, ): 220.8, 143.2, 135.9, 135.6, 
132.2, 124.8, 83.7, 50.6, 48.0, 44.8, 38.1, 35.9, 31.7, 29.2, 26.5, 25.7, 24.9, 24.9, 21.7, 13.9. 
To acetato palladium complex 2.15 (1.00 g, 1.64 mmol, 1.00 equiv) in a round-bottom flask in MeOH (30 
mL) and benzene (30 mL) under a N2 atmostphere at 23 ºC were added 3-pinacolatoboroestra-1,3,5-(10)-
triene-17-one
 
 (0.625 g, 1.64 mmol, 1.00 equiv) and K2CO3 (0.340 g, 2.47 mmol, 1.50 equiv).  The reaction 
                                                          
88. Ahmed, V.; Liu, Y.; Silvestro, C.; Taylor, S. D. Bioorgan.Med. Chem. 2006, 14, 8564.  
89. Furuya, T.; Strom, A. E.; Ritter, T. J. Am. Chem. Soc. 2009, 131, 1662. 
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mixture was stirred at 23 ºC for 20 hours, and then concentrated in vacuo.  To the solid residue was added 
CH2Cl2 (100 mL) and the solution was filtered through Celite, eluting with additional CH2Cl2 (50 mL). The 
solution was washed with water (3 × 20 mL), dried with Na2SO4, and concentrated in vacuo.  The residue 
was recrystallized by dissolving the solid in CH2Cl2 (20 mL) and layering with pentane (100 mL).  After 6 
hours, the solid was collected by filtration to afford 1.22 g of the title compound as a yellow solid (92% 
yield).   
NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ):  9.04 (d, J = 5.3 Hz, 2H), 8.37 (dd, J = 4.3, 4.3 
Hz, 1H), 7.98 (dd, J = 7.5, 2.1 Hz, 1H), 7.75–7.60 (m, 5H), 7.39 (d, J = 8.6 Hz, 1H), 7.31 (dd, J = 7.0, 7.0 
Hz, 2H), 7.11 (d, J = 8.6 Hz, 2H), 7.08–7.06 (m, 1H), 6.68 (dd, J = 7.5, 4.3 Hz, 1H), 6.55–6.49 (m, 2H), 
6.18 (d, J = 8.6 Hz, 2H), 3.54 (s, 3H), 2.72–2.51 (m, 2H), 2.46 (dd, J = 19.1, 10.8 Hz, 1H), 2.26–2.24 (m, 
1H), 2.15–2.06 (m, 2H), 2.02–1.97 (m, 1H), 1.88–1.85 (m, 2H), 1.60–1.22 (m, 6H), 0.86 (s, 3H); 13C NMR 
(125 MHz, CDCl3, 23 ºC, ):  221.3, 160.2, 154.2, 154.2, 153.4, 151.9, 144.9, 143.6, 137.5, 137.4, 136.3, 
136.2, 135.3, 135.2, 134.6, 134.5, 132.3, 132.2, 130.1, 129.9, 127.8, 127.7, 127.6, 127.3, 127.2, 124.8, 
124.8, 124.1, 123.5, 123.4, 123.4, 121.2, 121.1, 112.2, 55.3, 50.7, 50.7, 48.2, 44.3, 44.3, 38.3, 36.0, 31.8, 
29.4, 26.9, 26.8, 25.7, 25.6, 21.7, 14.1, 14.0. Anal: calcd for C43H41N3O4PdS: C, 64.37; H, 5.15; N, 5.24; 
found: C, 64.06; H, 5.21; N, 5.21. 
5-Chloro-2-iodophenol (2.22) 
 
Caution:  While no incident occurred, diazotation of aniline derivatives is dangerous and should be 
conducted with care using explosion safety equipment like a blast shield.   
A round-bottom flask open to air was charged with dimethylsulfoxide (DMSO) (150 mL) and cooled in an 
ice-water bath so that the solvent partly solidified.  Separately, concentrated sulfuric acid (45 mL) was 
mixed with 105 mL H2O.  The resulting 30% sulfuric acid solution was added to the DMSO at 0 ºC.  To the 
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solution was then added 2-amino-5-chlorophenol (4.50 g, 31.3 mmol, 1.00 equiv) with vigourous stirring 
followed by a solution of H2O (15 mL) containing sodium nitrite (3.24 g, 47.0 mmol, 1.50 equiv).  The 
reaction mixture was stirred at 0 ºC for 1 hour.  Sodium iodide (14.1 g, 93.9 mmol, 3.00 equiv) dissolved in 
H2O (15 mL) was added dropwise over 5 minutes at 0 ºC.  The ice-water bath was removed, and the 
reaction mixture was allowed to warm to 23 ºC and stirred for 1 hour.  An additional portion of sodium 
iodide (14.1 g, 93.9 mmol, 3.00 equiv) dissolved in H2O (15 mL) was added dropwise over 5 minutes.  The 
reaction mixture was stirred at 23 ºC for 1 hour.  The reaction mixture was transferred to a separatory 
funnel.  EtOAc (800 mL) and brine (150 mL) were added to the separatory funnel, which was shaken and 
the organic phase collected.  The organic phase was washed with brine (200 mL), 10% NaHSO3 aqueous 
solution (300 mL), and brine (150 mL).  The organic phase was dried with Na2SO4 and concentrated in 
vacuo.  The residue was purified by chromatography on silica gel, eluting with a gradient of 10–20% 
EtOAc in hexanes to afford 4.75 g of the title compound as a colorless oil (60% yield).  
Rf  = 0.25 (hexanes/EtOAc 9:1 (v/v)).  NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.56 (d, 
J = 8.3 Hz, 1H), 7.01 (d, J = 2.5 Hz, 1H), 6.70 (dd, J = 8.8, 2.4 Hz, 1H), 5.32 (s, 1H). 
13
C NMR (125 MHz, 
CDCl3, 23 ºC, ): 155.7, 138.8, 136.0, 122.9, 115.7, 83.2. HRMS-FIA (m/z): calcd for C6H5ClIO [M + H]
+
, 
254.9074; found, 254.9077. 
4-Chloro-1-iodo-2-(methoxymethoxy)benzene (2.23)  
 
To 5-chloro-2-iodophenol (2.22) (2.40 g, 9.43 mmol, 1.00 equiv) in CH2Cl2 (10 mL) in an oven-dried 
round-bottom flask under a N2 atmosphere at 0 ºC was added N,N-diisopropylethylamine (DIPEA) (1.34 g, 
1.81 mL, 10.4 mmol, 1.10 equiv) followed by the dropwise addition of chloromethyl methyl ether 
(MOMCl) (835 mg, 0.788 mL, 10.4 mmol, 1.10 equiv).  The reaction mixture was stirred at 23 ºC for 30 
minutes.  The reaction mixture was allowed to warm to 23 ºC and stirred for an additional 2 hours.   The 
reaction mixture was then poured onto a saturated NH4Cl aqueous solution (100 mL) in a separatory funnel.  
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The funnel was shaken and the organic phase collected.  The organic phase was washed with H2O (50 mL) 
and then brine (25 mL).  The organic phase was dried with Na2SO4 and concentrated in vacuo.  The residue 
was purified by chromatography on silica gel, eluting with a gradient of 5–8% EtOAc in hexanes to afford 
2.59 g of the title compound as a colorless oil (92% yield).  
Rf  = 0.55 (hexanes/EtOAc 9:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.67 (d, 
J = 8.2 Hz, 1H), 7.09 (d, J = 2.3 Hz, 1H), 6.77 (dd, J = 8.2, 2.3 Hz, 1H), 5.23 (s, 2H), 3.51 (s, 3H). 
13
C 
NMR (125 MHz, CDCl3, 23 ºC, ): 156.8, 139.9, 135.3, 123.9, 115.6, 95.2, 84.5, 56.7. HRMS-FIA (m/z): 
calcd for C8H8ClINaO2 [M + Na]
+
, 320.9155; found, 320.9185. 
5-(4-Chloro-2-(methoxymethoxy)phenyl)furan-2-carbaldehyde (2.24)  
 
A Schlenk tube was charged with (5-formylfuran-2-yl)boronic acid (839 mg, 6.00 mmol, 1.50 equiv) and 
Na2CO3 (848 mg, 8.00 mmol, 2.00 equiv).  A 6:1 solution of DME:H2O (v/v) (28 mL) was added followed 
by 4-chloro-1-iodo-2-(methoxymethoxy)benzene (2.23) (1.19 g, 4.00 mmol, 1.00 equiv).  The reaction 
mixture was degassed via two consecutive freeze/pump/thaw cycles.  The Schlenk tube was then refilled 
with N2.  Pd(OAc)2 (44.9 mg, 0.200 mmol, 0.0500 equiv) and tri-o-tolylphosphine (122 mg, 0.400 mmol, 
0.100 equiv) were added.  The reaction mixture was degassed again via two consecutive freeze/pump/thaw 
cycles.  The Schlenk tube was then refilled with N2 and immersed in an oil bath heated to 85 ºC for 3.25 
hours.  The reaction mixture was cooled and filtered through a plug consisting of a bottom layer of Celite 
and a top layer of NaHCO3 eluting with EtOAc (100 mL).  The solution was concentrated in vacuo, and the 
residue was purified by chromatography on silica gel, eluting with a gradient of 10–33% EtOAc in hexanes 
to afford 927 mg of the title compound as a white/beige solid (87% yield).  
Rf  = 0.20 (hexanes/EtOAc 3:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 9.65 (s, 
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1H), 7.95 (d, J = 8.7 Hz, 1H), 7.32 (d, J = 3.7 Hz, 1H), 7.24 (d, J = 1.8 Hz, 1H), 7.11–7.08 (m, 2H), 5.32 (s, 
2H), 3.51 (s, 3H). 
13
C NMR (125 MHz, CDCl3, 23 ºC, ): 177.3, 155.1, 154.8, 151.2, 136.2, 128.3, 123.8, 
122.5, 117.4, 115.3, 112.7, 94.7, 56.7. HRMS-FIA (m/z): calcd for C13H11ClNaO4 [M + Na]
+
, 289.0244; 
found, 289.0249. 
5-(2-(Methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)furan-2-carbaldehyde 
(2.25)  
 
Based on a reported procedure for the conversion of aryl chlorides to aryl pinacol boronic esters:
90
 An 
oven-dried Schlenk tube was charged with 5-(4-chloro-2-(methoxymethoxy)phenyl)furan-2-carbaldehyde 
(2.24) (600. mg, 2.25 mmol, 1.00 equiv), bis(pinacolato)diboron (1.71 g, 6.75 mmol, 3 equiv), potassium 
phosphate (1.43 g, 6.75 mmol, 3 equiv), Pd(OAc)2 (20.2 mg, 0.0900 mmol, 0.0400 equiv), and 
dicyclohexyl(2',6'-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine (SPhos) (92.0 mg, 0.225 mmol, 0.100 equiv).  
Three times, the Schlenk tube was evacuated and refilled with N2.  Dioxane (4.5 mL) was added and the 
reaction mixture was heated with vigorous stirring at 80 ºC for 2.75 hours.  The green suspension was 
cooled and filtered through Celite rinsing with EtOAc (25 mL).  The yellow solution was concentrated in 
vacuo and the residue was purified by chromatography on silica gel, eluting with a gradient of 10–25% 
EtOAc in hexanes to afford 625 mg of the title compound as a white/beige solid (78% yield).  
Rf  = 0.20 (hexanes/EtOAc 5:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 9.68 (s, 
1H), 8.05 (d, J = 7.3 Hz, 1H), 7.55–7.53 (m, 2H), 7.34 (d, J = 3.7 Hz, 1H), 7.22 (d, J = 3.7 Hz, 1H), 5.39 (s, 
2H), 3.52 (s, 3H), 1.36 (s, 12H). 
13
C NMR (125 MHz, CDCl3, 23 ºC, ): 177.4, 156.0, 153.7, 151.2, 128.4, 
                                                          
90. Billingsley, K. L.; Barder, T. E.; Buchwald, S. L. Angew. Chem., Int. Ed. 2007, 46, 5359.  
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126.8, 123.9, 121.1, 119.9, 113.4, 94.4, 84.2, 56.7, 25.0. HRMS-FIA (m/z): calcd for C19H24BO6 [M + H]
+
, 
359.1666; found, 359.1666. 
3-(Bis(4-methoxyphenyl)methyl)thiazolidine-2,4-dione (2.26)  
 
To thiazolidine-2,4-dione (250. mg, 2.13 mmol, 1.00 equiv) in an oven-dried round-bottom flask in THF 
(10 mL) under a N2 atmosphere was added hexamethylphosphoramide (HMPA) (2.29 g, 2.23 mL, 12.8 
mmol, 6.00 equiv).  The reaction mixture was cooled to 0 ºC in an ice-water bath.  Sodium hydride (128 mg 
(60% by weight in mineral oil), 3.2 mmol, 1.5 equiv) was added in one portion, which was accompanied by 
foaming.  The reaction mixture was stirred for 15 minutes at 0 ºC.  4,4'-
(bromomethylene)bis(methoxybenzene) (1.05 g, 3.42 mmol, 1.60 equiv) was added at 0 ºC.  The reaction 
mixture was stirred for 2 hours at 0 ºC.  Saturated aqueous NH4Cl solution (10 mL) was then added 
followed by H2O (10 mL).  The reaction mixture was transferred to a separatory funnel, diluted with 
CH2Cl2 (30 mL), shaken, and partitioned.  The aqueous phase was extracted from with CH2Cl2 (2 × 30 mL).  
The organic phases were combined and dried with Na2SO4, concentrated in vacuo, and the residue was 
purified by chromatography on silica gel, eluting with a gradient of 0–5% MeOH in CH2Cl2 to afford 590. 
mg of the title compound as a colorless solid (80% yield).  
Rf  = 0.35 (hexanes/EtOAc 3:1 (v/v)). NMR Spectroscopy: 
1
H NMR (600 MHz, CDCl3, 23 ºC, ): 7.26–
7.24 (m, 4H), 6.88–6.85 (m, 4H), 6.59 (s, 1H), 3.93 (s, 2H), 3.80 (s, 6H). 13C NMR (125 MHz, CDCl3, 23 
ºC, ): 171.5, 171.4, 159.4, 130.0, 129.2, 113.9, 60.6, 55.4, 33.6. HRMS-FIA (m/z): calcd for 
C18H17NNaO4S [M + Na]
+
, 366.0776; found, 366.0745. 
(Z)-3-(Bis(4-methoxyphenyl)methyl)-5-((5-(2-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-
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dioxaborolan-2-yl)phenyl)furan-2-yl)methylene)thiazolidine-2,4-dione (S19)  
 
To 3-(bis(4-methoxyphenyl)methyl)thiazolidine-2,4-dione (2.26) (537 mg, 1.56 mmol, 1.00 equiv) 
suspended in ethanol (10 mL) in a round-bottom flask open to air was added 5-(2-(methoxymethoxy)-4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)furan-2-carbaldehyde (2.25) (560. mg, 1.56 mmol, 
1.00 equiv) and piperidine (106 mg, 0.124 mL, 1.25 mmol, 0.800 equiv).  The round-bottom flask was 
fitted with a reflux condenser and submerged in an 80 ºC oil bath for 1 hour.  Upon cooling, a bright yellow 
solid precipitated which was collected by filtration and washed with hexanes (20 mL) to afford 825 mg of 
the title compound as a bright yellow solid (77% yield). 
Rf  = 0.30 (hexanes/EtOAc 3:1 (v/v)). NMR Spectroscopy: 
1
H NMR (600 MHz, CDCl3, 23 ºC, ): 7.91 (d, 
J = 7.6 Hz, 1H), 7.63 (s, 1H), 7.57 (d, J = 7.9 Hz, 1H), 7.54 (s, 1H), 7.31–7.29 (m, 4H), 7.21 (d, J = 3.7, 
1H), 6.90–6.86 (m, 5H), 6.75 (s, 1H), 5.39 (s, 2H), 3.81 (s, 6H), 3.51 (s, 3H), 1.35 (s, 12H). 13C NMR (125 
MHz, CDCl3, 23 ºC, ): 168.7, 166.1, 159.3, 154.9, 153.1, 148.6, 130.0, 129.6, 128.7, 126.1, 121.3, 120.7, 
119.9, 119.4, 118.2, 114.5, 113.9, 94.4, 84.2, 60.3, 56.8, 55.4, 25.0.  HRMS-FIA (m/z): calcd for 
C37H38BNNaO9S [M + Na]
+
, 706.2258; found, 706.2253.  
Palladium aryl complex 10  
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To (Z)-3-(bis(4-methoxyphenyl)methyl)-5-((5-(2-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)furan-2-yl)methylene)thiazolidine-2,4-dione (2.27) (100. mg, 0.146 mmol, 1.00 
equiv) in a round-bottom flask open to air in a 1:1 solution PhH:MeOH (4 mL) was added palladium 
acetate complex 2.15 (98.0 mg, 0.161 mmol, 1.10 equiv) and potassium carbonate (30.3 mg, 0.219 mmol, 
1.50 equiv).  The suspension was stirred at 23 ºC for 3.5 hours.  The reaction mixture was filtered through 
microfiber filter paper eluting with CH2Cl2 (10 mL).  The solution was concentrated in vacuo and the 
residue was purified by chromatography on silica gel, eluting with a gradient of 33–90% EtOAc in hexanes 
to afford 110. mg of the title compound as a bright yellow solid (68% yield).  
Rf = 0.25 (hexanes/EtOAc 1:5 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CD2Cl2, 23 ºC, ): 9.04 (d, 
J = 4.8 Hz, 2H), 8.39 (dd, J = 5.4, 1.5 Hz, 1H), 8.07 (dd, J = 7.8, 1.4 Hz, 1H), 7.84–7.80 (m, 2H), 7.68–
7.62 (m, 2H), 7.61 (dd, J = 6.8, 2.5 Hz, 1H), 7.55 (s, 1H), 7.47 (d, J = 8.8 Hz, 1H), 7.38 (dd, J = 6.8, 6.8 
Hz, 2H), 7.34 (d, J = 8.3 Hz, 1H), 7.26–7.24 (m, 4H), 7.13–7.10 (m, 3H),  6.95 (d, J = 3.9 Hz, 1H), 6.88–
6.86 (m, 5H), 6.72 (d, J = 5.4 Hz, 2H), 6.68 (s, 1H), 6.25–6.22 (m, 2H), 5.08 (d, J = 6.5 Hz, 1H),  5.02 (d, J 
= 6.5 Hz, 1H), 3.79 (s, 6H), 3.56 (s, 3H), 3.30 (s, 3H). 
13
C NMR (125 MHz CD2Cl2, 23 ºC, ): 169.1, 166.3, 
162.1, 160.7, 159.6, 156.6, 154.3, 153.5, 151.5, 147.8, 144.9, 143.6, 138.3, 138.2, 136.7, 130.3, 130.2, 
130.1, 130.0, 129.3, 127.9, 127.8, 127.4, 125.3, 124.5, 124.1, 123.9, 121.7, 121.5, 121.0, 119.5, 116.8, 
114.7, 114.0, 112.6, 112.5, 94.6, 60.4, 56.4, 55.6, 55.5. Anal: calcd for C56H46N4O10PdS2: C, 60.84; H, 
4.19; N, 5.07; found: C, 60.59; H, 4.36; N, 4.97. 
5-Bromo-2-(cyclopropylmethoxy)benzaldehyde (2.28) 
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To 5-bromo-2-hydroxybenzaldehyde (1.00 g, 4.97 mmol, 1.00 equiv) and K2CO3 (3.44 g, 24.9 mmol, 5.00 
equiv)  in THF (10 mL) in an oven-dried round-bottom flask fitted with a reflux condenser under a N2 
atmosphere at 23 ºC was added (bromomethyl)cyclopropane (1.01 g, 0.724 mL, 7.46 mmol, 1.50 equiv).  
The reaction mixture was warmed in an oil heating bath at a temperature of 70 ºC and heated at reflux with 
vigorous stirring for 40 hours.  The reaction mixture was cooled to 23 ºC and poured into H2O (30 mL) in a 
separatory funnel.  CHCl3 (30 mL) was added, the funnel was shaken and the organic phase collected.  The 
aqueous phase was then extracted with CHCl3 (2 × 30 mL).  The combined organic phases were washed 
with brine (30 mL), dried with Na2SO4, and concentrated in vacuo.  The residue was purified by 
chromatography on silica gel, eluting with 2–7% EtOAc in hexanes (v/v) to afford 1.05 g of the title 
compound as a colorless solid (83% yield).  
Rf = 0.30 (hexanes/EtOAc 19:1 (v/v)).  NMR Spectroscopy: 
1
H NMR (600 MHz, CDCl3, 23 ºC, ): 10.45 
(s, 1H), 7.91 (d, J = 2.5 Hz, 1H), 7.58 (dd, J = 8.9, 2.6 Hz, 1H), 6.84 (d, J = 8.9 Hz, 1H), 3.91 (d, J = 7.2 
Hz, 2H), 1.32–1.26 (m, 1H), 0.71–0.63 (m, 2H), 0.41–0.34 (m, 2H). 13C NMR (125 MHz, CDCl3, 23 ºC, ): 
188.7, 160.5, 138.3. 130.9, 126.5, 115.0, 113.5, 73.9, 10.1, 3.4. HRMS-FIA (m/z): calcd for C11H11BrNaO2 
[M + Na]
+
, 276.9840; found, 276.9820. 
(E)-Ethyl 3-(5-bromo-2-(cyclopropylmethoxy)phenyl)acrylate (2.29) 
 
To 5-bromo-2-(cyclopropylmethoxy)benzaldehyde (2.28) (3.10 g, 12.2 mmol, 1.00 equiv) and LiCl (0.541 
g, 12.8 mmol, 1.05 equiv)  in MeCN (45 mL) in a round-bottom flask under a N2 atmosphere at 0 ºC was 
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added triethyl phosphonoacetate (3.00 g, 2.68 mL, 13.4 mmol, 1.10 equiv) and 1,8-diazabicycloundec-7-
ene (DBU) (2.04 g, 2.02 mL, 13.4 mmol, 1.10 equiv).  Upon the addition of DBU, the reaction mixture 
turned yellow.  The reaction mixture was warmed to 23 ºC and stirred for 15 hours.  The reaction mixture 
was poured into H2O (75 mL) in a separatory funnel.  CHCl3 (75 mL) was added and the funnel was shaken 
and the organic phase collected.  The aqueous phase was extracted from with CHCl3 (2 × 50 mL).  All 
organic phases were combined and washed with brine (50 mL), dried with Na2SO4, and concentrated in 
vacuo.  The residue was purified by chromatography on silica gel, eluting with 5–10% EtOAc in hexanes 
(v/v) to afford 3.89 g of the title compound as a colorless solid (98% yield). 
Rf = 0.25 (hexanes/EtOAc 19:1 (v/v)).  NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.93 (d, 
J = 16.1 Hz, 1H), 7.60 (d, J = 2.4 Hz, 1H), 7.37 (dd, J = 8.8, 2.5 Hz, 1H), 6.74 (d, 8.8 Hz, 1H), 6.53 (d, J = 
16.1 Hz, 1H), 4.26 (q, J = 6.8 Hz, 2H), 3.84 (d, J = 6.8 Hz, 2H), 1.34–1.25 (m, 4H), 0.70–0.61 (m, 2H), 
0.40–0.31 (m, 2H).  13C NMR (125 MHz, CDCl3, 23 ºC, ): 167.3, 156.9, 138.7, 133.7, 131.3, 125.9, 120.0, 
114.4, 113.0, 73.9, 60.6, 14.4, 10.2, 3.4. HRMS-FIA (m/z): calcd for C15H18BrO3 [M + H]
+
, 325.0439; 
found, 325.0428. 
(E)-3-(5-Bromo-2-(cyclopropylmethoxy)phenyl)prop-2-en-1-ol (2.30) 
 
To (E)-ethyl 3-(5-bromo-2-(cyclopropylmethoxy)phenyl)acrylate (2.29) (3.78 g, 11.6 mmol, 1.00 equiv) in 
PhMe (30 mL) in a flame-dried round-bottom flask under a N2 atmosphere at –78 ºC was added a 1.0 M 
solution of diisobutylaluminum hydride (DIBAL-H) in PhMe (26 mL, 26 mmol, 2.2 equiv) in 6 portions 
dropwise every 10 minutes for 1 hour.  The reaction was warmed to 0 ºC over 2 hours and then warmed to 
23 ºC and stirred at this temperature for 1 hour.  The reaction mixture was poured onto a concentrated 
aqueous Rochelle’s salt (potassium sodium tartrate) solution (400 mL).  EtOAc (400 mL) was added and 
the mixture was stirred for 3 hour until two liquid phases separated cleanly.  The phases were partitioned 
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and the aqueous phase was extracted from with EtOAc (300 mL).  The organic phases were combined and 
washed with brine (200 mL), dried with Na2SO4, and concentrated in vacuo.  The residue was purified by 
chromatography on silica gel, eluting with a gradient of 10–25% EtOAc in hexanes (v/v) to afford 2.77 g of 
the title compound as a colorless solid (84% yield). 
Rf = 0.15 (hexanes/EtOAc 6:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.53 (d, J 
= 2.4 Hz, 1H), 7.26 (dd, J = 8.8, 2.4 Hz, 1H), 6.88 (d, J = 16.1 Hz, 1H), 6.69 (d, J = 8.8 Hz, 1H), 6.39 (dt, J 
= 16.1, 5.9 Hz, 1H), 4.33 (br dd, J = 4.6, 4.6 Hz, 2H), 3.79 (d, J = 6.8 Hz, 2H), 1.71 (br t, J = 5.1 Hz, 1H), 
1.31–1.23 (m, 1H), 0.68–0.58 (m, 2H), 0.38–0.30 (m, 2H). 13C NMR (125 MHz, CDCl3, 23 ºC, ): 155.4, 
131.2, 130.5, 129.7, 128.2, 125.0, 114.2, 113.2, 73.7, 64.1, 10.3, 3.4. HRMS-FIA (m/z): calcd for 
C13H15BrNaO2 [M + Na]
+
, 305.0153; found, 305.0123. 
((1S,2S)-2-(5-Bromo-2-(cyclopropylmethoxy)phenyl)cyclopropyl)methanol (2.31) 
 
Following a published procedure for asymmetric allylic cyclopropanation:
91
  To dimethoxyethane (DME) 
(1.39 g, 1.60 mL, 15.4 mmol, 1.90 equiv) in CH2Cl2 (50 mL) in a flame-dried round-bottom flask under a 
N2 atmosphere cooled in an ethylene glycol/CO2 bath at –15 ºC was added diethylzinc (2.01 g, 1.67 mL, 
16.3 mmol, 2.00 equiv), while maintaining the bath temperature between –15 and –10 ºC.  CH2I2 (8.70 g, 
2.62 mL, 32.5 mmol, 4.00 equiv) was added dropwise over 20 minutes at –15 ºC.  The reaction mixture 
was stirred at –15 ºC for 10 minutes.  A solution of (4R,5R)-2-butyl-N,N,N’,N’-tetramethyl-1,3,2-
dioxaborolane-4,5-dicarboxamide (2.63 g, 2.46 mL, 9.75 mmol, 1.20 equiv) in CH2Cl2 (10 mL) from a 
separate flame-dried round-bottom flask under a N2 atmosphere was added over 5 minutes via syringe.  A 
                                                          
91. Charette, A. B.; Juteau, H.; Lebel, H.; Molinaro, C. J. Am. Chem. Soc. 1998, 120, 11943.  
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solution of (E)-3-(5-bromo-2-(cyclopropylmethoxy)phenyl)prop-2-en-1-ol (2.30) (2.30 g, 8.12 mmol, 1.00 
equiv) in CH2Cl2 (10 mL) from a separate flame-dried round-bottom flask under a N2 atmosphere was 
added over 5 minutes via syringe.  The reaction mixture was allowed to warm to 23 ºC and stirred for 20 
hours.  Saturated aqueous NH4Cl solution (10 mL) and 1M HCl (50 mL) were added to the reaction 
mixture.   The reaction mixture was transferred to a separatory funnel.  Diethyl ether (200 mL) was added 
and the separatory funnel was shaken and the organic phase was separated.  The aqueous phase was 
extracted from with diethyl ether (200 mL) and then again with diethyl ether (100 mL).  The combined 
organic phases were transferred to an Erlenmeyer flask.  2 M NaOH solution (60 mL) and 30% H2O2 
solution (15 mL) were added.  The reaction mixture was stirred vigorously for 5 minutes.  The reaction 
mixture was transferred into a separatory funnel and partitioned.  The organic phase was washed with 1.0 
M aqueous HCl (75 mL), saturated aqueous Na2CO3 solution (75 mL), saturated aqueous NaHCO3 solution 
(75 mL) and brine (75 mL).  The organic phase was dried with MgSO4, and concentrated in vacuo.  The 
residue was purified by chromatography on silica gel, eluting with a gradient of 10–30% EtOAc in hexanes 
(v/v) to afford 2.21 g of the title compound as a colorless oil (92% yield and 96% ee as determined on a 
Chiracel OD-H column with 5% isopropanol/hexanes eluent (see Figure 4.2).  Racemic 2.31 was 
synthesized using the above procedures omitting the addition of (4R,5R)-2-butyl-N,N,N’,N’-tetramethyl-
1,3,2-dioxaborolane-4,5-dicarboxamide.  Absolute stereochemistry was assigned by analogy.
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Rf = 0.20 (hexanes/EtOAc 6:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.24 (dd, 
J = 8.8, 2.4 Hz, 1H), 7.09 (d, J = 2.4 Hz, 1H), 6.65 (d, J = 8.8 Hz, 1H), 3.95 (ddd, J  = 10.7, 8.8, 4.9 Hz, 
1H), 3.82 (d, J = 7.3 Hz, 2H), 3.19 (ddd, J = 10.7, 10.7, 2.0, 1H), 2.40 (dd, J = 8.5, 2.0 Hz, 1H), 1.86 (ddd, 
J = 8.5, 5.0, 5.0 Hz, 1H) 1.34–1.27 (m, 1H), 1.20–1.15 (m, 1H), 1.14–1.09 (m, 1H), 0.86 (ddd, J = 9.0, 5.0, 
5.0 Hz, 1H), 0.71–0.65 (m, 2H), 0.40–0.34 (m, 2H). 13C NMR (125 MHz, CDCl3, 23 ºC, ): 157.2, 132.4, 
130.2, 129.9, 112.8, 112.6, 73.6, 67.3, 24.5, 17.2, 10.2, 9.9, 3.7, 3.2. HRMS-FIA (m/z): calcd for 
C14H17BrNaO2 [M + Na]
+
, 319.0310; found, 319.0327. 
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Figure 4.2. Enantiodiscriminating HPLC trace of 2.31.  HPLC method: Chiracel OD-H column with 5% 
isopropanol/hexanes eluent for racemic 2.31 and enantioenriched 2.31.  Percent of total integration listed for each peak.  
2-((1S,2S)-2-(Azidomethyl)cyclopropyl)-4-bromo-1-(cyclopropylmethoxy)benzene (2.32) 
 
To ((1S,2S)-2-(5-bromo-2-(cyclopropylmethoxy)phenyl)cyclopropyl)methanol (2.31)  (2.15 g, 7.23 mmol, 
1.00 equiv) in CH2Cl2 (30 mL) in an oven-dried round-bottom flask under a N2 atmosphere at 0 ºC was 
added Et3N (2.20 g, 3.03 mL, 21.7 mmol, 3.00 equiv) and MsCl (1.66 g, 1.13 mL, 14.5 mmol, 2.00 equiv).  
The reaction mixture was stirred at 0 ºC for 2 hours.  The reaction mixture turned yellow and a precipitate 
formed.  The reaction mixture was poured into a separatory funnel with saturated NH4Cl solution (40 mL).  
The funnel was shaken and the organic phase collected.  The aqueous phase was extracted from with 
diethyl ether (3 × 75 mL).  The organic phases were combined and washed with saturated NaHCO3 (100 
mL) and brine (100 mL), dried with MgSO4, and concentrated in vacuo.  The residue was dissolved in 
DMF (30 mL) and NaN3 (1.88 g, 28.9 mmol, 4.00 equiv) was added.  The reaction mixture was heated at 
60 ºC for 1 hour.  The reaction mixture was cooled and poured into 60 mL of water.  The reaction mixture 
was extracted from with diethyl ether (3 × 75 mL).  The combined organic phases were washed with brine 
(100 mL), dried with MgSO4, and concentrated in vacuo.  The residue was purified by chromatography on 
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silica gel, eluting with a gradient of 5–10% EtOAc in hexanes (v/v) to afford 1.95 g of the title compound 
as a colorless oil (84% yield).  
Rf = 0.60 (hexanes/EtOAc 19:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.21 
(dd, J = 8.7, 2.3 Hz, 1H), 6.96 (d, J = 2.3 Hz, 1H), 6.66 (d, J = 8.7 Hz, 1H), 3.84-3.78 (m, 2H), 3.40 (dd, J 
= 12.8, 6.4, 1H), 3.24 (dd, J = 12.8, 7.1 Hz, 1H), 2.11 (ddd, J = 8.7, 5.0, 5.0 Hz, 1H), 1.38–1.32 (m, 1H), 
1.31–1.25 (m, 1H), 1.08–1.04 (m, 1H), 0.98–0.94 (m, 1H), 0.68–0.58 (m, 2H), 0.40–0.31 (m, 2H). 13C 
NMR (125 MHz, CDCl3, 23 ºC, ): 156.9, 132.8, 129.5, 128.8, 113.4, 112.9, 73.3, 55.3, 20.8, 16.2, 12.8, 
10.4, 3.3, 3.2. HRMS-FIA (m/z): calcd for C14H16BrN3NaO [M + Na]
+
, 344.0374; found, 344.0363. 
t-Butyl (((1S,2S)-2-(5-bromo-2-(cyclopropylmethoxy)phenyl)cyclopropyl)methyl) carbamate (2.33) 
 
To 2-((1S,2S)-2-(azidomethyl)cyclopropyl)-4-bromo-1-(cyclopropylmethoxy)benzene (2.32) (1.90 g, 5.90 
mmol, 1.00 equiv) in a round-bottom flask open to air in a 2:1 solution of dioxane:H2O (45 mL) cooled to 0 
ºC was added tin(II) chloride (5.59 g, 29.5 mmol, 5.00 equiv).  The reaction mixture was allowed to warm 
to 23 ºC and stirred for 15 hours.  Saturated aqueous NaHCO3 solution (50 mL) was carefully added.  The 
addition was accompanied by foaming.  H2O (15 mL) was added followed by Boc2O (3.86 g, 4.11 mL, 17.7 
mmol, 3.00 equiv).  The reaction mixture was stirred for 3 hours and then transferred to a separatory 
funnel.  The reaction mixture was extracted from with EtOAc  (3 × 75 mL).  The combined organic phases 
were washed with brine (75 mL), dried with Na2SO4, and concentrated in vacuo.  The residue was purified 
by chromatography on silica gel, eluting with a gradient of 5–20% EtOAc in hexanes (v/v) to afford 1.96 g 
of the title compound as a colorless solid (85% yield).  The enantioenriched product could be recrystallized 
by suspending the solid in hexanes (10 mL), heating the suspension to reflux to dissolve the solid, cooling 
the solution, and collecting the solid by filtration, affording the title compound in >99% ee as determined 
on a Chiracel OD-H column with 5% isopropanol/hexanes eluent (see Figure 4.3). 
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Rf = 0.25 (hexanes/EtOAc 19:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.23 
(dd, J = 8.3, 2.4 Hz, 1H), 7.06 (br d, J = 2.0 Hz, 1H), 6.66 (d, J = 8.8 Hz, 1H), 5.27 (br, 1H), 3.97 (dd, J = 
9.5, 7.1 Hz, 1H), 3.72–3.66 (m, 2H), 2.66 (br dd, J = 10.0, 10.0, 1H), 1.83 (ddd, J = 6.6, 6.6, 4.9 Hz, 1H), 
1.43 (br, 10H), 1.06–0.99 (br m, 2H), 0.83–0.80 (br m, 1H), 0.67 (br m, 2H), 0.38 (br m, 2H). 13C NMR 
(125 MHz, CDCl3, 23 ºC, ): 157.2, 155.9, 132.6, 130.3, 129.7, 112.8, 112.7, 79.1, 73.5, 45.7, 28.6, 21.1, 
17.4, 10.6, 10.3, 3.5. HRMS-FIA (m/z): calcd for C19H26BrNNaO3 [M + Na]
+
, 418.0988; found, 418.0994. 
 
Figure 4.3. Enantiodiscriminating HPLC trace of 2.33 HPLC method: Chiracel OD-H column with 5% isopropanol/hexanes 
eluent for racemic 2.33 and enantioenriched 2.33.  Percent of total integration listed for each peak.  
t-Butyl (((1S,2S)-2-(2-(cyclopropylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)cyclopropyl)methyl)carbamate (2.34) 
 
A flame-dried Schlenk tube under a N2 atmosphere was charged with t-butyl (((1S,2S)-2-(5-bromo-2-
(cyclopropylmethoxy)phenyl)cyclopropyl)methyl) carbamate (2.33) (250. mg, 0.631 mmol, 1.00 equiv), 
bis(pinacolato)diboron (176 mg, 0.694 mmol, 1.10 equiv), potassium acetate (186 mg, 1.89 mmol, 3.00 
equiv), and PdCl2(dppf)
.
CH2Cl2 (15.5 mg, 18.9 umol, 0.0300 equiv).  DMF (25 mL) was added via syringe.  
The reaction mixture was degassed via 2 consecutive freeze/pump/thaw cycles.  The Schlenk tube was then 
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backfilled with N2 and heated at 80 ºC for 16 hours.  The reaction mixture was cooled and poured into H2O 
(25 mL).  The reaction mixture was extracted from with diethyl ether (4 × 30 mL).  The combined organic 
phases were washed with brine (50 mL), dried with MgSO4, and concentrated in vacuo.  The residue was 
purified by chromatography on silica gel, eluting with a gradient of 5–20% EtOAc in hexanes (v/v) to 
afford 198 mg of the title compound as a colorless solid (71% yield).   
Rf = 0.40 (hexanes/EtOAc 4:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.63 (d, J 
= 8.2 Hz, 1H), 7.42 (s, 1H), 6.80 (d, J = 8.2 Hz, 1H), 5.36 (br, 1H), 4.04 (dd, J = 9.6, 6.9 Hz, 1H), 3.77 (dd, 
J = 9.6, 7.8 Hz, 1H), 3.70 (br m, 1H), 2.63 (br dd, J = 10.8, 10.8 Hz, 1H), 1.82 (ddd, J = 6.6, 6.6, 5.5 Hz, 
1H), 1.43 (br , 10H), 1.32 (br, 12H), 1.18–1.14 (m, 1H), 1.04–0.98 (br m, 1H), 0.80–0.76 (m, 1H), 0.70–
0.64 (br m, 2H), 0.41–0.36  (br m, 2H). 13C NMR (125 MHz, CDCl3, 23 ºC, ): 160.8, 155.9, 134.7, 134.1, 
129.3, 120.1 (br), 110.3, 83.7, 79.0, 73.1, 46.0, 28.6, 25.0, 24.9, 20.5, 17.6, 10.3, 3.5, 3.5. HRMS-FIA 
(m/z): calcd for C25H38BNNaO5 [M + Na]
+
, 466.2741; found, 466.2750. 
Palladium aryl complex 2.17  
 
To t-butyl (((1S,2S)-2-(2-(cyclopropylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)cyclopropyl)methyl)carbamate (2.34) (195 mg, 0.440 mmol, 1.00 equiv) in a round-bottom flask 
open to air in a 1:1 solution PhH:MeOH (8 mL) was added palladium acetate complex 2.15 (267 mg, 0.440 
mmol, 1.00 equiv) and potassium carbonate (91.0 mg, 0.660 mmol, 1.50 equiv).  The suspension was 
stirred at 23 ºC for 4 hours.  The reaction was filtered through microfiber filter paper using CH2Cl2 (10 
mL).  The solution was concentrated in vacuo and the residue was purified by chromatography on silica 
gel, eluting with a gradient of 25–75% EtOAc in hexanes to afford 180 mg of the title compound as a 
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yellow solid (47% yield).  
Rf = 0.30 (hexanes/EtOAc 1:2 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CD2Cl2, 23 ºC, ): 8.99 
(dd, J = 5.1, 1.7 Hz, 2H), 8.33 (ddd, J = 9.3, 5.4, 1.5 Hz, 1H), 8.06–8.03 (m, 1H), 7.82–7.77 (m, 2H), 7.66–
7.62 (m, 2H), 7.58–7.56 (m, 1H), 7.45 (dd, J = 8.5, 5.6 Hz, 1H), 7.35 (dd, J = 6.3, 6.3 Hz, 2H), 7.10–7.05 
(m, 3H), 6.58 (dd, J = 8.3, 1.5, 0.5H), 6.53 (dd, J = 8.3, 1.5, 0.5H), 6.37–6.34 (m, 2H), 6.28 (s, 1H), 6.23–
6.20 (m, 2H), 5.27 (br, 1H), 3.82 (br dd, J = 16.6, 9.8 Hz, 1H), 3.59–3.50 (m, 5H), 2.57–2.52 (br m, 0.5H), 
2.58–2.46 (br m, 0.5H), 1.64 (br m, 1H), 1.42–1.29 (m, 10H), 0.84–0.76 (br m, 1H), 0.64–0.53 (m, 4H) 
0.31–0.28 (m, 2H).  Note: fractional hydrogen integration and broad peaks are possibly due to slow rotation 
about bonds as seen for similar complexes.  
13
C NMR (125 MHz CD2Cl2, 23 ºC, ): 160.6, 155.9, 155.4, 
155.4, 154.5, 154.3, 153.6, 153.6, 145.1, 145.1, 144.8, 144.4, 143.9, 138.1, 138.0, 136.8, 136.7, 136.6, 
132.7, 132.6, 132.5, 130.0, 129.8, 128.9, 128.6, 127.9, 127.7, 127.6, 127.5, 125.9, 125.1, 124.5, 123.7, 
121.5, 121.4, 112.5, 110.5, 110.4, 78.8, 73.2, 55.5, 46.0, 28.5, 21.3, 17.6, 17.5, 10.7, 10.1, 3.4.  Note: There 
are more 
13
C peaks than could be expected, possibly due to slow rotation about bonds as seen for similar 
complexes (18). Anal: calcd for C44H46N4O6PdS: C, 61.07; H, 5.36; N, 6.47; found: C, 61.02; H, 5.22; N, 
6.20. 
1-(4-Bromophenyl)-3-((4-methoxyphenyl)amino)propan-1-one (2.35) 
 
To 1-(4-bromophenyl)-3-chloropropan-1-one  (43.4 g, 175 mmol, 1.00 equiv) and 4-methoxyaniline (23.8 
g, 193 mmol, 1.10 equiv) in THF (250 mL) in a round-bottom flask fitted with a reflux condenser open to 
air was added triethylamine (21.3 g, 29.3 mL, 210 mmol, 1.20 equiv).  The reaction mixture was heated at 
reflux for 4 hours and then cooled.  The reaction mixture was poured into H2O (400 mL).  EtOAc (300 mL) 
was added and the organic phase was collected, washed with brine (150 mL), dried with Na2SO4, and 
concentrated in vacuo.  The residual solid was triturated with diethyl ether (100 mL), collected by filtration, 
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and dried in vacuo to afford 47.4 g of the title compound as a light green solid (81% yield). 
Rf = 0.30 (hexanes/EtOAc 3:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.82–
7.79 (m, 2H), 7.61–7.59 (m, 2H), 6.80–6.77 (m, 2H), 6.63–6.60 (m, 2H), 3.83 (br s, 1H), 3.75 (s, 3H), 3.56 
(t, J = 6.3 Hz, 2H), 3.22 (t, J = 6.2 Hz, 2H).  
13
C NMR (125 MHz, CDCl3, 23 ºC, ): 198.5, 152.6, 141.9, 
135.6, 132.1, 129.7, 128.7, 115.1, 114.8, 55.9, 39.9, 37.8.  HRMS-FIA (m/z): calcd for C16H16BrNNaO2 [M 
+ Na]
+
, 356.0262; found, 356.0254. 
4-(4-Bromophenyl)-1-(4-methoxyphenyl)-5,6-dihydropyridin-2(1H)-one (2.36) 
 
To 1-(4-bromophenyl)-3-((4-methoxyphenyl)amino)propan-1-one (2.35) (19.7 g, 58.8 mmol, 1.00 equiv) 
suspended in CH2Cl2 (200 mL) in a round-bottom flask open to air was added ethyl 3-chloro-3-
oxopropanoate (9.32 g, 7.84 mL, 58.8 mmol, 1.00 equiv) and a saturated aqueous solution of Na2CO3 (100 
mL).  The reaction mixture was stirred at 23 ºC for 1 hour and then poured onto H2O (100 mL) in a 
separatory funnel.  The separatory funnel was shaken and the organic phase collected and concentrated in 
vacuo.  The residue was dissolved in CH2Cl2 (200 mL) and ethyl 3-chloro-3-oxopropanoate (4.66 g, 3.92 
mL, 29.4 mmol, 0.500 equiv) and a saturated aqueous solution of Na2CO3 (100 mL) were added.  The 
reaction mixture was stirred at 23 ºC for 1 hour and then poured onto H2O (100 mL) in a separatory funnel.  
The separatory funnel was shaken and the organic phase collected.  The aqueous phase was extracted from 
with CH2Cl2 (100 mL).  The combined organic phases were washed with brine (100 mL), dried with 
Na2SO4, and concentrated in vacuo.  The residue was dissolved in EtOH (400 mL).  NaOH (9.41 g, 235 
mmol, 4.00 equiv) was added, and the reaction mixture was stirred at 23 ºC for 15 minutes and then heated 
at reflux for 30 minutes.  The reaction mixture was cooled to 23 ºC and then poured into an Erlenmeyer 
flask containing H2O (600 mL).  The reaction suspension was cooled to 10 ºC in a refrigerator and the 
precipitate was collected on a frit.  Azeotropic removal of water by suspending the solid in benzene and 
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concentration in vacuo (3 × 50 mL) afforded 17.6 g of the title compound as a beige yellow solid (84% 
yield). 
Rf = 0.20 (hexanes/EtOAc 2:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.57–
7.54 (m, 2H), 7.42–7.40 (m, 2H), 7.28–7.24 (m, 2H), 6.94–6.91 (m, 2H), 6.43 (t, J = 1.0 Hz, 1H), 3.93 (t, J 
= 6.8 Hz, 2H), 3.81 (s, 3H), 2.90 (dt, J = 6.8, 1.0 Hz, 2H).  
13
C NMR (125 MHz, CDCl3, 23 ºC, ): 164.8, 
157.9, 148.7, 136.4, 135.5, 132.2, 127.4, 126.5, 124.1, 121.1, 114.4, 55.6, 48.9, 27.1. 
 
HRMS-FIA (m/z): 
calcd for C18H17BrNO2[M + H]
+
, 358.0443; found, 358.0440. 
(R)-4-(4-Bromophenyl)-1-(4-methoxyphenyl)piperidin-2-one (2.37) 
 
To 4-(4-bromophenyl)-1-(4-methoxyphenyl)-5,6-dihydropyridin-2(1H)-one (2.36) (28.8 g, 80.0 mmol, 1.00 
equiv) suspended in PhF (224 mL) in a round-bottom flask open to air was added t-amyl alcohol (113 g, 
141 mL, 1.29 mol, 16.0 equiv), polymethylhydrosiloxane (PMHS) (77.0 g, 76.5 mL, 1.29 mol, 16.0 equiv 
of [H
˗
], and (R)- 2,2'-bis(di-p-tolylphosphino)-1,1'-binaphthalene ((R)-tol-BINAP) (1.36 g, 2.01 mmol, 
0.0250 equiv) and then CuCl2 (0.270 g, 2.01 mmol, 0.0250 equiv) and NaO
t
Bu (0.773 g, 8.04 mmol, 0.100 
equiv).  Gas evolved and the reaction mixtureturned orange and then was stirred at 23 ºC for 7 hours.  The 
reaction mixture was poured onto a 1.0 M aqueous solution of HCl (1000 mL), and then the aqueous 
mixture was extracted with EtOAc (2 × 500 mL).  The combined organic phases were washed with brine 
(300 mL), dried with Na2SO4, and concentrated in vacuo.  The residual solid was triturated with diethyl 
ether (100 mL), collected by filtration, and dried in vacuo to afford 19.1 g of the title compound as a 
colorless solid (66% yield and 88% ee as determined by analysis of (3S,4R)-methyl 4-(4-bromophenyl)-1-
(4-methoxyphenyl)-2-oxopiperidine-3-carboxylate (2.38) (see next section and Figure 4.4)).  Racemic 2.37 
was synthesized using the above procedures using a 1:1 mixture of (R)-tol-BINAP and (S)-tol-BINAP.  
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Absolute stereochemistry was assigned by analogy.
92
  
Rf = 0.20 (hexanes/EtOAc 1:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.50–
7.48 (m, 2H), 7.19–7.14 (m, 4H), 6.95–6.92 (m, 2H), 3.81 (s, 3H), 3.74 (ddd, J = 12.1, 10.1, 4.6 Hz, 1H), 
3.61 (ddd, J = 12.4, 5.3, 3.9 Hz, 1H), 3.23 (dddd, J = 10.5, 10.5, 5.0, 3.2 Hz, 1H),  2.86 (ddd, J = 17.4, 5.3, 
2.1 Hz, 1H), 2.64 (dd, J = 17.4, 11.0 Hz, 1H), 2.24–2.19 (m, 1H), 2.10 (dddd, J = 13.4, 10.7, 10.7, 5.3 Hz, 
1H).  
13
C NMR (125 MHz, CDCl3, 23 ºC, ): 169.3, 158.4, 142.5, 135.9, 132.0, 128.4, 127.5, 120.8, 114.7, 
55.6, 50.9, 39.8, 38.4, 30.7.  HRMS-FIA (m/z): calcd for C18H19BrNO2 [M + H]
+
, 360.0599; found, 
360.0588. 
(3S,4R)-Methyl 4-(4-bromophenyl)-1-(4-methoxyphenyl)-2-oxopiperidine-3-carboxylate (2.38) 
 
To (R)-4-(4-bromophenyl)-1-(4-methoxyphenyl)piperidin-2-one (2.37) (19.0 g, 53.7 mmol, 1.00 equiv) and 
NaH (12.7 g (60% by weight NaH), 320 mmol, 6.0 equiv) in a flame-dried round-bottom flask fitted with a 
reflux condenser was added toluene (270 mL), MeOH (5.07 g, 6.40 mL, 158 mmol, 3.00 equiv), and 
dimethyl carbonate (14.3 g, 13.3 mL, 158 mmol, 3.00 equiv).  The reaction mixture was heated at reflux for 
4 hours, cooled to 23 ºC, and poured onto H2O (300 mL).  The aqueous layer was extracted from with 
EtOAc (2 × 300 mL).  The combined organic phases were washed with brine (300 mL), dried with Na2SO4, 
and concentrated in vacuo.  The residual solid was triturated with hexanes/EtOAc (150 mL, 1:1 (v/v)), 
collected by filtration, and dried in vacuo to afford 20.0 g of the title compound as a colorless solid (91% 
yield).  Enantiomeric excess (ee) of the product was determined to be 88% on a Chiralpak IB column with 
35% isopropanol/hexanes eluent (see Figure 4.4). 
Rf = 0.40 (hexanes/EtOAc 1:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.49–
                                                          
92. Hughes, G.; Kimura, M.; Buchwald, S. L. J. Am. Chem. Soc. 2003, 125, 11253.  
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7.46 (m, 2H), 7.21–7.18 (m, 2H), 7.15–7.13 (m, 2H), 6.93–6.90 (m, 2H), 3.88–3.80 (m, 4H), 3.70 (d, J = 
10.5 Hz, 1H), 3.66–3.56 (m, 5H), 2.23–2.17 (m, 2H).  13C NMR (125 MHz, CDCl3, 23 ºC, ): 170.3, 165.7, 
158.5, 140.6, 135.2, 132.2, 128.7, 127.3, 121.4, 114.6, 56.7, 55.6, 52.6, 50.7, 42.1, 29.9. HRMS-FIA (m/z): 
calcd for C20H21BrNO4[M + H]
+
, 418.0654; found, 418.0659.  
 
Figure 4.4. Enantiodiscriminating HPLC trace of 2.38.  HPLC method: Chiralpak IB column with 35% 
isopropanol/hexanes eluent for racemic 2.38 and enantioenriched 2.38.  Percent of total integration listed for each peak.   
((3S,4R)-4-(4-Bromophenyl)-1-(4-methoxyphenyl)piperidin-3-yl)methanol (2.39) 
 
To (3S,4R)-methyl 4-(4-bromophenyl)-1-(4-methoxyphenyl)-2-oxopiperidine-3-carboxylate (2.38) (5.33 g, 
12.7 mmol, 1.00 equiv) in a 340 mL pressure tube open to air was added BH3 (1.0 M solution in THF, 76 
mL, 76 mmol, 6.0 equiv).  The pressure tube was sealed and the reaction mixture was heated at 90 ºC for 
18 hours and then cooled.  The reaction mixture was added dropwise over 1 minute to a 1.0 M aqueous 
solution of NaOH (100 mL).  The reaction mixture was extracted from with EtOAc (3 × 60 mL).  The 
combined organic phases were washed with brine (50 mL), dried with Na2SO4, and concentrated in vacuo.  
The residue was purified by chromatography on silica gel, eluting with a gradient of 33–50% EtOAc in 
hexanes (v/v).  The resulting solid was then triturated with pentane/diethyl ether (50 mL, 1:1 (v/v)), 
collected by filtration, and dried in vacuo to afford 4.05 g of the title compound as a colorless solid (85% 
yield).  The enantioenriched product could be recrystallized by suspending the solid in MeOH (30 mL), 
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heating the suspension to reflux to dissolve the solid, cooling the solution, and collecting the solid by 
filtration, affording 3.40 g (71% yield) of the title compound in >99% ee as determined on a Chiracel OD-
H column with 10% isopropanol/hexanes eluent (see Figure 4.5). 
Rf = 0.20 (hexanes/EtOAc 2:1 (v/v)). NMR Spectroscopy: 
1
H NMR (600 MHz, CDCl3, 23 ºC, ): 7.44–
7.43 (m, 2H), 7.12–7.10 (m, 2H), 6.99–6.97 (m, 2H), 6.87–6.84 (m, 2H), 3.82 (ddd, J = 11.8, 3.8, 1.8 Hz, 
1H), 3.78 (s, 3H), 3.61–3.58 (br m, 1H), 3.48–3.44 (br m, 1H), 3.31–3.27 (br m, 1H), 2.71 (ddd, J = 12.0, 
12.0, 2.9 Hz, 1H), 2.59 (dd, J = 11.5, 11.5 Hz, 1H), 2.42 (ddd, J = 11.6, 11.6, 4.1 Hz, 1H), 2.15–2.09 (m, 
1H), 1.95 (ddd, J = 25.0, 12.3, 4.1 Hz, 1H) 1.90–1.87 (m, 1H).  13C NMR (125 MHz, CDCl3, 23 ºC, ): 
154.1, 146.2, 143.4, 131.9, 129.4, 120.3, 119.2, 114.6, 63.9, 55.7, 55.3, 52.2, 44.2, 44.1, 34.5. HRMS-FIA 
(m/z): calcd for C19H23BrNO2 [M + H]
+
, 376.0912; found, 376.0915. 
 
Figure 4.5. Enantiodiscriminating HPLC trace of 2.39. HPLC method: Chiralcel OD-H column with 10% 
isopropanol/hexanes eluent for racemic  2.39 and enantioenriched 2.39.  Percent of total integration listed for each peak.  
(3S,4R)-t-Butyl 4-(4-bromophenyl)-3-(hydroxymethyl)piperidine-1-carboxylate (2.40) 
 
To ((3S,4R)-4-(4-bromophenyl)-1-(4-methoxyphenyl)piperidin-3-yl)methanol (2.39) (6.00 g, 16.0 mmol, 
1.00 equiv) suspended in 3:1 solution MeCN/H2O (320 mL) in a round-bottom flask open to air was added 
ceric ammonium nitrate (CAN) (35.0 g, 63.8 mmol, 4.00 equiv).  The reaction mixture turned purple/red 
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and then red/orange upon stirring for 30 minutes at 23 ºC.  Sodium sulfite (5.02 g, 39.9 mmol, 2.50 equiv) 
was added and the reaction mixture turned yellow upon stirring for 15 minutes at 23 ºC.  The suspension 
was concentrated in vacuo to approximately 50 mL.  H2O (100 mL) and PhMe (150 mL) were added 
followed by a 3.0 M aqueous solution of NaOH until the reaction mixture pH was greater than 10.  Boc2O 
(6.96 g, 7.33 mL, 31.9 mmol, 2.00 equiv) was added and the reaction mixture was stirred at 23 ºC for 3 
hours.  The reaction mixture was filtered through celite. The celite was washed with EtOAc (200 mL) and 
combined with the reaction mixture in a separatory funnel.  The funnel was shaken and the organic phase 
collected.  The aqueous phase was extracted from with EtOAc (2 × 200 mL).  The combined organic 
phases were washed with brine (150 mL), dried with Na2SO4, and concentrated in vacuo.  The residue was 
purified by chromatography on silica gel, eluting with a gradient of 25–50% EtOAc in hexanes (v/v) to 
afford 5.70 g of the title compound as a colorless solid (97% yield). 
Rf = 0.20 (hexanes/EtOAc 3:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.47–
7.44 (m, 2H), 7.08–7.05 (m, 2H), 4.38 (br s, 1H), 4.22 (br s, 1H), 3.97 (dd, J = 10.1, 2.7 Hz, 1H), 3.81 (dd, 
J = 10.1, 6.8 Hz, 1H), 2.78–2.71 (br m, 2H) 2.53 (ddd, J = 11.9, 11.9, 3.8 Hz, 1H), 2.08–2.02 (m, 1H), 1.80 
(dd, J = 13.3, 2.7 Hz, 1H), 1.66 (ddd, J = 25.6, 12.6, 4.4 Hz, 1H), 1.49 (s, 9H).  
13
C NMR (125 MHz, 
CDCl3, 23 ºC, ): 154.7, 141.5, 132.2, 129.2, 121.1, 80.2, 69.5, 44.3, 41.0, 37.3, 34.0, 28.6.  Note: The 
13
C 
NMR spectrum contains one less carbon signal than is expected.  HRMS-FIA (m/z): calcd for 
C17H23BrNO3 [M - X]
-
, 368.0861; found, 368.0839. 
(3S,4R)-t-Butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-bromophenyl)piperidine-1-carboxylate 
(2.41) 
 
To (3S,4R)-t-Butyl 4-(4-bromophenyl)-3-(hydroxymethyl)piperidine-1-carboxylate (2.40) (1.00 g, 2.70 
mmol, 1.00 equiv), sesamol (0.746 g, 5.40 mmol, 2.00 equiv), triphenyl phosphine (0.921 g, 3.51 mmol, 
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1.30 equiv) in a 5:1 solution THF:PhMe (18 mL) in a flame-dried round-bottom flask fitted with a reflux 
condenser under nitrogen was added diisopropyl azodicarboxylate (DIAD) (0.710 g, 0.691 mL, 3.51 mmol, 
1.30 equiv).  The reaction mixture was heated at reflux for 18 hours, cooled to 23 ºC, and then poured into 
a 1.0 M aqueous solution of NaOH in a separatory funnel.  The reaction mixture was extracted from with 
diethyl ether (3 × 50 mL).  The combined organic phases were washed with brine (100 mL), dried with 
MgSO4, and concentrated in vacuo.  The residue was purified by chromatography on silica gel, eluting with 
a gradient of 10–20% EtOAc in hexanes (v/v) to afford 0.987 g of the title compound as a colorless solid 
(75% yield). 
Rf = 0.30 (hexanes/EtOAc 5:1 (v/v)). NMR Spectroscopy: 
1
H NMR (600 MHz, CDCl3, 23 ºC, ):  7.42–
7.40 (m, 2H), 7.07–7.05 (m, 2H), 6.63 (d, J = 8.4 Hz, 1H), 6.35 (d, J = 2.5 Hz, 1H), 6.13 (dd, J = 8.5, 2.5 
Hz, 1H), 5.88 (s, 2H), 4.43 (br s, 1H), 4.24 (br s, 1H), 3.60 (dd, J = 9.5, 2.8 Hz, 1H), 3.45 (dd, J = 9.4, 6.5 
Hz, 1H), 2.82–2.78 (br m, 2H), 2.66 (br dd, J = 10.3, 10.3 Hz, 1H), 2.04–1.98 (br m, 1H), 1.80–1.79 (br m, 
1H), 1.70 (br ddd, J = 25.3, 12.6, 4.1 Hz, 1H), 1.49 (s, 9H).  
13
C NMR (125 MHz, CDCl3, 23 ºC, ): 154.9, 
154.4, 148.3, 142.6, 141.8, 132.0, 129.3, 120.6, 108.0, 105.7, 101.3, 98.1, 79.9, 68.9, 44.4, 41.8, 33.9, 28.6.  
Note: The 
13
C NMR spectrum contains two less carbon signals than is expected.  HRMS-FIA (m/z): calcd 
for C24H29BrNO5 [M + H]
+
, 490.1229; found, 490.1207. 
(3S,4R)-t-Butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)phenyl)piperidine-1-carboxylate (2.42) 
 
A flame-dried Schlenk tube under a N2 atmosphere was charged with (3S,4R)-t-butyl 3-
((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-bromophenyl)piperidine-1-carboxylate (2.41) (975 mg, 1.99 
mmol, 1.00 equiv), bis(pinacolato)diboron (555 mg, 2.19 mmol, 1.10 equiv), potassium acetate (585 mg, 
5.96 mmol, 3.00 equiv), and PdCl2(dppf)
.
CH2Cl2 (49.0 mg, 60.0 µmol, 0.0300 equiv).  DMF (30 mL) was 
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added via syringe.  The reaction mixture was degassed via 2 consecutive freeze/pump/thaw cycles.  The 
Schlenk tube was then backfilled with N2 and heated at 80 ºC for 2.5 hours.  The reaction mixture was 
cooled and poured into H2O (100 mL).  The reaction mixture was extracted from with diethyl ether (3 × 
100 mL).  The combined organic phases were washed with brine (100 mL), dried with MgSO4, and 
concentrated in vacuo.  The residue was purified by chromatography on silica gel, eluting with a gradient of 
15–25% EtOAc in hexanes (v/v) to afford 882 mg of the title compound as a colorless solid (83% yield).   
Rf = 0.25 (hexanes/EtOAc 5:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.77–
7.75 (m, 2H), 7.22–7.21 (m, 2H), 6.63 (d, J = 8.2 Hz, 1H), 6.36 (d, J = 2.7 Hz, 1H), 6.14 (dd, J = 8.5, 2.6 
Hz, 1H), 5.89 (s, 2H), 4.48 (br s, 1H), 4.27 (br s, 1H), 3.62 (dd, J = 9.2, 2.8 Hz, 1H), 3.45 (dd, J = 9.6, 6.9 
Hz, 1H), 2.82–2.77 (br m, 2H), 2.69 (br dd, J = 9.4, 9.4 Hz, 1H), 2.15–2.09 (br m, 1H), 1.84–1.72 (br m, 
2H), 1.52 (s, 9H), 1.35 (s, 12H). 
13
C NMR (125 MHz, CDCl3, 23 ºC, ): 154.9, 154.4, 148.2, 146.9, 141.7, 
135.3, 127.0, 107.9, 105.7, 101.2, 98.2, 83.9, 79.7, 69.0, 45.2, 41.6, 33.8, 28.6, 25.0. Note: The 
13
C NMR 
spectrum contains three less carbon signals than is expected.  HRMS-FIA (m/z): calcd for C30H41BNO7 [M 
+ H]
+
, 538.2976; found, 538.2991. 
Palladium aryl complex 2.17 
 
To (3S,4R)-t-butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)phenyl)piperidine-1-carboxylate (2.42) (820 mg, 1.53 mmol, 1.00 equiv) in a round-bottom flask open 
to air in a 1:1 solution PhH:MeOH (30 mL) was added palladium acetate complex 2.15 (928 mg, 1.53 
mmol, 1.00 equiv) and potassium carbonate (316 mg, 2.29 mmol, 1.50 equiv).  The suspension was stirred 
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at 23 ºC for 6 hours.  The reaction mixture was filtered through a frit eluting with CH2Cl2 (30 mL).  The 
solution was concentrated in vacuo and the residue was purified by chromatography on silica gel, eluting 
with a gradient of 33–80% EtOAc in hexanes to afford 795 mg of the title compound as a yellow solid 
(54% yield).  
Rf = 0.40 (hexanes/EtOAc 1:3 (v/v)). NMR Spectroscopy: 
1
H NMR (600 MHz, CD2Cl2, 23 ºC, ): 8.99 
(ddd, J = 5.0, 3.4, 1.6 Hz, 2H), 8.32 (ddd, J = 16.7, 5.4, 1.7 Hz, 1H), 8.00 (ddd, J = 17.9, 4.0, 1.6 Hz, 1H), 
7.79–7.76 (m, 2H), 7.65–7.60 (m, 3H), 7.44 (dd, J = 8.8, 4.1 Hz, 1H), 7.32 (ddd, J = 7.6, 5.1, 1.5 Hz, 2H), 
7.12–7.09 (m, 2H), 6.94 (ddd, J = 15.5, 7.9, 5.3 Hz, 1H), 6.85 (dd, J = 9.1, 8.1 Hz, 2H), 6.65–6.61 (m, 3H), 
6.27 (dd, J = 14.0. 2.4 Hz, 1H), 6.24–6.21 (m, 2H), 6.09 (ddd, J = 8.5, 2.3, 2.3 Hz, 1H), 5.91 (dd, J = 4.5, 
1.3 Hz, 1H), 5.90 (dd, J = 2.0, 1.4 Hz, 1H), 4.38 (br s, 1H), 4.15 (br s, 1H), 3.55 (s, 3H), 3.47 (ddd, J = 9.4, 
9.4, 3.0 Hz, 1H), 3.33 (ddd, J = 19.7, 9.7, 7.8 Hz, 1H), 2.73–2.63 (br m, 2H), 2.37–2.31 (m, 1H), 2.91–1.85 
(br m, 1H), 1.69–1.56 (m, 2H), 1.45 (s, 9H).  13C NMR (125 MHz, CD2Cl2, 23 ºC, ): 160.5, 154.9, 154.8, 
154.3, 153.4, 148.5, 145.0, 143.8, 141.9, 138.5, 138.1, 138.0, 136.9, 136.6, 135.1, 130.0. 127.9, 127.7, 
127.3, 126.3, 126.3, 125.1, 124.5, 123.7, 121.3, 112.5, 108.1, 106.1, 101.1, 98.1, 97.9, 79.4, 69.7, 55.5, 
44.7, 42.3, 42.1, 33.9, 28.5.  Note: The 
13
C NMR spectrum contains two less carbon signals than is 
expected.  ):.  Anal: calcd for C49H48N4O8PdS: C, 61.34; H, 5.04; N, 5.84; found: C, 61.09; H, 4.84; N, 
5.74. 
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Fluorination of aryl palladium complexes 
3-Benzyloxyphenyl fluoride (2.5) 
 
In a glove box under a N2 atmosphere, palladium aryl complex 2.3 (100 mg, 0.140 mmol, 1.00 equiv) was 
dissolved in acetone (7 mL) and added to a soda lime glass bottle charged with Pd(IV)-F complex 2.2 (102 
mg, 0.140 mmol, 1.00 equiv).  The bottle was sealed, taken out of the glove box, and immersed in an oil 
bath heated at 85 ºC for 10 minutes.  The reaction mixture was cooled and concentrated in vacuo.  The 
residue was extracted from with diethyl ether (5 × 5 mL).  The extract was concentrated in vacuo and the 
residue was purified by chromatography on silica gel eluting with hexanes/EtOAc 10:1 (v/v) to afford 25.6 
mg of the title compound as a colorless oil (93% yield).   
Rf = 0.55 (hexanes/EtOAc 20:1 (v/v)).  NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.44–
7.33 (m, 5H), 7.26–7.21 (m, 1H), 6.78–6.66 (m, 3H), 5.06(s, 2H).  13C NMR (125 MHz, CDCl3, 23 ºC, ):  
163.8 (d, J = 246 Hz), 160.3 (d, J = 11 Hz), 136.6, 130.4 (d, J = 10 Hz), 128.8, 128.3, 127.6, 110.8 (d, J = 3 
Hz), 107.9 (d, J = 22 Hz), 102.8 (d, J = 25 Hz), 70.4.  
19
F NMR (375 MHz, CD3CN, 23 ºC, ): –112.2 (m).  
These spectroscopic data correspond to previously reported data.
93
 
 
3-Deoxy-3-fluoroestrone (2.6) 
                                                          
93. Watson, D. A.; Su, M. J.; Teverovskiy, G.; Zhang, Y.; Garcia-Fortanet, J.; Kinzel, T.; Buchwald, S. L. Science 2009, 325, 
1661.  
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In a glove box under a N2 atmosphere, palladium aryl complex 2.4 (100 mg, 0.124 mmol, 1.00 equiv) was 
dissolved in acetone (7 mL) and added to a soda lime glass bottle charged with Pd(IV)-F complex 2.2 (90.7 
mg, 0.124 mmol 1.00 equiv).  The bottle was sealed, taken out of the glove box, and immersed in an oil 
bath heated at 85 ºC for 10 minutes.  The reaction mixture was cooled and concentrated in vacuo.  The 
residue was extracted from with diethyl ether (5 × 5 mL).  The extract was concentrated in vacuo and the 
residue was purified by chromatography on silica gel eluting with hexanes/EtOAc 10:1 (v/v) to afford 31.1 
mg of the title compound as a colorless solid (92% yield).   
Rf = 0.33 (hexanes/EtOAc 9:1 (v/v)).  NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.23 (dd, 
J = 8.5 Hz, 3.2 Hz, 1H), 6.83 (td, J = 8.5 Hz, 2.1 Hz, 1H), 6.79 (dd, J = 9.6 Hz, 3.2 Hz, 1H), 2.91–2.89 (m, 
2H), 2.54–2.48 (m, 1H), 2.42–2.38 (m, 1H), 2.29–2.23 (m, 1H), 2.18–1.94 (m, 4H), 1.67–1.41 (m, 6H,), 
0.92 (s, 3H).  
13
C NMR (125 MHz, CDCl3, 23 ºC, ): 220.8, 161.2 (d, J = 244 Hz), 138.8 (d, J = 6 Hz), 
135.5 (d, J = 3 Hz), 126.9 (d, J = 8 Hz), 115.3 (d, J = 20 Hz), 112.6 (d, J = 21 Hz), 50.5, 48.1, 44.1, 38.3, 
36.0, 31.7, 29.6, 26.5, 26.0, 21.7, 14.0.  
19
F NMR (375 MHz, CDCl3, 23 ºC, ):–117.1.  These 
spectroscopic data correspond to previously reported data.
94
 
(Z)-3-(Bis(4-methoxyphenyl)methyl)-5-((5-(4-fluoro-2-(methoxymethoxy)phenyl)furan-2-
yl)methylene)thiazolidine-2,4-dione (2.19)  
                                                          
94. Tang, P. P.; Furuya, T.; Ritter, T. J. Am. Chem. Soc. 2010, 132, 12150. 
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In a glove box under a N2 atmosphere, palladium aryl complex 2.16 (90.0 mg, 81.4 umol, 1.00 equiv) was 
dissolved in acetone (5 mL) and added to a soda lime glass bottle charged with Pd(IV)-F complex 2.2 (62.6 
mg, 85.5 umol, 1.05 equiv). The bottle was sealed, taken out of the glove box, and immersed in an oil bath 
heated at 85 ºC for 10 minutes.  The reaction mixture was cooled and concentrated in vacuo.  The residue 
was purified by chromatography on silica gel, eluting with a gradient of 10–25% EtOAc in hexanes to 
afford 31.5 mg of the title compound as a bright yellow solid (67% yield).  
Rf = 0.20 (hexanes/EtOAc 3:1 (v/v)). NMR Spectroscopy: 
1
H NMR (600 MHz, CDCl3, 23 ºC, ): 7.88 (dd, 
J = 7.6, 6.6 Hz, 1H), 7.61 (s, 1H), 7.31–7.29 (m, 4H), (7.06 (dd, J = 3.7, 1.0 Hz, 1H), 6.99 (dd, J = 10.6, 1.3 
Hz, 1H), 6.89–6.87 (m, 5H), 6.74 (s, 1H), 5.32 (s, 2H), 3.81 (s, 6H), 3.51 (s, 3H). 13C NMR (125 MHz, 
CDCl3, 23 ºC, ): 168.7, 166.1, 163.5 (d, J = 251 Hz), 159.3, 155.1 (d, J = 10 Hz), 154.3, 148.2, 130.1, 
129.6, 128.1 (d, J = 10 Hz), 120.7, 119.4, 117.8, 115.4, 113.9, 112.8, 109.4 (d, J = 22 Hz), 102.9 (d, J = 26 
Hz), 94.7, 60.3, 56.6, 55.4. 
19
F NMR (375 MHz, CDCl3, 23 ºC, ): –108.4 (ddd, J = 11.0, 7.3, 7.3 Hz). 
HRMS-FIA (m/z): calcd for C31H26FNNaO7S [M + Na]
+
, 598.1312; found, 598.1322. 
t-Butyl (((1S,2S)-2-(2-(cyclopropylmethoxy)-5-fluorophenyl)cyclopropyl)methyl)carbamate (2.20) 
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In a glove box under a N2 atmosphere, palladium aryl complex 2.17 (25.0 mg, 29.4 umol, 1.20 equiv) was 
dissolved in acetone (3 mL) and added to a soda lime glass bottle charged with Pd(IV)-F complex 2.2 (18.0 
mg, 24.5 umol, 1.00 equiv). The bottle was sealed, taken out of the glove box, and immersed in an oil bath 
heated at 85 ºC for 10 minutes.  The reaction mixture was cooled and concentrated in vacuo.  The residue 
was purified by chromatography on silica gel, eluting with a gradient of 10–15% EtOAc in hexanes to 
afford 5.9 mg of the title compound as a colorless solid (72% yield).  
Rf = 0.35 (hexanes/EtOAc 85:15 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 6.80 
(ddd, J = 8.8, 8.8, 2.9 Hz, 1H), 6.72 (dd, J = 9.1, 4.9, Hz, 1H), 6.66 (dd, J = 9.3, 3.0 Hz, 1H), 5.27 (br s, 
1H),  3.96 (dd, J = 9.8, 6.8 Hz, 1H), 3.71 (dd, J = 9.8, 7.8 Hz, 1H), 3.66 (br s, 1H), 2.69 (br m, 1H), 1.88 
(ddd, J = 6.8, 6.8, 4.9 Hz, 1H), 1.43–1.38 (m, 10H), 1.05–0.99 (m, 2H), 0.85–0.80 (m, 1H), 0.72–0.62 (m, 
2H), 0.42–0.32 (m, 2H).  13C NMR (125 MHz, CDCl3, 23 ºC, ): 157.2 (d, J = 238 Hz), 155.9, 154.1, 132.3 
(d, J = 7 Hz), 114.1 (d, J = 24 Hz), 112.7 (d, J = 23 Hz), 112.2 (d, J = 9 Hz), 79.1, 73.9, 45.7, 28.6, 21.3, 
17.5, 10.8, 10.4, 10.2, 3.5. 
19
F NMR (375 MHz, CDCl3, 23 ºC, ): –123.8 (dd, J = 12.8, 8.0 Hz).  HRMS-
FIA (m/z): calcd for C19H26FNNaO3 [M + Na]
+
, 358.1794; found, 358.1808. 
(3S,4R)-t-Butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
(2.21) 
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In a glove box under a N2 atmosphere, palladium aryl complex 2.18 (135 mg, 141 µmol, 1.00 equiv) was 
dissolved in acetone (6 mL) and added to a soda lime glass bottle charged with Pd(IV)-F complex 2.2 (103 
mg, 141 µmol, 1.00 equiv).  The bottle was sealed, taken out of the glove box, and immersed in an oil bath 
heated at 85 ºC for 10 minutes.  The reaction mixture was cooled and concentrated in vacuo.  The residue 
was purified by chromatography on silica gel, eluting with a gradient of 10–20% EtOAc in hexanes to 
afford 42.7 mg of the title compound as a colorless solid (71% yield).  The enantiomeric excess of the title 
compound remained >99% ee as determined on a Chiracel OD-H column with 3% isopropanol/hexanes 
eluent.  The absolute configuration was identical to a sample of the title compound prepared from 
commercially available paroxetine (see Figure 4.6). 
Rf = 0.25 (hexanes/EtOAc 6:1 (v/v)). NMR Spectroscopy: 
1
H NMR (500 MHz, CDCl3, 23 ºC, ): 7.15–
7.11 (m, 2H), 6.99–6.96 (m, 2H), 6.62 (d, J = 8.3 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 6.13 (dd, J = 8.8, 2.4 
Hz, 1H), 5.88 (s, 2H), 4.43 (br s, 1H), 4.24 (br s, 1H), 3.60 (dd, J = 9.7, 2.9 Hz, 1H), 3.44 (dd, J = 9.5, 6.5 
Hz, 1H), 2.82–2.77 (br m, 2H), 2.67 (br ddd, J = 11.5, 11.5, 2.7 Hz, 1H), 2.04–1.99 (br m, 1H), 1.81–1.78 
(br m, 1H), 1.70 (br ddd, J = 24.9, 12.7, 4.4 Hz, 1H), 1.50 (s, 9H).  
13
C NMR (125 MHz, CDCl3, 23 ºC, ):  
161.7 (d, J = 244 Hz), 155.0, 154.4, 148.3, 141.8, 139.3 (d, J = 3 Hz), 128.9 (d, J = 7 Hz), 115.6 (d, J = 19 
Hz), 108.0, 105.7, 101.2, 98.1, 79.8, 69.0, 44.2, 42.1, 34.1, 28.6. Note: The 
13
C NMR spectrum contains 
two less carbon signals than is expected.  
19
F NMR (375 MHz, CDCl3, 23 ºC, ): –116.0– –116.1 (m).  
HRMS-FIA (m/z): calcd for C24H29FNO5 [M + H]
+
, 430.2030; found, 430.1998. 
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Figure 4.6. Enantiodiscriminating HPLC trace of 2.21.  HPLC method: Chiralcel OD-H column with 3% 
isopropanol/hexanes eluent for 90% ee 2.21 and for >99% ee 2.21 and 2.21 synthesized from commercially available 
paroxetine.  Percent of total integration listed for each peak.  
Deprotection of aryl fluorides 
((1S,2S)-2-(2-(Cyclopropylmethoxy)-5-fluorophenyl)cyclopropyl)methanaminium 2,2,2-
trifluoroacetate (2.43) 
 
t-butyl(((1S,2S)-2-(2-(cyclopropylmethoxy)-5-fluorophenyl)cyclopropyl)methyl)carbamate (2.20) (65.0 
mg, 0.194 mmol, 1.00 equiv) was dissolved in a 1:1 solution CH2Cl2:CF3CO2H (2 mL).  The solution was 
stirred at 23 ºC for 10 minutes.  The solution was then dripped into saturated aqueous NaHCO3 solution (20 
mL).  The aqueous layer was extracted with EtOAc (3 × 10 mL).  The combined organic phases were 
washed with brine (15 mL), dried with Na2SO4, and concentrated in vacuo.  The residue was purified by 
chromatography on silica gel that had been washed with Et3N, eluting with 0–10% MeOH in CH2Cl2 (v/v) 
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to afford the amine base.  The title compound was isolated by adding a 10% CF3CO2H in CH2Cl2 solution 
(1 mL) to the amine base.  The solution was concentrated in vacuo and heated in vacuo at 50 ºC to provide 
65.5 mg of the title compound (96% yield). 
NMR Spectroscopy: 
1
H NMR (500 MHz, D2O, 23 ºC, ):  6.99 (dd, J = 9.0, 5.0 Hz, 1H), 6.95 (ddd, J = 9.0, 
9.0, 3.0 Hz, 1H),  6.78 (dd, J = 10.0, 3.0 Hz, 1H), 3.95 (dd, J = 10.0, 7.0, 1H), 3.87 (dd, J = 10.0, 2.5 Hz, 
1H), 3.16 (dd, J = 12.0, 7.0 Hz, 1H), 3.02 (dd, J = 13.0, 8.0 Hz, 1H), 2.16 (ddd, J = 7.0, 7.0, 5.0 Hz, 1H), 
1.38–1.27 (m, 2H), 1.16 (ddd, J = 5.5, 5.3, 5.3 Hz, 1H), 1.07 (ddd, J = 7.3, 7.3, 5.5 Hz, 1H), 0.65–0.62 (m, 
2H), 0.37–0.34 (m, 2H). 19F NMR (375 MHz, D2O, 23 ºC, ):  -76.1 (s, 3F), -123.9 (ddd, J = 7.2, 7.2, 6.0, 
1F). 
13
C NMR (125 MHz, D2O, 23 ºC, ): 157.7 (d, J = 237 Hz), 153.4 (d, J = 2 Hz), 132.4 (d, J = 7 Hz), 
115.4 (d, J = 9 Hz), 113.4 (d, J = 23 Hz), 113.1 (d, J = 24 Hz), 75.8, 43.9, 18.7, 16.7, 12.6, 9.9, 2.9, 2.6.  
HRMS-FIA (m/z): [C14H19FNO + Na]
+
 calcd for C14H19FNNaO, 258.1270; found, 258.1274. 
(3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine (2.44) 
 
(3S,4R)-t-butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate (2.21) 
(35.0 mg, 81.5 µmol, 1.00 equiv) was dissolved in a 7:1 solution CH2Cl2:CF3CO2H (2 mL).  The solution 
was stirred at 23 ºC for 15 minutes.  The solution was then dripped into saturated aqueous NaHCO3 
solution (10 mL).  The aqueous layer was extracted with CH2Cl2 (3 × 10 mL).  The combined organic 
phases were washed with brine (15 mL), dried with Na2SO4, and concentrated in vacuo.  The residue was 
purified by chromatography on silica gel that had been washed with Et3N, eluting with 0–10% MeOH in 
CH2Cl2 (v/v) to afford 25.6 mg of the title compound as a colorless oil (95% yield).  
Rf = 0.35 (CH2Cl2/MeOH 19:1 (v/v) (Et3N washed silica)). NMR Spectroscopy: 
1
H NMR (600 MHz, 
CDCl3, 23 ºC, ): 7.18–7.16 (m, 2H), 6.98–6.96 (m, 2H), 6.61 (d, J = 8.5 Hz, 1H), 6.33 (d, J = 2.3 Hz, 1H), 
6.13 (dd, J = 8.5, 2.5 Hz, 1H), 5.86 (s, 2H), 4.65 (br s, 1H), 3.56 (dd, J = 9.4, 2.6 Hz, 1H), 3.56 (dd, J = 9.4, 
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2.6 Hz, 1H), 3.48 (dd, J = 12.4, 3.6 Hz, 1H), 3.44 (dd, J = 9.2, 6.7 Hz, 1H), 3.28 (d, J = 12.2 Hz, 1H), 2.83–
2.76 (m, 2H), 2.65 (ddd, J = 11.0, 11.0, 5.7 Hz, 1H), 2.22–2.17 (m, 1H), 1.91–1.84 (m, 2H).  13C NMR 
(125 MHz, CDCl3, 23 ºC, ): 161.7 (d, J = 244 Hz), 154.3, 148.3, 141.8, 139.4 (d, J = 3 Hz), 128.9 (d, J = 8 
Hz), 115.6 (d, J = 21 Hz), 107.9, 105.6, 101.2, 98.0, 69.1, 49.6, 46.5, 44.0, 42.2, 34.2. 
19
F NMR (375 MHz, 
CDCl3, 23 ºC, ): -116.0 (tt, J = 8.6, 5.5 Hz).  HRMS-FIA (m/z): calcd for C19H21FNO3 [M + H]
+
, 
330.1505; found, 330.1497. 
 
4.3 Radiochemistry General Methods 
No-carrier-added [
18
F]fluoride was produced from water 97% enriched in 
18
O (Sigma-Aldrich®) by the 
nuclear reaction 
18
O(p,n)
18
F using a Siemens Eclipse HP cyclotron and a silver-bodied target at MGH 
Athinoula A. Martinos Center for Biomedical Imaging. The produced [
18
F]fluoride in water was transferred 
from the cyclotron target by helium push. Liquid chromatographic analysis (LC) was performed with 
Agilent 1100 series HPLCs connected to a Carol and Ramsey Associates Model 105-S radioactivity 
detector. An Agilent Eclipse XDB-C18, 5 µm, 4.6 x 150 mm HPLC column was used for analytical 
analysis and a Macherey-Nagel VP 250/10 Nucleosil 100-5 C18 Nautilus column was used for preparative 
HPLC.  In the analysis of the 
18
F-labeled compounds, isotopically unmodified reference substances were 
used for identification. Radioactivity was measured in a Capintec, Inc. CRC-25PET ion chamber.  Solvents 
and reagents for radiochemical experiments: Acetone (HPLC grade) was distilled over B2O3 and 
subsequently redistilled before use.  2-Butanone was distilled over B2O3.  Acetonitrile was distilled over 
P2O5.  Water was obtained from a Millipore Milli-Q Integral Water Purification System. 18-crown-6 was 
sublimed.  Potassium bicarbonate (≥99.99%) and JandaJel™-polypyridine (100-200 mesh, extent of 
labeling: ~8.0 mmol/g loading, 1% cross-linked) were purchased from Sigma-Aldrich
®
 and dried at 23 °C 
for 24 hours under dynamic vacuum (10
-4
 Torr) before use.  Cotton was washed with acetone and water and 
dried at 150°C.  
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4.4 Radiosynthesis of 
18
F-labeled Molecules 
[
18
F]Fluoride solution obtained from a cyclotron was loaded onto a Macherey-Nagel SPE Chromafix 30-
PS-HCO3 cartridge that had been previously washed with 2.0 mL of 5.0 mg/mL KHCO3 in Millipore Milli-
Q water and then 20 mL of Millipore Milli-Q water.  After loading, the cartridge was washed with 2 mL of 
Millipore Milli-Q water.  [
18
F]Fluoride was eluted with 2.0 mL of a 5.0 mg/mL KHCO3 in Millipore Milli-
Q water solution.  The solution was diluted with 8.0 mL of acetonitrile providing 10. mL of 4:1 MeCN:H2O 
solution containing 1.0 mg/mL KHCO3.  1.0 mL of this solution was then put in a magnetic-stir-bar-
containing conical vial that had been washed with acetone, deionized water, sodium hydroxide/ethanol 
solution, and deionized water, and dried at 150 °C prior to use.  0.50 mL of a stock solution containing 18-
crown-6 (26.2 mg/mL MeCN) was then added.  The solution was evaporated at 108 °C with a constant 
nitrogen gas stream.  At dryness, 0.5 mL of acetonitrile was added and evaporated at 108 °C with a 
constant nitrogen gas stream.  Another 0.5 mL of acetonitrile was added and evaporated at 108 °C with a 
constant nitrogen gas stream to leave a white precipitate around the bottom and sides of the vial.  0.5 mL of 
acetone was added and evaporated to dryness at 108 °C with a constant nitrogen gas stream to leave a 
glassy film on the bottom and sides of the vial.  The vial was cooled in a water bath, purged with nitrogen, 
and sealed with a cap fitted with a septum.   
First step: 10. mg of Pd(IV) complex 2.1 dissolved in 0.5 mL of acetone was added via the septum to the 
vial.  The vial was sonicated and then the reaction mixure was allowed to stir at 23 °C for 10 minutes.  
During this time, the orange/brown clear solution became opaque.   At the end of 10 minutes, the vial was 
opened and the suspension was loaded with a glass pipette into another glass pipette containing 10 mg of 
cotton and 25 mg of JandaJel™-polypyridine that had been suspended in 0.3 mL of acetone for 15 minutes 
(to swell the JandaJel™-polypyridine) and then drained prior to loading the reaction suspension.  The 
  
 
 
99 
conical vial was washed with 0.5 mL of acetone and the acetone wash was added onto the JandaJel™-
polypyridine in the glass pipette.  At this point the combined reaction suspension and acetone wash were 
fully pushed through the JandaJel™-polypyridine and cotton with air into a new 1 dram vial equipped with 
a magnetic stir bar.  An additional 0.5 mL of acetone was used to wash the conical vial.  The acetone wash 
was added onto the JandaJel™-polypyridine in the glass pipette and pushed through with air into the 1 
dram vial.   
Second step: To the 1.5 mL acetone solution was added 10. mg of the Pd(II) aryl complex.  The vial was 
capped securely, and the mixture heated at 85 °C.  After 10 minutes the solution was cooled.  A capillary 
tube was used to spot the solution on a silica gel TLC plate.  The TLC plate was emerged in an appropriate 
organic solvent mixture.  The TLC plate was scanned with a Bioscan AR-2000 Radio TLC Imaging 
Scanner. 
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Measurement of radiochemical yield: 
Radiochemical yield was determined by multiplying the percentage of radioactivity in the final solution and 
the relative peak integrations of a radio TLC scan.  First, the radioactivity of the 1.5 mL solution collected 
after filtration was measured in an ion chamber, followed by the amount of radioactivity on the JandaJel™-
polypyridine/cotton pipette and the amount of radioactivity left on the walls of the initial conical vial.  
These measurements determined the fraction of radioactivity that entered the second step (typically 55–
75%).  After the second step was complete the solution was transferred to a second 1 dram vial using an 
additional 0.5 mL acetone wash and the amount of radioactivity in this solution was measured.  The amount 
of radioactivity on the original 1 dram vial was then measured to determine the percentage of radioactivity 
of the solution that spotted onto the TLC plate (typically 90%).  After radio TLC quantification, the 
radiochemical yield was determined by multiplying the product quantified during TLC by the fraction of 
radioactivity in solution over two steps (typically 50–70%).   
For example, Entry 1 of Radiochemical Yield Data section:   
Measured radioactivity in 1.5 mL acetone solution after first step: 256 µCi 
Measured radioactivity of pipette containing JandaJel™-polypyridine and cotton: 30 µCi 
Measured radioactivity of conical vial from first step: 26 µCi 
Radioactivity percentage that entered second step: 82% ((256 + 30 + 26) / 256 * 100) 
Measured radioactivity of acetone solution after second step: 215 µCi 
Measured radioactivity of dram vial from second step:16 µCi 
Radioactivity percentage from second step that was spotted on to TLC plate: 93% ((215 + 16) / 
215 * 100) 
Percent 
18
F in solution: 76% (0.82 * 0.93 * 100) 
Radio TLC yield (RTLC yield): 43% 
Radiochemical yield (RCY): 33% (0.76 * 0.43 * 100) 
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Table 4.1. Radiochemical yield data 
Entry Molecule RTLC yield % 
18
F in solution  RCY Average RCY 
1 [
18
F]2.6 43 76% 33  
2 [[
18
F]2.6 51 68% 35  
3 [
18
F]2.6 36 76% 27  
4 [
18
F]2.6 43 69% 30  
5 [
18
F]2.6 58 68% 40  
6 [
18
F]2.6 57 66% 38  
7 [
18
F]2.6 49 57% 28  
8 [
18
F]2.6 44 66% 29 33 
9 [
18
F]2.19 21 54% 11  
10 [
18
F]2.19 21 55% 11  
11 [
18
F]2.19 16 50% 8  
12 [
18
F]2.19 25 46% 11  
13 [
18
F]2.19 19 46% 9  
14 [
18
F]2.19 17 65% 11  
15 [
18
F]2.19 19 58% 11 10 
16 [
18
F]2.20 45 51% 23  
17 [
18
F]2.20 30 59% 18  
18 [
18
F]2.20 27 60% 16  
19 [
18
F]2.20 27 61% 16  
20 [
18
F]2.20 30 58% 17  
21 [
18
F]2.20 31 54% 17  
22 [
18
F]2.20 30 53% 16  
23 [
18
F]2.20 29 61% 18 18 
24 [
18
F]2.21 52 51% 26  
25 [
18
F]2.21 27 67% 18 22 
 
  
 
 
102 
Example radio TLC scans: 
 
Figure 4.7. Example crude radio TLC scan of [
18
F]2.6. Entry 5 of Table 4.1.  Percent of total integration listed for [
18
F]2.6.
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Figure 4.8. Example crude radio TLC scan of [
18
F]2.19. Entry 12 of Table 4.1.  Percent of total integration listed for 
[
18
F]2.19.
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Figure 4.9. Example crude radio TLC scan of [
18
F]2.20. Entry 16 of Table 4.1.  Percent of total integration listed for 
18
F]2.20. 
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Figure 4.10. Example crude radio TLC scan of [
18
F]2.21. Entry 24 of Table 4.1.  Percent of total integration listed for 
[
18
F]2.21. 
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Characterization of 
18
F-labeled molecules 
All 
18
F-labeled molecules were characterized by comparing the radioactivity HPLC trace of the crude 
reaction mixture to the HPLC UV trace of authentic reference sample.  An Agilent Eclipse XDB-C18, 5 
µm, 4.6 x 150 mm HPLC column was used for analytical HPLC analysis.  Note: radioactivity 
chromatographs have been offset (–0.125 min) to account for the delay volume (time) between the diode 
array detector and the radioactivity detector. 
In addition 
18
F-labeled molecules were characterized by comparing the TLC Rf of radioactive products 
from a radio TLC scan to the Rf of authentic reference sample in two different TLC solvent mixtures. 
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Figure 4.11. Characterization of [
18
F]2.6.  HPLC method as described above.  TLC plate solvent mixtures: 20% EtOAc in 
hexanes (right top); 1% MeOH in CH2Cl2 (right bottom).  A sample of 2.6 was spotted to the right of the crude 
radiochemistry reaction mixture, identified by UV visualization, and circled on the TLC plate. 
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Figure 4.12. Characterization of [
18
F]2.19.  HPLC method as described above.  TLC plate solvent mixtures: 40% EtOAc in 
hexanes (right top); 0.5% MeOH in CH2Cl2 (right bottom).  A sample of 2.19 was spotted to the right of the crude 
radiochemistry reaction mixture, identified by UV visualization, and circled on the TLC plate. 
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Figure 4.13. Characterization of [
18
F]2.20.  HPLC method as described above.  TLC plate solvent mixtures: 20% EtOAc in 
hexanes (right top); 1% MeOH in CH2Cl2 (right bottom).  A sample of 2.20 was spotted to the right of the crude 
radiochemistry reaction mixture, identified by UV visualization, and circled on the TLC plate. 
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Evidence for formation of [
18
F]2.2 during radiochemical experiments 
 
To provide evidence for the formation of [
18
F]2.2 during radiochemical experiments, PET conditions were 
mimicked using only [
19
F]fluoride in order to observe 2.2 directly by NMR spectroscopy.  Typical specific 
radioactivity of [
18
F]fluoride from the nuclear reaction 
18
O(p,n)
18
F is 5 Ci/µmol so that 1 Ci of 
18
F contains 
200 nmol of total fluoride (0.6 nmol of [
18
F]fluoride).
95
  Based on this assumption, we used 40 nmol of KF, 
to mimic a 200 mCi sample at 5 Ci/µmol.  Complex 2.2 was identified during the experiment by 
19
F NMR 
spectroscopy (Figure 4.14).  The direct observation of 2.2 shows that the complex is stable relative to other 
reagents such as 18-cr-6, KHCO3, 2.1 as well as H2O in reaction conditions used for the described 
radiochemistry. 
Experimental: 1.0 mL of a 4:1 MeCN:H2O solution containing 1.0 mg KHCO3 was transferred to a conical 
vial that contained KF (0.0023 mg, from a solution that contained 1.0 mg of KF per 1.0 mL of H2O) and a 
magnetic stir bar.  0.50 mL of a stock solution containing 18-crown-6 (26.2 mg/mL MeCN) was then added.  
The solution was evaporated at 108 °C with a constant nitrogen gas stream.  At dryness 0.5 mL of 
acetonitrile was added and evaporated at 108 °C with a constant nitrogen gas stream.  Another 0.5 mL of 
acetronitrile was added and evaporated at 108 °C with a constant nitrogen gas stream to leave a white 
precipitate around the bottom and sides of the vial.  0.5 mL of acetone was added and evaporated to dryness 
at 108 °C with a constant nitrogen gas stream to leave a glassy film on the bottom and sides of the vial.  
                                                          
95. Ting, R.; Adam, M. J.; Ruth, T. J.; Perrin, D. M. J. Am. Chem. Soc. 2005, 127, 13094. 
 
 
  
 
 
111 
The vial was cooled in a water bath, purged with nitrogen, and sealed with a cap fitted with a septum.  10 
mg of 1 dissolved in 0.6 mL of d6-acetone was added via the septum.  The vial was sonicated for 20 
seconds and then allowed to stir at 23 °C for 10 minutes.  During this time, the orange/brown clear solution 
became opaque.  At the end of 10 minutes, the solution was transferred to a NMR tube and analyzed by 
19
F 
NMR spectroscopy (Figure 4.14). 
 
Figure 4.14. 
19
F NMR spectra of 2.2. 
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Automated syntheses of [
18
F]2.43 and [
18
F]2.44 using high specific activity [
18
F]Fluoride 
Automated syntheses were accomplished using Eckert and Ziegler automated synthesis modules and 
Modular-Lab in a hot cell.  Reaction procedures were identical to the described “by hand” method (see 
beginning of Section 4.4), with the following exceptions: 1) The initial azeotrope contained 0.8 mL MeCN 
and 0.2 mL H2O instead of 1.3 mL MeCN and 0.2 mL H2O, 2) the first step of the reaction was stopped 
after 7.5 minutes instead of 10 minutes, and 3) 1.0 mL of 2-butanone was used to wash the vial and 
JandaJel™-polypyridine, so that the second step of the reaction proceeded in a 1.5 mL solution of 2:1 2-
butanone:acetone.  After the reaction, the solution was filtered through preconditioned SepPak® Plus 
Waters Accell™ Plus QMA cartridge (to capture leftover [18F]fluoride.  The second vial and anion 
exchange cartridge were washed with 1 mL acetone.  The combined organic solutions were taken out of the 
hot cell.  The reaction mixture was concentrated and the residue was suspended in a solution of 
EtOAc:hexanes (1.0 mL, 1:1 (v/v)) and filtered through a small plug of silica gel using an addition 2.0 mL 
as eluent.  The reaction mixture was concentrated to dryness and the residue was dissolved in a solution of 
trifluoroacetic acid:CH2Cl2 (1.0 mL, 1:1 (v/v)).  The solution was immediately concentrated to dryness and 
the residue was dissolved in a solution of MeCN:H2O (0.10 mL, 1:3 (v/v)).  The sample was then purified 
by preparative HPLC on a Macherey-Nagel VP 250/10 Nucleosil 100-5 C18 Nautilus column.  (For 
[
18
F]2.43: Method: 32% MeCN/H2O with 0.1% CF3CO2H, 5 mL/min, elution time: 10.7–11.7 min (see 
Figure 4.15); For [
18
F]2.44: Method: 29% MeCN/H2O with 0.1% CF3CO2H, 5 mL/min, elution time: 13.5–
14.5 min, (see Figure 4.16))  The purified product in HPLC solvent was diluted to 25 mL using a basic 
aqueous buffer (0.1 M K2CO3, 0.1 M KHCO3) was loaded on to a Grace Extract-Clean™ SPE 50mg/1.5mL 
column.  The column was washed with H2O (10 mL).  The product was eluted from the column using 
EtOH (0.5 mL), diluted with pH 5 0.1 M NaOAc solution (1 mL) and sterile saline solution (3.5–8.5 mL), 
and finally filtered through a sterile filter (Millex® Syringe-Driven Filter Unit LG 0.2 µm 25mm).  For 
analytical HPLC of final products compared to authentic reference samples, see Figure 4.17 for [
18
F]2.43 
and Figure 4.18 for [
18
F]2.44. 
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Figure 4.15. Preparatory HPLC chromatograph (280 nm and radioactivity trace) for synthesis of [
18
F]2.43. 
 
Figure 4.16. Preparatory HPLC chromatograph (280 nm and radioactivity trace) for synthesis of [
18
F]2.44.   
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Figure 4.17. Characterization of purified [
18
F]2.43.  Note: radioactivity chromatographs have been not been offset (–0.125 
min) to account for the delay volume (time) between the diode array detector and the radioactivity detector. 
  
 
 
115 
 
Figure 4.18. Characterization of purified [
18
F]2.44.  Note: radioactivity chromatographs have been not been offset (–0.125 
min) to account for the delay volume (time) between the diode array detector and the radioactivity detector. 
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Specific activity of [
18
F]2.43 and [
18
F]2.44 were determined by measuring the UV absorbance of a known 
amount of radioactivity and comparing to a standard curve of UV absorbance vs amount of unlabeled 2.43 
and 2.44.  For 122 µCi of [
18
F]2.43 a UV absorbance of 5.1 was measured corresponding to 120 pmol for a 
specific activity of 1.0 Ci/µmol at time of injection (TOI).  For 89 µCi of [
18
F]2.44 a UV absorbance could 
note be detected.  The smallest amount that has been detected corresponded to 7 pmol for a specific activity 
of at least 13 Ci/µmol at time of injection (TOI). The standard curves were generated by integration of the 
UV absorbance signal (at 280 nm) of at least 5 different known amounts of 2.43 and 2.44 in triplicate (see 
Tables 4.2 and 4.3 Figure 4.19 and 4.20). 
Table 4.2. Data for standard curve of UV absorbance vs amount of 2.43. 
pmol 2.43 UV Absorbance 
29 0.93 
72 1.8 
286 8.4 
716 27.3 
2863 128.1 
 
Figure 4.19. Standard curve of UV absorbance vs amount of 2.43. 
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Table 4.3. Data for standard curve of UV absorbance vs amount of 2.44. 
pmol 2.44 UV Absorbance 
7 2.0 
26 8.0 
65 25.7 
260 133.0 
651 341.6 
2603 1439.2 
 
 
Figure 4.20. Standard curve of UV absorbance vs amount of 2.44. 
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Purification of 
18
F-labeled Molecules and Determination of Palladium Content 
At the end of the synthesis and reformulation of [
18
F]2.43, A portion of the sample was analyzed using an 
Agilent 7500a ICP-MS to determine palladium content.  An average of 2 samples (HPLC fraction:ICP 
diluent 1:99 (m/m)) were compared to a standard curve of relative ion count versus palladium concentration.  
The standard curve was generated by creating a dilution series of known palladium concentrations (from 
0.020 ppb to 50.0 ppb) and an internal lutetium control (see Table 4.4 and Figure 4.21).  The samples 
averaged less than 0.02 ppb palladium.  The final palladium content of the reformulated sample was 2 ppb 
palladium. 
Table 4.4. ICP/MS data for standard curve and reformulated samples 
ppb Pd Pd-105 cps Lu cps Pd-105/Lu 
0.02 204.44 1337281 0.000152877 
0.1 801.67 1338268 0.000599035 
0.5 4074.44 1346762 0.00302536 
2 14839.44 1333299 0.011129867 
10 77070.56 1322516 0.058275711 
50 290764.3 1326804 0.219146385 
sample 1 62.22 1324434 4.69786E-05 
sample 2 69.44 1293053 5.37024E-05 
 
 
Figure 4.21. Standard curve of relative ion Count vs palladium concentration. 
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5. DEVELOPMENT OF REACTIVITY-DEPENDENT PCR 
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Note: The following chapters represent a research endeavor that was a collaboration between the 
Liu and Ritter Groups that is separate from the project described in the previous sections.  Dr. David Gorin 
and I collaborated on this project.  Dr. David Gorin contributed the experiments described in Figures 5.3, 
5.5, and 5.7, and partially to Figure 5.4.  I obtained the initial results that demonsrated RDPCR was viable 
as an in vitro selection method and contributed the experiments described in Figure 5.6 and partially to 
Figure 5.4. 
 
In vitro selection is a key component of efforts to discover functional nucleic acids and 
small molecules from libraries of DNA, RNA, and DNA-encoded small molecules.
96
  When the 
desired activity is binding affinity, as is the case for aptamer evolution
97
 or for the discovery of 
DNA-linked small molecules that bind to protein targets,
98
 a direct selection is possible; the 
library is typically incubated with immobilized target molecules, and bound library members are 
washed and eluted before being subjected to PCR amplification (Figure 5.1a).  
In vitro selections have also been applied to evolve RNA and DNA catalysts,
99
 and more 
recently to discover new reactions from DNA-encoded libraries of potential substrates.
100
  For 
these applications, desired library members undergo bond formation or bond cleavage.  Selections 
                                                          
96. Seminal reports: (a) Tuerk, C.; Gold, L. Science 1990, 249, 505; (b) Ellington, A. D.; Szostak, J. W. Nature 1990, 346, 
818; (c) Robertson, D. L.; Joyce, G. F. Nature 1990, 344, 467; (d) Wilson, D. S.; Szostak, J. W. Annu. Rev. Biochem. 1999, 
68, 611. 
97. Recent reviews of evolved DNA/RNA aptamers: (a) Shamah, S. M.; Healy, J. M.; Cload, S. T. Acc. Chem. Res. 2008, 41, 
130; (b) Gopinath, S. C. B. Anal. Bioanal. Chem. 2007, 387, 171. 
98. In Vitro selections of DNA-linked small molecules: (a) Wrenn, S. J.; Weisinger, R. M.; Halpin, D. R.; Harbury, P. B. J. 
Am. Chem. Soc. 2007, 129, 13137; (b) Melkko, S.; Zhang, Y.; Dumelin, C. E.; Scheuermann, J.; Neri, D. Angew. Chem., 
Int. Ed. 2007, 46, 4671.  Mock selections: (c) Doyon, J. B.; Snyder, T. M.; Liu, D. R. J. Am. Chem. Soc. 2003, 125, 12372; 
(d) Gartner, Z. J.; Tse, B. N.; Grubina, R.; Doyon, J. B.; Snyder, T. M.; Liu, D. R. Science 2004, 305, 1601. 
99. (a) Silverman, S. K. Chem. Commun. 2008, 3467; (b) Joyce, G. F. Annu. Rev. Biochem. 2004, 73, 791. 
100. (a) Kanan, M. W.; Rozenman, M. M.; Sakurai, K.; Snyder, T. M.; Liu, D. R. Nature 2004, 431, 545; (b) Rozenman, M. M.; 
Liu, D. R. ChemBioChem 2006, 7, 253; (c) Rozenman, M. M.; Kanan, M. W.; Liu, D. R. J. Am. Chem. Soc. 2007, 129, 
14933. 
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for reactivity are significantly more complicated than selections for binding affinity.  Typically, 
libraries are incubated with biotinylated substrates or potential reaction partners.  Bond formation 
results in the attachment of biotin to a library member, which in turn enables its capture by 
immobilized avidin (Figure 5.1b).
101
  For bond cleavage, an inverse approach is commonly used 
in which immobilized, biotinylated library members liberate themselves upon bond scission.
102
  
While effective, such selections for reactivity are indirect, require the synthesis of biotin-linked 
substrates, and involve multiple solution-phase and solid-phase manipulations.  
 
Figure 5.1. Traditional approaches to in vitro selection. 
Motivated by our ongoing interest in applying in vitro selection to discovery problems 
that involve chemical reactivity,
103
 we sought to develop a new method that more directly links 
                                                          
101.  (a) Tarasow, T. M.; Tarasow, S. L.; Eaton, B. E. Nature 1997, 389, 54; (b) Seelig, B.; Jaschke, A. Chem. Biol. 1999, 6, 
167.  Other tags may be used.  For selected examples, see: (c) Chandra, M.; Silverman, S. K. J. Am. Chem. Soc. 2008, 130, 
2936; (d) Pradeepkumar, P. I.; Hobartner, C.; Baum, D. A.; Silverman, S. K. Angew. Chem., Int. Ed. 2008, 47, 1753; (e) 
Johnston, W. K.; Unrau, P. J.; Lawrence, M. S.; Glasner, M. E.; Bartel, D. P. Science 2001, 292, 1319. 
102. (a) Breaker, R. R.; Joyce, G. F. Chem. Biol. 1994, 1, 223; (b) Sheppard, T. L.; Ordoukhanian, P.; Joyce, G. F. Proc. Natl. 
Acad. Sci. U. S. A. 2000, 97, 7802; (c) Hobartner, C.; Pradeepkumar, P. I.; Silverman, S. K. Chem. Commun. 2007, 2255.  
103. (a) Rozenman, M. M.; McNaughton, B. R.; Liu, D. R. Curr. Opin.Chem. Biol. 2007, 11, 259; (b) Wrenn, S. J.; Harbury, P. 
B. In Annu. Rev. Biochem. 2007; Vol. 76, p 331. 
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bond formation or bond cleavage with the amplification of desired sequences,
104
 and that obviates 
the need for solid-phase capture, washing, and elution steps.  Here we report the development and 
validation of such a method, reactivity-dependent PCR (RDPCR).   
 
Figure 5.2.  Principles underlying reactivity-dependent PCR (RDPCR).  Conditions in (a): 10 nM DNA, 2 mM Mg
2+
, 100 
mM NaCl. 
RDPCR is based on the well-established observation that the melting temperature (Tm) 
of double-stranded nucleic acids is substantially higher when hybridization occurs 
intramolecularly as opposed to intermolecularly.
105
  For example, the DNA hairpin 5.1 with an 8 
bp stem is predicted
106
 to exhibit a Tm of 48 °C, while the intermolecular hybridization of two 
DNA strands of the same sequence (5.2 and 5.3) is predicted to be far less favorable, with a Tm 
of only 11 °C (Figure 5.2). We hypothesized that the significant difference in intramolecular 
versus intermolecular duplex stability could enable a new type of in vitro selection, wherein bond 
formation or bond cleavage is transduced into the formation of a self-priming DNA hairpin.  This 
                                                          
104. Note that in contrast with a conventional selection in which unfit library members are discarded and sequences encoding 
surviving members are replicated in a subsequent step, RDPCR achieves the selective replication of only those sequences 
encoding desired library members. 
105. Ogawa, A.; Maeda, M. Bioorg. Med. Chem. Lett. 2007, 17, 3156.  
106. Computation carried out using the Oligonucleotide Modeling Platform (OMP, DNA Software, Inc.). 
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hairpin enables the selective PCR amplification of those DNA sequences that encode the reactive 
species (Figure 5.2b).107 
We first assessed the ability of intramolecular self-priming to result in preferential DNA 
amplification.  We synthesized a series of oligonucleotide pairs (5.4a+5.5), each predicted to 
hybridize intermolecularly at their 3’ ends to form a short duplex region of 8 or 10 bp (Figure 
5.3).  The 5’ end of each DNA oligonucleotide in the pair contained a sequence identical to either 
primer 5.6 or primer 5.7.  PCR amplification cannot occur until after DNA hybridization and 3’ 
extension take place to generate a single-stranded DNA molecule containing both primer 5.6 and 
a sequence complementary to primer 5.7.  This 3’-extended species can then hybridize with 
primer 5.7 and initiate PCR amplification.  
 
Figure 5.3.  Comparison of PCR efficiency of intramolecularly primed versus intermolecularly primed DNA templates.  
PCR conditions for PAGE samples: 19 fmol 5.8 or 19 fmol 5.4a+5.5 in 30 µL, 25 cycles. 
We also prepared an analogous series of DNA oligonucleotides capable of hybridizing 
                                                          
107  For examples of phosphodiester bond formation-dependent PCR, see: (a) Bartel, D. P.; Szostak, J. W. Science 1993, 261, 
1411; (b) Makrigiorgos, G. M. Human Mutation 2004, 23, 406; (c) Troutt, A. B.; McHeyzerwilliams, M. G.; Pulendran, B.; 
Nossal, G. J. V. Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 9823. 
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intramolecularly to form hairpin structures with 10-, 8-, or 6-bp stems (5.8a-5.8c).  As with the 
intermolecularly hybridizing oligonucleotides, PCR amplification must be initiated by primer 
extension of the 3’ end.  Quantitative, real-time PCR (qPCR)108 was used to compare the ability 
of these oligonucleotides to undergo PCR amplification.   
Consistent with our initial hypothesis, under identical PCR conditions and with equal 
starting concentrations of DNA, the intramolecularly hybridizing templates were amplified much 
more efficiently than their intermolecular counterparts (5.8a vs. 5.4a+5.5a, 5.8b vs. 5.4a+5.5b).  
The intramolecularly hybridizing templates reached a threshold level of amplified product 13 to 
15 PCR cycles (CT) earlier than the intermolecular templates, corresponding to a > 213-fold (> 
8,000-fold) difference in effective initial template abundance.  These qPCR results were 
corroborated by PAGE analysis; after 25 cycles of PCR, amplified product was only detected in 
reactions containing hairpin DNA.  Collectively, these findings demonstrate that intramolecularly 
hybridizing templates can be amplified to abundant levels under conditions that fail to 
appreciably amplify the corresponding intermolecularly hybridizing templates.  Subsequent 
experiments in this work were carried out with an 8-base stem, which was found to optimally 
balance robust intramolecular priming and poor intermolecular priming. 
In order to use RDPCR in a general selection for bond formation, the covalently linked 
functional groups in the hairpin loop must not interfere with the required hybridization and 3’-
extension events.  To test the compatibility of non-natural linkers with the preferential 
amplification of self-priming templates, we repeated the qPCR experiment in Figure 5.3 with a 
series of non-natural linker structures, including ether, disulfide, and amide hairpin linkers.  In all 
cases tested, DNA templates containing non-natural linkers (5.9a-5.9c) were far more efficiently 
                                                          
108.  For a general review, see: Kubista, M.; Andrade, J. M.; Bengtsson, M.; Forootan, A.; Jonak, J.; Lind, K.; Sindelka, R.; 
Sjoback, R.; Sjogreen, B.; Strombom, L.; Stahlberg, A.; ZoriC, N. Mol. Aspects Med. 2006, 27, 95. 
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amplified than the analogous intermolecularly hybridizing templates (5.4+5.10) (Figure 5.4).  
 
Figure 5.4.  Non-natural hairpin linkers support self-priming PCR.  R = (CH2)6OH. 
Since RDPCR will ultimately be applied to mixtures of both active (resulting in DNA 
hairpins) and inactive (resulting in separate linear oligonucleotides) library members, we next 
tested the ability of hairpin templates to undergo preferential amplification in the presence of 
large excesses of corresponding linear molecules (Figure 5.5).  For these library-format 
experiments, the hairpin (5.11) and linear (5.12) template sequences vary only by a single base, 
such that DNA amplified from the hairpin contains a cleavage site for the restriction enzyme 
HindIII, while DNA arising from 5.12 does not. 
The quantity of 5.11 spiked into an equimolar mixture of 5.12 and 5.13 was varied to 
determine the selectivity of RDPCR in a library format.  As little as 1 attomole of 5.11 (600,000 
molecules) could be selectively amplified in the presence of a 10,000-fold excess of 5.12 and 
5.13.  The use of larger quantities of hairpin (corresponding to a 10- to 1,000-fold excess of 5.12 
and 5.13) overwhelmingly provided the desired product.  These results demonstrate the ability of 
hairpin templates to be preferentially amplified even in the presence of large excesses of linear 
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templates, and indicate that RDPCR can be applied to library-format selections.
109
  
 
Figure 5.5.  Selectivity of RDPCR in a library-format mock selection.  PCR conditions: 19 fmol of 5.12 and 5.13 in 60 µL, 
25-35 cycles. 
Following these foundational studies, RDPCR was applied to two model in vitro 
selections.  First, RDPCR was validated as a bond-formation selection for DNA-encoded reaction 
discovery.  Previously, DNA-encoded reaction discovery required the capture, washing, and 
elution of active library members on avidin-linked beads (Figure 5.1b).
100
 In a RDPCR version of 
reaction discovery, pairs of functional groups are attached to encoding DNA strands (Figure 5.6).  
A disulfide linker temporarily joins each substrate pair (5.9b, 5.9d).  Exposure to a set of reaction 
conditions and subsequent cleavage of the disulfide bond provides one of two possible outcomes.  
If a new covalent bond has formed between the functional groups, the hairpin-forming 
nucleotides remain tethered together through the reaction product, leaving a self-priming DNA 
hairpin (5.14).  If no bond has formed, then only intermolecular hybridization is possible 
(5.15+5.16), resulting in inefficient PCR amplification.  In contrast with previous reaction 
discovery selections, the RDPCR version requires no solid-phase steps and minimal 
                                                          
109. Gartner, Z. J.; Liu, D. R. J. Am. Chem. Soc. 2001, 123, 6961. 
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manipulation. 
 
Figure 5.6.  RDPCR-based DNA-encoded reaction discovery selection.  PCR conditions for PAGE 
samples: 1 fmol of 5.9 in 20 µL, 23 cycles. 
To test the ability of RDPCR to support reaction discovery, we synthesized a disulfide-
linked substrate (5.9d) with pendant alkene and aryl iodide groups, which should undergo a Pd-
mediated Heck-type reaction (Figure 5.6).
110
  An unreactive control substrate (5.9b) containing an 
azide and an aldehyde was similarly generated.  Each substrate was treated with 1 mM Na2PdCl4 
(which is reduced to Pd(0) in situ) in aqueous pH 7.5 buffer for 30 min at 65 °C, followed by 
DTT to cleave the disulfide bond.  The resulting material was subjected to PCR.  The DNA 
attached to the alkene-aryl iodide pair (5.9d) amplified efficiently (Figure 5.6).  Omission of 
Na2PdCl4 resulted in much less efficient amplification.  Likewise, the unreactive substrate pair 
5.9b did not undergo PCR amplification after identical treatment.  Omission of DTT, however, 
enabled the disulfide-linked starting substrate to amplify efficiently.  Collectively, these results 
                                                          
110. Heck, R. F. Org. Reactions 1982, 27, 345.  
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indicate that RDPCR can selectively and efficiently amplify DNA templates that have undergone 
bond formation, and that amplification is dependent on the intramolecularity of the resulting 
template-primer species.
111
  These experiments were corroborated using an azide/alkyne substrate 
that undergoes Cu(I)-catalyzed cycloaddition reaction. 
In principle, RDPCR can also enable an efficient selection for bond cleavage, which has 
yet to be studied in a DNA-encoded context.  To explore this possibility, we evaluated the ability 
of DNA-linked peptides to undergo cleavage mediated by a protease (Figure 5.7).  We anticipated 
that protease-mediated cleavage of a DNA-peptide conjugate would expose a primary amine 
group, which would then undergo DNA-templated amide bond formation to generate a hairpin 
template for efficient PCR.
112
  In contrast, the absence of proteolysis should result in no amide 
formation and thus inefficient PCR amplification.  
A DNA–N-acetyl-pentapeptide conjugate (5.17), synthesized by solid phase co-synthesis, 
was exposed to subtilisin A.  The peptide sequence (Ac-N-AFGPA) was designed to include 
cleavage sites for subtilisin A.
113
  The enzyme-treated DNA was combined with a carboxylic 
acid-linked DNA primer (5.10c) under conditions (DMT-MM or sNHS+EDC) that support DNA-
templated amide bond formation.
114
  
                                                          
111. As little as 10 fmol of 5.9d and 5.9b could be carried through the process with similar results, suggesting that selections 
can be performed on a very small scale. 
112. For approaches to protease substrate profiling by derivitization of free R-amines, see: (a) Mahrus, S.; Trinidad, J. C.; 
Barkan, D. T.; Sali, A.; Burlingame, A. L.; Wells, J. A. Cell 2008, 134, 866; (b) McDonald, L.; Robertson, D. H. L.; Hurst, 
J. L.; Beynon, R. J. Nat. Methods 2005, 2, 955; (c) Gevaert, K.; Goethals, M.; Martens, L.; Van Damme, J.; Staes, A.; 
Thomas, G. R.; Vandekerckhove, J. Nat. Biotechnol. 2003, 21, 566. 
113.  Substrate designed in consultation with Sigma-Aldrich Protease finder (http://sigma-aldrich.com/proteasefinder). 
114.  DNA-templated amide bond formation with DMT-MM: (a) Li, X. Y.; Gartner, Z. J.; Tse, B. N.; Liu, D. R. J. Am. Chem. 
Soc. 2004, 126, 5090.  With EDC/sNHS: (b) Gartner, Z. J.; Kanan, M. W.; Liu, D. R. Angew. Chem., Int. Ed. 2002, 41, 
1796.  For a review of DTS, see: (c) Li, X. Y.; Liu, D. R. Angew. Chem., Int. Ed. 2004, 43, 4848. 
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Figure 5.7.  RDPCR-based protease-mediated peptide cleavage selection.  PCR conditions for PAGE samples: 19 fmol 
DNA in 30 µL, 23 cycles (lanes 1-5) or 25 cycles (lanes 6-9).  D = DMT-MM; E = EDC + sNHS. 
Addition of the protease-digested and carboxylate-ligated DNA-peptide conjugate (5.18) 
to a PCR reaction resulted in efficient PCR amplification.  In contrast, no PCR product was 
detected by PAGE when unfunctionalized DNA (5.4a) was used in place of the pentapeptide, or 
when subtilisin A was omitted.  Likewise, omission of the amide formation reagents also resulted 
in inefficient PCR amplification, consistent with the necessity of intramolecular primer 
hybridization for rapid amplification.  These findings together demonstrate the ability of RDPCR 
to rapidly detect DNA-linked peptide substrates of protease enzymes.  
In conclusion, we have developed and validated RDPCR as a new, entirely solution-
phase method for the selective amplification of DNA sequences encoding molecules that undergo 
bond formation or bond cleavage.  By obviating the need to perform solid-phase capture, 
washing, and elution steps, RDPCR can greatly streamline the selection process for applications 
such as DNA-encoded reaction discovery and protease activity profiling.  Compared with the 
performance characteristics of previous in vitro selection methods, the data above suggests that 
RDPCR may also offer superior enrichment factors (signal:background ratios).  In addition, 
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RDPCR may be applicable to the evolution of ribozymes and DNAzymes that catalyze bond-
forming or bond-cleaving reactions including those that do not generate nucleic acid-like 
products. 
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6. EXPERIMENTAL FOR CHAPTER 5115 
                                                          
115. I thank Dr. David Gorin for performing experiments in the following chapter (see note at the beginning of Chapter 5). 
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General Methods.  DNA oligonucleotides were synthesized using standard automated solid-phase 
phosphoramidite coupling methods on a PerSeptive Biosystems Expedite 8909 DNA synthesizer or 
purchased from Integrated DNA Technologies.  All reagents and phosphoramidites for DNA synthesis 
were purchased from Glen Research.  Oligonucleotides were purified by reverse-phase high-pressure liquid 
chromatography (HPLC) using a C18 stationary phase and an acetonitrile/100 mM triethyl ammonium 
acetate gradient or by Oligonucleotide Purification Cartridge (Applied Biosystems).  Oligonucleotide 
concentrations were quantitated by UV spectroscopy on a Nanodrop ND1000 Spectrophotometer.  Non-
commercial, modified oligonucleotides were characterized by LCMS on Waters Aquity UPLC equipped 
with a Waters Aquity UPLC BEH C18 column using an aqueous 6 mM tetraethyl ammonium 
bicarbonate/MeOH mobile phase.  Electrospray mass spectrometry was carried out on a Waters Q-TOF 
premier instrument.  All DNA sequences are written in the 5’ to 3’ orientation. 
Gels stained with ethidium bromide were visualized on an Alpha Innotech AlphaImager HP.  
Fluorescence images were acquired on a GE Typhoon Trio variable mode imager.  Solid phase peptide 
synthesis was carried out on an Applied Biosystems 433A peptide synthesizer using standard Fmoc 
chemistry.  Water was purified with a Milli-Q purification system.  All chemical reagents were purchased 
from Sigma-Aldrich, unless otherwise noted.  DMT-MM was synthesized according to the method of 
Kunishima et al.
116
  Subtilisin A was purchased from Sigma-Aldrich.  HindIII and PvuII-HF were 
purchased from New England Biolabs.   
 
General Method for PCR. All PCR reactions were carried out with AmpliTaq Gold DNA Polymerase (0.1 
μL/20 μL reaction volume, Applied Biosystems) in the provided buffer.  PCR reactions included Mg2+ (3 
mM), dNTPs (200 μM each, BioRad), and primers (500 nM each).  Templates were amplified from a 
standard initial concentration of 625 pM, unless otherwise noted.  The thermal cycling sequence was as 
follows: 95 °C for 10 minutes, then iterated cycles of 95 °C for 30 seconds, 58 °C for 30 seconds, and 72 
°C for 30 seconds.  In preparative PCR reactions, upon completion of the iterated cycles, a final incubation 
at 72 °C for 2 minutes was performed.  For qPCR, conditions were identical to those above, except that 
Sybr Green I Nucleic Acid gel stain (0.5x final concentration from a 10,000x stock solution, Invitrogen) 
was added to the reaction mixture.  Quantitative PCR experiments were performed in triplicate on a BioRad 
CFX96 Real-Time PCR Detection System.   
 
Oligonucleotide Modeling Program (OMP) Calculation (Figure 5.2a): 
Sequence for Hairpin Architecture (Complementary Region in Bold) 
                                                          
116. Kunishima, M.; Kawachi, C.; Iwasaki, F.; Terao, K.; Tani, S. Tetrahedron Lett. 1999, 40, 5327. 
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5.1: GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG TCT GAC TAC AGA GTG GGA 
TGC ATA GAA C 
Sequences for Intermolecular Architecture 
5.2: GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG 
5.3: TCT GAC TAC AGA GTG GGA TGC ATA GAA C 
OMP calculation was performed using the following parameters: assay temperature: 37 °C.  Mg
2+
: 2 mM.  
Monovalent cations: 0.1 M.  DNA concentration: 10 nM. 
 
Hairpin vs. Intermolecular Architecture Comparison (Figure 5.3): 
Primer Sequences 
5.6: GCT GAC TAC AGA GTG GGA TG 
5.7: GCA GTA CCA ACC CTG TAC AC 
Sequences for Intermolecular Architecture 
5.4a: GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG 
5.5a: GCT GAC TAC AGA GTG GGA TGC ATA GAA CTT (10 bp duplex)  
5.5b: GCT GAC TAC AGA GTG GGA TGC ATA GAA C (8 bp duplex)  
Sequences for Intramolecular Architecture 
5.8a: GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG GCT GAC TAC AGA GTG 
GGA TGC ATA GAA CTT (10 bp duplex)  
5.8b: GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG GCT GAC TAC AGA GTG 
GGA TGC ATA GAA C (8 bp duplex) 
5.8c: GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG GCT GAC TAC AGA GTG 
GGA TGC ATA GA (6 bp duplex) 
qPCR: The appropriate hairpin 5.8 (625 pM) or a 1:1 mixture of 5.4a and 5.5 for the intermolecular cases 
(625 pM each) were subjected to qPCR under the standard conditions.   
PAGE:  The appropriate hairpin 5.8 or a 1:1 mixture of 5.4a and 5.5 for the intermolecular cases were 
subjected to 25 cycles of PCR under the standard conditions.  The reactions were analyzed by PAGE (10% 
TBE gel, 200 V, 20 minutes).   
 
Non-Natural Linker Experiments: Oligo-Ethylene Glycol (Figure 5.4) 
Primer Sequences 
6.1: GCA GTA CCA ACC CTG TAC AC 
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6.2: CCT GAC TAC AGA GTG GGA TG 
Sequences for Intermolecular Architecture 
5.4a: GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG 
5.10a: CCT GAC TAC AGA GTG GGA TGC ATA GAA C (8 bp duplex) 
6.3: CCT GAC TAC AGA GTG GGA TGC ATA GAA TT (10 bp duplex) 
Sequences for Hairpin Architecture (s9 = Spacer Phosphoramidite 9, Glen Research) 
6.4: GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG s9 CCT GAC TAC AGA GTG 
GGA TGC ATA GAA CTT (10 bp hairpin) 
5.9a: GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG s9 CCT GAC TAC AGA GTG 
GGA TGC ATA GAA C (8 bp hairpin) 
6.5: GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG s9 CCT GAC TAC AGA GTG 
GGA TGC ATA GA (6 bp hairpin) 
 
Optimization of Stem Length 
The appropriate hairpin was subjected to qPCR under the standard conditions.  The substrates with 10- and 
8-bp stems were amplified to threshold detection levels in 17-18 cycles, while the 6-bp stem was far less 
efficient in initiating PCR (Figure 6.1).   
 
Figure 6.1.  Optimization of stem length. 
 
qPCR Standard Curve 
To verify that the hairpin structures were well-behaved PCR templates over a range of concentrations, we 
generated a standard curve by qPCR.  Five different concentrations of hairpin 5.9a (625 pM, 31 pM, 1.6 
pM, 80 aM, 4 aM) were subjected to qPCR under the standard conditions, except that a 64 
°
C annealing 
step was used instead of 58 
°
C.  The log of starting copy number was plotted vs. threshold cycle, and a 
linear function was fit to the data (Figure 6.2).   
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Figure 6.2.  CT is linearly correlated to initial log[5.9a]. 
 
Non-Natural Linker Experiments: Disulfide (Figure 5.4) 
Sequences 
amine = Amino-Modifier Serinol Phosphoramidite; 3’thiol = 3’-Thiol-Modifier C6 S-S CPG; 5’thiol = 
Thiol-Modifier C6 S-S 
6.6: GAG CTC GTT GAT ATC CGC AGA CAT GAG CCC CAC TAC ACA CAC C (amine)(3’ thiol) 
6.7: (5’thiol)(amine)ACC TAA AGC TAG CAG CTG GCC GTG ATC AGC TTG GTG TGT G 
 
Synthesis of 5.9b 
The disulfide 5.9b was synthesized using the route shown in Figure 6.3.  6.6 and 6.7 were first 
functionalized with small-molecule carboxylic acid derivatives, providing 5.4b and 5.10b.  A mixed 
disulfide was then generated from 5.10b, which was reacted with the free thiol analog of 5.4b to yield 5.9b. 
Figure 6.3.  Synthesis of 5.9b. 
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Acylation of 6.6 and 6.7 
The appropriate carboxylic acid (0.1 mmol) and N-hydroxyl-succinimide (0.1 mmol) were dissolved in 0.1 
mL DMF in a 1.5 mL eppendorf  tube.  N,N’-dicyclohexylcarbodiimide (DCC) (0.1 mmol) was added, and 
the resulting mixture was agitated at room temperature for 30 minutes.  During this time, a white precipitate 
formed.  The reaction was briefly centrifuged, and 0.05 mL of the supernatant was added to a solution of 
6.6 or 6.7 (10 nmol) in 0.1 mL of 0.2 M phosphate buffer (pH 8) in a separate eppendorf tube.  The 
resulting solution was vigorously agitated for 6 hours, and then diluted (0.5 mL total volume) prior to 
purification by Nap5 column.  The recovered DNA was further purified by HPLC, typically yielding 1-2 
nmol of the desired product (5.10b or 5.4b).   
 
4-azidobutyric acid
117
 was coupled to 6.6 to give 5.4b. 
4-formylbenzoic acid was coupled to 6.7 to give 5.10b. 
 
Ligation of 5.4b and 5.10b 
A solution of 5.4b (500 pmol) and DL-dithiothreitol (DTT, 0.3 M) in 0.1 mL of HEPES buffer (0.1 M, pH 
8.5) was agitated for 30 minutes in a 1.5 mL eppendorf tube.  A second solution with 5.10b (instead of 
5.4b) was treated equivalently.  The deprotected, thiol-containing DNA was precipitated with ethanol from 
each reaction.  The residue containing 5.10b was taken up in 0.1 mL of 9:1 50 mM TrisHCl (pH 
7.5):ethanol containing 10 mM 2,2’-dipyridyl disulfide. The resulting suspension was agitated for 1 hour, 
and the DNA was then recovered by ethanol precipitation.  The activated residue containing 5.10b and the 
residue containing 5.4b were separately dissolved in 10 µL of 50 mM TrisHCl (pH 7.5), and the 
concentration of DNA in each solution was determined.  An equimolar quantity of the 5.4b solution was 
added to the solution of 5.10b (the total volume did not exceed 20 µL), and the resulting solution was 
agitated at 4 ºC for 12 hours.  The DNA was precipitated with ethanol, and the desired product (5.9b) was 
isolated by gel purification (3% Ambion Agarose-HR gel).  Typically, 100 pmol of disulfide 5.9b was 
obtained. 
 
qPCR Analysis   
Primer Sequences 
6.8: GAG CTC GTT GAT ATC CGC AG  
                                                          
117. Kanan, M. W.; Rozenman, M. M.; Sakurai, K.; Snyder, T. M.; Liu, D. R. Nature 2004, 431, 545. 
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6.9: ACC TAA AGC TAG CAG CTG GC 
The hairpin 5.9b (500 pM) or a 1:1 mixture of 5.4b and 5.10b (500 pM each) for the intermolecular case 
was subjected to qPCR under the standard conditions.   
PAGE analysis: The appropriate hairpin 5.9b (500 pM) or a 1:1 mixture of 5.4b and 5.10b for the 
intermolecular case was subjected to 20 cycles of PCR under the standard conditions.  The reactions were 
analyzed by PAGE (10% TBE gel, 200 V, 20 minutes) (Figure 6.4). 
Figure 6.4. Disulfide-linked hairpin supports self-priming PCR.  PCR conditions:  500 pM 5.9b or 500 pM 5.4b and 500 
pM 5.10b, 20 cycles. 
 
Non-Natural Linker Experiments: Amide (Figure 5.4) 
Sequences 
NH2 = 3’amino modifier C7 CPG, CO2H = 5’ carboxy modifier C10 
5.4c. GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG-NH2 
5.10c. CO2H-CTG AGC TCG TTG ATA TCC GCA GCA TAG AAC 
 
Formation of 5.9c from 5.4c and 5.10c 
To a 45 μL solution of 5.4c (2.5 pmol) and 5.10c (3.75 pmol) in 8:1 MOPS buffer (100 mM MOPS, 1 M 
NaCl, pH 7.5):CH3CN was added 5 μL of a 0.14 mg/μL solution of DMT-MM in MOPS buffer.  The 
resulting solution (50 μL total volume, 9:1 MOPS:CH3CN) was briefly vortexed and then left at 4 °C for 14 
hours.  The reaction was allowed to warm to room temperature and diluted with 50 μL of 0.1M aqueous 
NaCl.  The DNA was precipitated with ethanol prior to subsequent analysis.  Control experiments were 
performed analogously, but with omission of DMT-MM or with substitution of the amine-terminated DNA 
(5.4c) for hydroxyl-terminated DNA (5.4a).   
 
qPCR Analysis 
Primer sequences 
6.1: GCA GTA CCA ACC CTG TAC AC 
6.10: CTG AGC TCG TTG ATA TCC GCA G 
DNA from the acylation reaction (5.9c) was subjected to qPCR under the standard conditions.  DNA from 
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control reactions was identically treated.  A dramatic dependence of CT upon addition of DMT-MM was 
observed, consistent with acylation and subsequent intramolecular priming through the amide linker 
(Figure 6.5).  Upon replacement of amine-modified DNA 4c with unmodified, 3’-OH 4a, DMT-MM did 
not influence PCR efficiency (Figure 6.5).   
 
Figure 6.5.  Amide formation-dependent PCR.   
 
Optimization of DNA-Templated Amide Bond Formation.   
Experiments with fluorescently-tagged, amine-modified DNA enabled direct determination of conversion 
from amine-DNA to carboxylate-ligated DNA.   
 
Sequences  
Cy3 = Cy3 Phosphoramidite (Glen Research) 
6.11: Cy3-GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATC-NH2 
6.12: CO2H-CCT GAC TAC AGA GTG GGA TGC ATA GAA C 
6.13: CO2H- CCT GAC TAC AGA GTG GGA TGT TGA CCG T 
 
DMT-MM-Mediated Coupling of 6.11 and 6.12 
To a 90 μL solution of 6.11 (5.0 pmol) and 6.12 (7.5 pmol) in 8:1 MOPS buffer (100 mM MOPS, 1 M 
NaCl, pH 7.5):CH3CN was added 10 μL of a 0.14 mg/μL solution of DMT-MM in MOPS buffer.  The 
resulting solution (100 μL total volume, 9:1 MOPS:CH3CN) was briefly vortexed and then left at the 
appropriate temperature (see conditions, Figure 6.6) for 14 hours.  The DNA was precipitated with ethanol 
prior to subsequent analysis.   
 
sNHS/EDC-Mediated Coupling of 6.11 and 6.12 
A 90 μL solution of 6.11 (5.0 pmol) and 6.12 (7.5 pmol) in 8:1 MES buffer (100 mM MES, 1 M NaCl, pH 
6.0):CH3CN was added to 0.3 mg of sNHS in a 1.5 mL eppendorf tube.  10 μL of a 0.04 mg/μL solution of 
EDC in MES buffer was then added.  The resulting solution (100 μL total volume, 9:1 MES:CH3CN) was 
briefly vortexed and then left at the appropriate temperature for 14 hours.  The DNA was precipitated with 
ethanol prior to subsequent analysis.   
  
 
 
139 
 
PAGE Analysis of Acylation Reactions 
Denaturing PAGE (15% TBE-urea gel, 300 V, 25 minutes) and subsequent fluorescence quantitation was 
used to monitor the acylation reactions.  Regardless of the acylation reagent employed, amide-bond 
formation was markedly more efficient at 4 °C compared with the room temperature reactions (Figure S6, 
lanes 1 vs. 2, 5 vs. 6).  This result was consistent with our expectation that the melting temperature of the 8 
bp intermolecular duplex is ~10 °C, and therefore lower temperature provides higher reactivity by 
stabilizing the duplex intermediate.  Furthermore, an experiment with a mismatched stem sequence 
(6.11+6.13), such that no intermolecular hybridization is possible, resulted in no amide product, 
demonstrating that DNA hybridization is essential to the reaction under our experimental conditions 
(Figure S6, lane 4).   
 
Figure 6.6.  Fluorescence quantitation of the DNA-templated acylation reaction. 
 
Library-Format Experiments (Figure 5.5) 
Sequences: 
Stem-forming nucleotides are in bold, point mutations are italicized, and the HindIII recognition site is 
underlined. 
5.6: GCT GAC TAC AGA GTG GGA TG 
6.10: CTG AGC TCG TTG ATA TCC GCA G 
Sequences for Intermolecular Architecture 
5.12: GCT GAC TAC AGA GTG GGA TGA ATC TTC ATC TCA AGT TCT ATG 
5.13: CTG AGC TCG TTG ATA TCC GCA GCA TAG AAC 
Sequences for Intramolecular Architecture 
5.11: GCT GAC TAC AGA GTG GGA TGA AGC TTC ATC TCA AGT TCT ATG-spacer9-CTG AGC 
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TCG TTG ATA TCC GCA GCA TAG AAC 
 
Restriction Digestion Experiments 
PCR reactions (60 μL total volume) were performed with constant concentrations of 5.12 and 5.13 (625 
pM) but varying concentrations of 5.11 (62.5 pM, 6.25 pM, 0.625 pM, 0.0625 pM).  The appropriate cycle 
number for each reaction was determined by prior qPCR evaluation, such that each reaction proceeded 
while exponential amplification was occurring, but not beyond, in order to minimize dynamic compression.  
Following PCR, each reaction was split into two aliquots (40 and 20 μL, respectively).  To the larger 
aliquot was added 1 μL of HindIII in glycerol (10,000 units/mL).  The resulting solution was incubated at 
37 °C for 1 h, and then heated to 65 °C for 20 minutes to deactivate the enzyme.  The other aliquot was 
treated equivalently, but with omission of HindIII.  The resulting samples were analyzed by PAGE (10% 
TBE, 175 V, 25 minutes).   
 
Library-Format PvuII Experiments 
A parallel set of experiments were carried out to corroborate the HindIII digestion results.  All sequences 
and procedures were identical to the HindIII experiments, except for those noted below.  A double point 
mutation was used to distinguish the intermolecular and intramolecular substrates to take into account the 
lower sequence fidelity of PvuII.   
 
Sequences 
Sequences for Intermolecular Architecture 
6.15: GCT GAC TAC AGA GTG GGA TGC AAG TGC ATC TCA AGT TCT ATG 
Sequences for Intramolecular Architecture 
6.16: GCT GAC TAC AGA GTG GGA TGC AGC TGC ATC TCA AGT TCT ATG-spacer9-CTG AGC 
TCG TTG ATA TCC GCA GCA TAG AAC 
Restriction digestion of the PCR reactions was carried out with 1 μL of PvuII-HF (10,000 units/mL stock in 
glycerol).  Heat inactivation was achieved by incubation at 80 °C for 20 minutes following the 1 h 
incubation at 37 °C.  Reactions were analyzed as described above (Figure 6.7). 
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Figure 6.7. Library-format experiment with PvuII. 
 
Reaction Discovery Model System (Figure 5.6) 
Sequences 
Amine = Amino-Modifier Serinol Phosphoramidite; 3’thiol = 3’-Thiol-Modifier C6 S-S CPG; 5’thiol = 
Thiol-Modifier C6 S-S 
6.17: GAG CTC GTT GAT ATC CGC AGA GCG TTA TGG TCC GAC ACA CAC C (amine)(3’thiol) 
6.18: (5’thiol)(amine)ACC TAA AGC TAG CAG CTG GCG AGG TTC CAG ATG GTG TGT G 
6.19: (5’thiol)(amine)ACC TAA AGC TAG CAG CTG GCC GCA CAC TTT CTG GTG TGT G 
 
The free amine of each substrate above was coupled to a small-molecule carboxylic acid derivative as 
described earlier.  For the reactions with 6-heptenoic acid and 10-undecynoic acid, the active ester was 
formed in 0.15 mL DMF, and 0.1 mL of the resulting soluble fraction was added to the DNA-NH2, giving a 
total volume of 0.2 mL.  This modification led to increased yields, presumably due to greater solubility of 
the hydrophobic carboxylic acids in DMF.    
 
6-heptenoic acid was coupled to 6.17 to give 6.20. 
4-iodophenylacetic acid was coupled to 6.18 to give 6.21. 
10-undecynoic acid was coupled to S19 to give S22. 
 
Three substrates were made by formation of a disulfide bond: 
5.4b was coupled to 5.10b to give 5.9b. 
6.20 was coupled to 6.21 to give 5.9d. 
5.4b was coupled to 6.22 to give 6.23. 
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Reaction of Disulfide-Linked DNA with Pd 
5 pmol of the substrate oligo (5.9b or 5.9d) was added to 0.1 mL of a 1 mM disodium tetrachloropalladate 
solution in MOPS buffer (50 mM MOPS, 0.5 M NaCl, pH 7.5).   The resulting solution was heated at 65 ºC 
for 30 minutes.  The DNA was recovered by ethanol precipitation, and then taken up in 0.1 mL of a 0.3 M 
DTT solution in HEPES buffer (0.1 M HEPES, pH 8.5).  The reaction was left for 1 hour at 65 ºC to ensure 
full cleavage of the disulfide bond, and the DNA was then recovered by ethanol precipitation. 
 
qPCR of Pd-treated DNA     
Primer Sequences 
6.8: GAG CTC GTT GAT ATC CGC AG  
6.9: ACC TAA AGC TAG CAG CTG GC 
DNA recovered from the Pd reactions and various controls was subjected to qPCR under slightly modified 
conditions.  The starting concentration of DNA was 50 pM. 
 
PAGE Analysis 
DNA recovered from the Pd reactions and various controls was subjected to 23 cycles of PCR under 
slightly modified conditions.  The starting concentration of DNA was 50 pM.  The reactions were analyzed 
by PAGE (10% TBE gel, 200 V, 20 minutes). 
 
Detection of Cu(I)-Catalyzed Huisgen Cycloaddition.
118
  
1 pmol of the substrate oligo (5.9b or 6.23) was added to 0.1 mL of a 9:1 H2O:CH3CN solution containing 
2 mM Cu(I)Cl.  After 30 minutes at room temperature, the reactions were subjected to ethanol 
precipitation.  The DNA pellet was taken up in 0.1 mL of 0.3 M DTT in HEPES buffer (0.1 M HEPES, pH 
8.5) and heated for 1 hour at 65 ºC to ensure full cleavage of the disulfide bond.  The DNA was then 
recovered by ethanol precipitation.   
 
qPCR of Cu-Treated DNA     
Primer Sequences 
                                                          
118.  Himo, F.; Loveli, T.; Hilgraf, R.; Rostovtsev, V. V.; Noodleman, L.; Sharpless, K. B.; Fokin, V. V. J. Am. Chem. Soc. 
2005, 127, 210. 
  
 
 
143 
6.8: GAG CTC GTT GAT ATC CGC AG  
6.9: ACC TAA AGC TAG CAG CTG GC 
DNA recovered from the Cu reactions and various controls was subjected to qPCR under slightly modified 
conditions.  The starting concentration of DNA was 5 pM. 
 
PAGE Analysis 
DNA recovered from the Cu reactions and various controls was subjected to 24 cycles of PCR under 
slightly modified conditions.  The starting concentration of DNA was 5 pM.  The reactions were analyzed 
by PAGE (10% TBE gel, 200 V, 20 minutes). 
 
 
Figure 6.8. RDPCR-based DNA-encoded reaction discovery selection validation using Cu-catalyzed Huisgen 
cycloaddition. PCR conditions: 5 pM template, 24 cycles. 
 
Protease Activity Detection Model System (Figure 5.7) 
Primers  
6.1: GCA GTA CCA ACC CTG TAC AC 
6.10: CTG AGC TCG TTG ATA TCC GCA G 
Sequences 
3a = 3’amino modifer C7 CPG 
DNA-peptide 5.17. GCA GTA CCA ACC CTG TAC ACC ATC TCA AGT TCT ATG-3a-Ala-Pro-Gly-
Phe-Ala-NHAc 
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Carboxylate 5.10c: CO2H- CTG AGC TCG TTG ATA TCC GCA GCA TAG AAC 
Synthesis of DNA-Peptide Conjugate 5.17 
Compound 5.17 was synthesized by solid-phase co-synthesis.  0.2 µmol of 3’ amino modifier C7 CPG was 
subjected to solid-phase peptide synthesis to install the pentapeptide on the Fmoc-amine group.  The 
peptide synthesis comprised iterated rounds of Fmoc deprotection (20% pipiridine/NMP), coupling (Fmoc-
amino acid/HATU/DIPEA/NMP), and capping (5% acetic anhydride and 6% 2,6-lutidine in NMP). 
The CPG was then subjected to standard solid-phase DNA synthesis to install the oligonucleotide 
at the site of the DMT-protected hydroxyl group.  The substrate was cleaved from the resin by standard 
methods (NH4OH/methylamine).  The 5’-DMT-protected DNA was then purified by HPLC.  Following 
lyophilization and deprotection of the DMT group by standard methods (3% TFA), the DNA was repurified 
by HPLC to yield 5.17 (26.6 nmols).  
 
Detection of Bond Cleavage by Subtilisin A 
DNA-peptide 5.17 (2.6 pmol/uL) was treated with subtilisin A (65 ng/uL) in PBS buffer.
119
  After 
incubation at 37 °C for 90 minutes, the DNA and enzyme were separated by phenol/chloroform extraction.  
The DNA was recovered by ethanol precipitation, and taken up in the appropriate buffer (MOPS or MES) 
for acylation with 5.10c under the conditions described earlier.  Quantitative PCR and PCR/PAGE analysis 
were performed as described earlier. 
Table 6.1. LCMS characterization of functionalized oligonucleotides. 
Compound observed ion’s charge Expected m/z Observed m/z 
5.9c (3’-NH2) –6 1854.504 1854.484 
5.10c (5’-CO2H) –5 1899.930 1899.963 
5.17 (DNA-peptide) –7 1658.732 1658.683 
5.4b (3’SSR) –6 2290.563 2290.628 
5.10b (5’SSR) –6 2174.367 2174.353 
6.20 –6 2307.401 2307.337 
6.21 –5 2641.629 2641.669 
6.22 –6 2166.382 2166.339 
 
                                                          
119.  Subsequent experiments demonstrated that lower concentrations (to 650 pg/uL) of subtilisin A were sufficient to affect 
bond cleavage under otherwise identical conditions. 
